

City-wide Analysis of Electronic Health Records Reveals Gender and Age Biases in the Administration of Known Drug-Drug Interactions

Rion Brattig Correia^{1,2,3}, Luciana P. de Araújo⁴, Mauro M. Mattos⁴, Luis M. Rocha^{1,3,*}

¹School of Informatics, Computing & Engineering, Indiana University, Bloomington, IN 47408 USA

²CAPES Foundation, Ministry of Education of Brazil, Brasília, DF 70040-020, Brazil

³Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal

⁴Universidade Regional de Blumenau (FURB), Blumenau, SC 89030-903, Brazil

*rocha@indiana.edu

Abstract

The occurrence of drug-drug-interactions (DDI) from multiple drug dispensations is a serious problem, both for individuals and health-care systems, since patients with complications due to DDI are likely to re-enter the system at a costlier level. We present a large-scale longitudinal study (18 months) of the DDI phenomenon at the primary- and secondary-care level using electronic health records (EHR) from the city of Blumenau in Southern Brazil (pop. \approx 340,000). This is the first study of DDI we are aware of that follows an entire city longitudinally for more than 3 months. We found that 181 distinct drug pairs known to interact were dispensed concomitantly to 12% of the patients in the city's public health-care system. Further, 4% of the patients were dispensed DDI combinations, likely to result in major adverse reactions with costs estimated to be larger than previously reported in smaller studies. DDI results are integrated into associative networks for inference and visualization, revealing key medications and interactions involved in the DDI phenomenon. Analysis of the large EHR data set reveals that women have a 60% increased risk of DDI as compared to men; the increase becomes 90% when only major DDI are considered. Furthermore, DDI risk increases substantially with age. Patients aged 70-79 years have a 34% risk of DDI when they are dispensed two or more drugs concomitantly. In contrast, this risk is less than 10% for patients under 40 years of age and negligible for children under 14. Interestingly, a null model demonstrates that age- and women-specific risks from increased polypharmacy fail by far to explain the observed risks of DDI in those populations. This suggests that social and biological factors are at play. Finally, we demonstrate that machine learning classifiers accurately predict patients likely to be administered DDI given their history of drug dispensations, gender, and age ($MCC=.7, AUC=.97$). These results demonstrate that considerable gender and age biases exist, but that accurate warning systems for known DDI can be devised for health-care systems and public-health policy management, to reduce DDI-related adverse reactions and health-care costs.

Adverse drug reactions (ADR) from drug-drug interactions (DDI) is a well-known public health problem worldwide [1, 2, 3]. Most efforts to measure the scale of ADR from DDI focus on hospitalizations and emergency visits [4, 5, 6, 7, 8, 9, 10] or literature meta-analysis [3, 11, 12]. Very few studies so far have been able to characterize this problem in primary and secondary care settings. Lack of access to longitudinal data from Electronic Health Records (EHR) of large populations continues to be the main barrier to measuring the prevalence of DDI and characterizing the phenomenon in medical care [13, 14, 15]. For instance, Molden *et al* [16] searched 43,500 patients in pharmacy databases in southeastern Norway, studying only DDI from CYP inhibitor-substrate drugs. Pinto *et al* [17] studied DDI prevalence in a small cohort of forty elderly hypertensive patients in a primary health care unit in Brazil. Iyer *et al* [18] mined 50 million clinical notes from the private EHR database STRIDE [19], to identify signals of unknown potential DDI from clinical text. While STRIDE contains EHR from multiple care levels, this analysis did not address the concomitant dispensation of pairs of drugs with *known* DDI in primary- and secondary-care. Lastly, Guthrie *et al* [20] performed a repeated cross-sectional comparison of 84 days in 1995 and 2010, to study the increase in

polypharmacy and DDI at the primary- and secondary-care level in the Tayside region of Scotland (pop. 405,721); DDI was defined according to the *British National Formulary*, a private publication. This study estimated that 13% of adults (≥ 20 y.o.) were prescribed a “potentially serious” known DDI in 2010, and that the number of drugs dispensed was the characteristic most predictive of DDI. Patients dispensed 15 or more drugs had an almost 27 fold DDI risk increase over those dispensed two to four drugs. However, by using only 84-day windows, this analysis misses potential co-administrations from separate prescriptions made outside of the relatively short windows.

Here we pursue a large-scale longitudinal study of the DDI phenomenon at the primary- and secondary-care levels in an entire city, using considerably larger time-windows and relying on public DDI and ADR standards. We obtained 18 months of EHR data for the city of Blumenau in Southern Brazil (pop. 338,876), a city with a very high Human Development Index (HDI=0.806 [21])—at the level of the top quartile of countries according to this United Nations Development Programme index [22]. Brazil has a universal public health-care system, and Blumenau possesses a city-wide Health Information System (HIS) with prescription and dispensation information for its entire population (§1). The analysis of Blumenau’s EHR data is thus an opportunity to understand the DDI phenomenon in a highly developed city in a country where DDI is known to occur similarly to other nations [10, 11]. The study provides a novel understanding of both prevalence and bias in the dispensation of known DDI outside of hospital settings.

From a public-health perspective, the concomitant dispensation of drugs with adverse interactions is also of great concern [5, 10, 11]. Since over 30% of all ADR are thought to be caused by DDI [18], better identification and prediction of known DDI prescription in primary- and secondary-care could reduce the number of patients seeking urgent care in hospitals, resulting in substantial savings for health systems worldwide [3, 7, 14]. A systematic review from 2009 showed that the proportion of hospital inpatients with ADR (in general, not DDI only) ranged from 1.6 to 41.4% [11]. Furthermore, an estimated 52% (45%) of ADR in outpatients (inpatients) were preventable [12]. In the elderly population alone (> 65 y.o.), the yearly financial burden of ADR was estimated to reach \$11.9 million for the province of Ontario (pop. 12M) [9], or about \$1 per capita, per year. As we report below, the yearly cost of major DDI estimated from the Blumenau EHR data for the same age group is higher, at least \$2 per capita, per year, after adjusting for inflation and exchange rates—though for less stringent assumptions it can be as high as \$7 per capita, per year. This suggests that the financial burden of DDI is more severe than previously thought. Moreover, the rate of major DDI found in Blumenau is smaller than what was reported in Scotland [20]. Therefore the financial burden of DDI is likely higher in other health-care systems, especially those with older populations.

To characterize the significant factors in DDI, we study demographic variables such gender and age, as well as the drugs involved in DDI in greater detail, and reveal previously unknown factors in this phenomenon. We show that women in Blumenau are at a greater risk of being dispensed known DDI than men, with a 1.6 risk multiplier. This increased risk for females is not confounded by the larger number of women present in the data nor their age. The analysis also identifies the drug pairs that most lead to DDI in women which, surprisingly, are not attributable to female-specific medicines (e.g. hormone therapy). We also demonstrate that there is a significant increase of DDI risk with age, with a pronounced growth in adults over 30 years of age—10% risk of DDI when co-administered two or more drugs. Risk reaches more than 30% for adults over 65 years of age. Importantly, using a statistical null model, we show that the age risk growth is not explained simply by the increase in polypharmacy in older age. This suggests that the specific drugs dispensed to older populations are more prone to DDI and/or that insufficient attention is paid to this phenomenon in primary care for this population.

While the number of drugs dispensed and the number of concomitant drug dispensations are the best predictors of DDI (previously only observed for drugs dispensed [20]), we show that these quantities by themselves are poor predictors of DDI. We look at demographic variables such as education and neighborhood affluence and show they do not to play a significant role in the risk for DDI in our data. Other factors, however, play very significant roles, chiefly age, gender, and the specific drugs dispensed. Indeed, we demonstrate that the automatic prediction of which patients are dispensed known DDI is quite accurate when those factors are included. This makes decision-support systems for predicting DDI risk in HIS not only feasible, but necessary to lower the rates of known DDI being dispensed.

To better understand which drugs are most involved in the DDI phenomenon, we integrate all DDI information of the Blumenau population into easy-to-visualize DDI networks. Looking at gender differences,

for example, analysis of these networks identifies key drugs and interactions in the DDI phenomenon, and demonstrates that the higher DDI risk women face is not associated with any type of hormone therapy. Indeed, drugs that most contribute to the gender-disparity in DDI risk are not female-specific. This suggests there may be social or biological processes at play in primary- and secondary-care that lead to increased DDI risk for women. A full listing of the drugs that most contribute to the DDI observed in our study are presented in our DDI network analysis and accompanying tables.

1 Data and Methods

Eighteen months of drug dispensing data (Jan 2014-Jun 2015) were gathered from the *Pronto* HIS [23, 24] (see Appendix A for a system description). Drugs reported in this system are available via medical prescription only, free of charge, and dispensed to citizens of Blumenau (population $\Omega = 338,876$ [25]) during the observation period. Doctors prescribe medications by selecting drug and dosage via the HIS. Low-cost drugs can generally be directly dispensed at the primary-care facilities, whereas specialized and higher-cost medication is distributed in three central facilities across the city. All drugs are dispensed by pharmacists who must select in *Pronto* the drug and quantity to be dispensed, allowing the length of administration to be estimated. It must be noted that patients are not required to retrieve drugs from the public system. They can buy prescribed medications from private pharmacies at their own expense, without such transactions being recorded in *Pronto*. However, there is no incentive to pay more at private pharmacies for the same medication. Indeed, our analysis indicates that use of *Pronto* is similar across all neighborhoods of Blumenau, irrespective of their average income (see Fig. S3).




Figure 1: Left. A hypothetical patient-drug dispensing timeline with three drugs (i, j & k). Drug administration length (a , in days, n) are shown for each dispensation. **Right.** The three possible pairwise comparisons (i, j), (i, k) and (j, k) between the dispensed drugs are shown with their co-administration overlap marked with either an orange (no known DDI) or red (known DDI) background.

EHR were anonymized at the source and only drug dispensation and demographic variables, including gender, age, neighborhood, marital status and educational level¹, were kept. This study was approved by Indiana University’s Institutional Review Board (IRB). Drug names originally in Portuguese were converted to English, disambiguated and matched to their DrugBank ID (e.g., *Cefalexina 500mg Comprimido* and *Cefalexina 250MG/5ml Suspensão Oral* were matched to Chlorphenamine, DBID DB01114). Medications with multiple drug compounds (e.g., Amoxicillin 500mg & Clavulanate 125mg) were split into their constituent individual drugs. Other dispensed substances (e.g., infant formula milk or vitamin complexes) unmatched to DrugBank were discarded. In total, 122 unique drugs were kept for analysis. Because we have no means to know whether patients actually took the dispensed drugs, the analysis below assumes that drugs dispensed were administered. Note, however, that we are tallying drugs that were actually dispensed to patients, not simply prescribed. Thus, prescriptions to be used “as needed” but not dispensed do not appear in our analysis.

¹since the large amount of data may enable de-anonymization, for privacy we will only release data aggregates.

A drug interaction between a pair of drugs is measured if both drugs were concomitantly administered *and* the pair is identified as a known DDI in the 2011 version of *DrugBank*, an open-source drug database containing DDI information [26]. Figure 1 displays a co-administration timeline example. More formally (see also Table 1 and Appendix B), let us denote patients by $u \in U$ and drugs by $i, j \in D$ ($|D| = 122$); $U_i \in U$ is the subset of users who were dispensed drug i , $D^u \subseteq D$ is the subset of drugs administered to patient u , and $\nu^u \equiv |D^u|$ is the number of distinct drugs dispensed to patient u . Patients can be administered a drug i multiple times in the observation period, therefore $A_i^u \equiv \{a_n^{i,u}\}$ denotes the set of distinct administration intervals a of drug i to patient u , where $a \in \mathbb{N}$ is measured in days (n). $\alpha_i^u = |A_i^u|$ and $\lambda_i^u = \sum_n a_n^{i,u}$ denote the number of times and total number of days drug i was administered to patient u , respectively.

Similarly, $\alpha_{i,j}^u$ and $\lambda_{i,j}^u$ denote the number of times and total number of days (*co-administration length*) drugs i and j were co-administered to patient u , respectively (see §S2 for more details of co-administration measurement). To identify the *co-administration* of drug pair (i, j) to patient u we define a Boolean variable $\psi_{i,j}^u \in \{0, 1\}$ as:

$$\psi_{i,j}^u = (\lambda_{i,j}^u > 0) \quad (1)$$

a logical variable measuring whether patient u was co-administered drug pair (i, j) for at least one day. Next, we define a symmetrical binary map $\Delta : D \times D \rightarrow \{0, 1\}$ to indicate whether drug pair $(i, j) \in D \times D$ is ($\delta_{i,j} = 1$) a known DDI in *DrugBank*, or not ($\delta_{i,j} = 0$). Thus, to flag the co-administration of a *known drug interaction* (i, j) to patient u we similarly define a Boolean variable $\varphi_{i,j}^u \in \{0, 1\}$ as:

$$\varphi_{i,j}^u = (\psi_{i,j}^u = 1 \wedge \delta_{i,j} = 1). \quad (2)$$

For each DDI pair observed, literature references and a severity score $s \in \{major, moderate, minor, n/a\}$ were retrieved from *Drugs.com* [27]. From these values, other quantities and sets are computed per patient u , drug i or drug pair (i, j) as listed in Table 1.

quantity notation	number of co-administrations
$\Psi^u = \sum_{i,j \in D^u} \psi_{i,j}^u$	to patient u .
$\Psi_{i,j} = \sum_{u \in U} \psi_{i,j}^u$	of drug pair (i, j) to all patients.
$\Phi^u = \sum_{i,j \in D^u} \varphi_{i,j}^u$	of known DDI pairs to patient u .
$\Phi_{i,j} = \sum_{u \in U} \varphi_{i,j}^u$	of known DDI pair (i, j) to all patients.
subset notation	subset of patients
$U^{\nu > x} = \{u \in U : \nu^u > x\}$	who had at least $x \in \mathbb{N}$ drug administrations.
$U^\Psi = \{u \in U : \Psi^u > 0\}$	who had at least 1 co-administration.
$U_{i,j}^\Psi = \{u \in U : \psi_{i,j}^u = 1\}$	who were co-administered pair (i, j) .
$U^\Phi = \{u \in U : \Phi^u > 0\}$	who had at least 1 known DDI.
$U_{i,j}^\Phi = \{u \in U : \varphi_{i,j}^u = 1\}$	who were co-administered known DDI pair (i, j) .
$U^g = \{u \in U : gender(u) = g\}, g \in \{M, F\}$	per gender.
$U^{[y_1, y_2]} = \{u \in U : age(u) \in [y_1, y_2]\}, y_1, y_2 \in \mathbb{N}$	per age bracket.
$U^N = \{u \in U : neighborhood(u) \in N\}, N \in \mathbb{N}$	per neighborhood.
$U^E = \{u \in U : education(u) \geq E\}, E \in \mathbb{N}$	per education level. $U^{E=\emptyset}$ is the subset of patients who did not report their education level.

From these subsets we also denote their possible intersections by combining the appropriate sub and superscripts.

Table 1: Co-administration and interaction quantities and subsets used throughout the analysis.

The drug pairs (i, j) with the largest “footprint” in the population, are the pairs that maximize $|U_{i,j}^\Psi|$. Out of these most co-administered pairs, we are naturally most interested in those that are known DDI and

thus maximize $|U_{i,j}^\Phi|$ (see §2.2 and Table S3). A normalized version of this measure is computed as

$$\gamma_{i,j}^\Phi = \frac{|U_{i,j}^\Phi|}{|U_i|}, \quad (3)$$

which conditions the number of users co-administered known DDI pair (i, j) on the number of users that are administered drug i . This measure is not symmetrical: $\gamma_{i,j}^\Phi \neq \gamma_{j,i}^\Phi$. Maximizing it yields DDI pairs (i, j) that tend to be co-administered to patients who are administered either i or j independently; see Table S8 for top 20 such DDI pairs.

Another facet of the DDI phenomenon we can observe is related to the co-administration length of drug pairs $(\lambda_{i,j}^u)$. A normalized version is computed as: $\tau_{i,j}^u = \lambda_{i,j}^u / (\lambda_i^u + \lambda_j^u - \lambda_{i,j}^u)$, where $\tau \in [0, 1]$. This symmetric proximity measure [28] allows us to distinguish drug pairs that tend to be co-administered to patient u only simultaneously ($\tau_{i,j}^u \rightarrow 1$), or with small temporal overlap ($\tau_{i,j}^u \rightarrow 0$). A normalized measure for the entire patient population is then computed as:

$$\tau_{i,j}^\Psi = \frac{\sum_{u \in U_{i,j}^\Psi} \tau_{i,j}^u}{|U_{i,j}^\Psi|} \quad (4)$$

This proximity measure defines a weighted graph T^Ψ [28] on set D ; the graph’s edges, $\tau_{i,j}^\Psi \in [0, 1]$, link drugs that were co-administered in the patient population. $\tau_{i,j}^\Psi$ is larger when drug pairs (i, j) tend to be co-administered when either i or j is administered (correlated), and smaller otherwise (independent). Therefore, $\tau_{i,j}^\Psi$ is a measure of *the strength of drug association* in the data for drug pairs (i, j) ; high values can pick drugs prescribed together for common comorbidities, which physicians should be aware of, as well as for uncommon comorbidities (especially involving distinct specialists prescribing drugs independently). Since we do not know the underlying comorbidities, we cannot separate the two cases with this dataset. However, to focus on the DDI phenomenon for common and uncommon comorbidity, we obtain a subgraph T^Φ , restricted to known DDI pairs by computing $\tau_{i,j}^\Phi = \tau_{i,j}^\Psi \cdot \delta_{i,j}$; thus, T^Φ is a weighted version of Δ .

2 Results

2.1 DDI Demographics, Severity, and Cost

Throughout the year of 2014 and the first six months of 2015, Blumenau’s *Pronto* HIS registered 1,573,678 distinct drug interval administrations, dispensed to $|U| = 132,722$ distinct patients—39.17% of the city population. The male/female proportions are 41.5/58.5%, respectively. Of the 46% who declared their education level, a large proportion (46.77%) reported having incomplete elementary school and 20.49% had finished high school or above (see Fig. 2 and SI for details). $|U^{\nu \geq 2}| = 104,811$ patients, corresponding to 78.97% of the *Pronto* patient population, were dispensed two or more distinct drugs in the period; only this set could have been dispensed known DDI.

The relationship between volume of drug dispensation (α^N) and DDI (Φ^N) across neighborhoods (N), provides very compelling evidence that the DDI problem does not depend on average neighborhood income in the Blumenau public health care system. Indeed, there is a very strong linear relationship between the two quantities for all neighborhoods, which fits a regression line almost perfectly ($R^2 = .92$, $p < 10^{-6}$); see Figure S12-right in SI and discussion therein. This demonstrates that the DDI phenomenon is similarly observed in all neighborhoods irrespective of average income, which suggests a balanced and fair access to medical care in Blumenau.

Our analysis tallied $\Psi = 1,025,754$ distinct drug pair co-administrations. Almost 3% of these, or $\Phi = 26,524$, are known DDI in *DrugBank* and involve 75 distinct drugs that participate in $|\Delta| = 181$ observed distinct interaction drug pairs (see Table S3 in SI for the complete list and interaction description). The distribution of these DDI pairs per the *Drugs.com* severity class is detailed in Table 2. A majority (69%) are labeled *Moderate*, although, worryingly, 22.5% are classified as *Major* DDI. The observed DDI pairs were dispensed to $|U^\Phi| = 15,527$ unique patients, which represent 12% of the *Pronto* patient population




Figure 2: Distribution of patients given gender, age and education level. In total $|U^M| = 55,032$ (41.46%) were males and $|U^F| = 77,690$ (58.54%) were females. On education, a majority $|U^{e=\emptyset}| = 71,662$ (53.99%) did not report their education level. $|U^{e-}| = 48,547$ (36.58%) declared having at most some high school education whereas $|U^{e+}| = 12,513$ (9.43%) had completed high school education or above. On age, patients $|U^{y=[20-24]}| = 10,382$ (7.82%) and $|U^{y=[50-54]}| = 10,650$ (8.02%) accounted for the two largest age groups. Labels K-6 and K-12 are *Completed elementary* and *Completed high school* education, respectively. Labels for age $y \geq 80$ and education level above *Completed college* not shown.

(and almost 5% of the entire Blumenau population). In other words, almost 12% of all *Pronto* users were dispensed a known DDI; looking only at the adult *Pronto* population, this number is raised to 15% (15,336).

severity s	Φ	$ U^\Phi $	$ U^\Phi / U $	$ U^\Phi /\Omega$	$ U^{\Phi, [y>20]} / U^{[y>20]} $
<i>Major</i>	5,968 (22.50%)	5,224	3.94%	1.54%	5.01%
<i>Moderate</i>	18,335 (69.13%)	12,711	9.58%	3.75%	12.15%
<i>Minor</i>	542 (2.04%)	528	0.4%	0.16%	0.51%
<i>n/a</i>	1,679 (6.33%)	1,493	1.12%	0.44%	1.43%
<i>Major</i> \vee <i>Moderate</i>	24,303 (91.63%)	15,030	11.32%	4.44%	14.35%
<i>Moderate</i> \vee <i>Minor</i>	18,877 (71.17%)	12,791	9.64%	3.77%	12.22%

Table 2: Number and proportions of DDI observations and affected patients per DDI severity class. Drugs or interactions identified in *DrugBank* but not present in *Drugs.com* are tallied as *n/a*, see SI for details. First column: Φ , number and proportion of observed DDI co-administrations. Second column: $|U^\Phi|$, number of patients affected by at least one DDI. Third and Fourth columns: proportion of patients from the *Pronto* system and entire Blumenau populations, respectively. Fifth column: proportion of adult patients ($y \geq 20$ y.o) from the pronto system. \vee denotes the logical disjunction. Notice that the same patient may have been administered DDI of more than one severity class.

Regarding severity, almost 4% of all *Pronto* patients (5.01% of adults) were administered a major DDI, and 9.58% (12.15% of adults) were administered a moderate DDI; these numbers represent 1.54% and 3.75% of the entire Blumenau population, respectively. To give some perspective, the risk of *Pronto* patients receiving a major DDI co-administration in the 18 months of this study, is more than twice the risk of firearm related death in the US for the same period (15.8 in 100,000, or $\approx 1.6\%$) [29].

Given the lack of similar studies, we cannot directly compare the rate of DDI severity observed in Blumenau to other public health systems. The Tayside, Scotland 2010 study (with a smaller, 84 day observation window) reported a rate of 13% “potentially serious” DDI for adult patients [20]². If this severity is similar to the *Drugs.com* major DDI class, then Blumenau has a considerably lower rate of this type of DDI than Tayside—5% to 13%. If, on the other hand, “potentially serious” encompasses both the major and moderate *Drugs.com* DDI classes, then the rates observed in Blumenau are similar to those observed in Tayside—14.35% to 13%.

The financial burden of DDI to Blumenau, can be estimated by evaluating how many of the 24,592 hospital admissions billed to this public health system in the same period [30] were due to ADR from DDI—since ADR is also expected to occur after the observation period, our estimate errs on the conservative side. This estimation relies on conjecturing what proportion (p_h) of patients who where dispensed a *major* DDI are likely to have an ADR that requires hospitalization. In supporting materials (§S7), a detailed study of the financial burden of DDI is presented. It considers various rates of hospitalization expected for major DDI administration, and is based on a cost estimate of ADR hospitalizations in Canada [9], since no comparable studies were found for other countries. In summary, we focus on the most conservative value from available

²This severity class was derived from the *British National Formulary*, a private publication we do not have access to.

rankp(τ, U)	$\tau_{i,j}^\Phi$	$ U_{i,j}^\Phi $	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRI_{i,j}^F$	class
1 (2,4)	0.60	1249	141 ± 124	ASA	Glyburide	0.89	Moderate
2 (1,12)	0.70	524	243 ± 188	Haloperidol	Biperiden	0.62	Moderate
3 (4,11)	0.58	535	152 ± 132	Atenolol	Glyburide	1.22	Moderate
4 (3,17)	0.60	385	155 ± 125	Digoxin	Furosemide	0.61	Moderate
5 (62,1)	0.26	5078	102 ± 95	Omeprazole	Clonazepam	2.28	Moderate
6 (8,16)	0.55	470	160 ± 133	Diltiazem	Simvastatin	1.27	Major
7 (26,5)	0.45	1190	127 ± 127	Amitriptyline	Fluoxetine	3.55	Major
8 (82,2)	0.23	2117	53 ± 74	ASA	Ibuprofen	1.42	Major
9 (10,22)	0.55	272	140 ± 114	Digoxin	Spironolactone	0.58	Minor
10 (5,46)	0.57	95	140 ± 126	Propranolol	Glyburide	1.61	Moderate
11 (15,18)	0.50	377	143 ± 138	Fluoxetine	Carbamazepine	0.98	Moderate
12 (91,3)	0.21	1460	54 ± 77	Atenolol	Ibuprofen	1.88	Moderate
13 (61,6)	0.27	999	87 ± 86	Omeprazole	Diazepam	1.21	Moderate
14 (16,26)	0.49	226	151 ± 145	Amitriptyline	Carbamazepine	0.99	Moderate
15 (6,84)	0.56	25	157 ± 136	Diltiazem	Amiodarone	1.26	Major
16 (12,47)	0.52	91	154 ± 142	Atenolol	Diltiazem	1.19	Major
17 (21,27)	0.47	222	148 ± 139	Fluoxetine	Lithium	1.79	Major
18 (40,15)	0.36	496	103 ± 87	ASA	Gliclazide	0.78	None
19 (96,7)	0.20	892	56 ± 61	Fluconazole	Simvastatin	2.63	Major
19 (14,48)	0.50	90	161 ± 157	Imipramine	Carbamazepine	1.35	Moderate

Table 3: Top 20 known DDI pairs (i, j) by rank product (1st column; individual rank in parenthesis) of the ranks of $\tau_{i,j}^\Phi$, the strength of DDI association from eq. 4, and $|U_{i,j}^\Phi|$, the number of patients affected by the DDI (2nd and 3rd columns, respectively). Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 5 and 6. Relative gender risk of DDI pair co-administration, $RRI_{i,j}^F$ is shown in column 7. DDI severity classification, according to *Drugs.com*, shown in column 8, with DDIs not found in *Drugs.com* labeled as *None*.

literature [3] which yields $p_h = 2.68\%$, as well as on a less conservative estimate also previously reported [9] of $p_h = 8.35\%$. Both of these conjectures are likely to err on the side of under-reporting emergency room admissions due to DDI or ADR, since this a well-known problem in studies of this phenomenon [31, 32, 33, 34, 35]. Therefore, the tables in SI also report cost estimates for various values of p_h , so that readers can judge what is an appropriate value to consider (§S7).

The most conservative estimate leads to a cost of DDI-related hospitalization in Blumenau of over \$1M in the 18-month period, or a *per capita* cost of \$2.03. The extrapolated costs to the state and the country are \$21M and \$565M, respectively (see Tables S30 and S31). The less conservative estimate reaches a *per capita* cost of \$6.33, or \$3.2M, \$61M, and \$1.5B, for the city, state and country levels respectively. All estimations lead to very substantial costs for the various levels of government, suggesting that the financial burden of DDI is at least double what was previously reported—\$1 per capita in Ontario [9]—even when considering the most conservative estimate of the proportion of hospitalizations that derive from co-administration of known major DDIs.

2.2 Drugs Involved in Interactions

Table 3 lists the top 20 DDI pairs, ordered by the rank product of their strength of DDI association, $\tau_{i,j}^\Phi$ (eq. 4), with the number of patients they were administered to, $|U_{i,j}^\Phi|$ (§1). A complete list of DDI pairs ranked by $|U_{i,j}^\Phi|$ is provided in Table S3. $\tau_{i,j}$ is largest (smallest) for DDI pairs (i, j) that are more (less) likely to be co-administered when either one of drugs i or j is administered. Computing the rank product of the ranks obtained from $\tau_{i,j}^\Phi$ and the number of patients $|U_{i,j}^\Phi|$ co-administered drug pair (i, j) , identifies the DDI pairs that are very prevalent in the population but which also tend to be co-administered—downranking drug pairs that are simply very prevalent because their constituent drugs very dispensed on their own.

Only 2% of the observed DDI administrations are considered of *minor* risk, affecting 542 patients (see Table 2). The highest ranked one (9th) in Table 3 is (Digoxin, Spironolactone) and it was administered to $|U_{i,j}^\Phi| = 272$ patients (for $\langle \lambda_{i,j}^u \rangle = 140$ days on average); it leads to increased levels of Digoxin while decreasing the effect of Spironolactone. The vast majority (almost 70% per Table 2) of observed DDI administrations fall in the *moderate* risk class, which raise alarming flags depending on the patients’ underlying conditions. For instance, (Digoxin, Furosemide) can cause “possible electrolyte variations and arrhythmia” (4th, $|U_{i,j}^\Phi| = 385$, $\langle \lambda_{i,j}^u \rangle = 155$). Others, like the pair (Haloperidol, Biperiden; 2nd, $|U_{i,j}^\Phi| = 524$, $\langle \lambda_{i,j}^u \rangle = 243$) give rise to

various ADR, such as central nervous system depression and tardive dyskinesia; despite the known ADR this pair has been used clinically [27], which explains the large value of $\tau_{i,j}^{\Phi} = 0.7$, meaning that these drugs are more likely to be co-administered. It is noteworthy that in hot weather this DDI increases the risk of hyperthermia and heat stroke, and Blumenau has a humid subtropical climate with temperatures reaching 30°C with 100% humidity during summer.

(Omeprazole, Clonazepam) is the most frequent DDI pair observed, by a large margin to the second (5th, $|U_{i,j}^{\Phi}| = 5,078$, $\langle \lambda_{i,j}^u \rangle = 102$). Omeprazole is used to treat acid reflux and other gastroesophageal problems, while Clonazepam is a benzodiazepine anti-epileptic. Evidently, the concomitant dispensation of this drug pair is very prevalent in the public system. However, it requires particular attention to dosage since “Omeprazole may increase the pharmacological effect and serum levels of certain benzodiazepines via hepatic enzyme inhibition” [27, 36]. Similarly, (Acetylsalicylic Acid (ASA), Glyburide) is the top ranked pair in Table 3 and very frequently dispensed (1st, $|U_{i,j}^{\Phi}| = 1,249$, $\langle \lambda_{i,j}^u \rangle = 141$). It is especially problematic for diabetic patients since “the salicylate increases the effect of sulfonylurea;” It causes hypoglycemia by enhancing insulin sensitivity, particularly in patients with advanced age and/or renal impairment [27, 37].

Of particular concern are the *major* DDI pairs, which represent 22.5% of all observed DDI administrations per Table 2. The top 20 major DDI pairs are listed in SI Table S7 (top 7 also shown in Table 3) and include:

- (Diltiazem, Simvastatin), 6th, $|U_{i,j}^{\Phi}| = 470$, $\langle \lambda_{i,j}^u \rangle = 160$, where “Diltiazem increases the effect and toxicity of simvastatin” possibly causing liver damage as a side effect [38];
- (Fluoxetine, Amitriptyline), 7th, $|U_{i,j}^{\Phi}| = 1,190$, $\langle \lambda_{i,j}^u \rangle = 127$, where “Fluoxetine increases the effect and toxicity of tricyclics” [39]. The same ADR affects (Fluoxetine, Imipramine), 23rd, $|U_{i,j}^{\Phi}| = 257$, and (Fluoxetine, Nortriptyline), 33rd, $|U_{i,j}^{\Phi}| = 154$.
- (ASA, Ibuprofen), 8th, $|U_{i,j}^{\Phi}| = 2,117$, $\langle \lambda_{i,j}^u \rangle = 53$, where “Ibuprofen reduces ASA cardioprotective effects”. In 2015 the European Medicines Agency issued an updated advice that occasional use of Ibuprofen should not affect the benefits of low-dose ASA [40]. Our analysis shows that patients were dispensed (no just prescribed “as needed”) this pair on average for 53 days (± 74 s.d.), conflicting with occasional use. While Aspirin and Ibuprofen are common medication, their interaction is considered major when taken for long periods.
- (Fluoxetine, Lithium), 17th, $|U_{i,j}^{\Phi}| = 222$, $\langle \lambda_{i,j}^u \rangle = 148$, where “the SSRI increases serum levels of lithium” potentiating the risk of serotonin syndrome, which is rare but serious and potentially fatal [27, 41];
- (Fluconazole, Simvastatin), 19th, $|U_{i,j}^{\Phi}| = 892$, $\langle \lambda_{i,j}^u \rangle = 56$, which leads to “increased risk of myopathy/rhabdomyolysis”. Also from theazole class, Ketoconazole and Itraconazole are considered potent inhibitors generally causing less clinically significant interactions with Simvastatin than Fluconazole [27]. Both substitutes are available free of charge in the public health care system [42].

Many other major interactions, while not ranked at the top, are nonetheless of concern due to severe ADR. For instance, in 2011 the FDA issued a warning [43] contraindicating the concomitant use of Simvastatin with Erythromycin, due to increased risk of myopathy by “possibly increasing the statin toxicity”. Still, our analysis identified 10 patients concomitantly administrating this major DDI (117th, $|U_{i,j}^{\Phi}| = 10$). This major DDI is also known for its increased risk of liver damage and a rare but serious condition of rhabdomyolysis that involves the breakdown of skeletal muscle tissue [27, 44]. The full list of DDI pairs observed in the analysis, including the severity class and all other measures, is provided in Table S3 ordered by the number of affected patients; the top 20 DDI pairs ranked by the normalized “footprint” (eq. 3) are shown in Table S8.

2.3 Gender Risk and DDI Networks

The set of patients who were co-administered known DDI was comprised of $|U^{\Phi,M}| = 4,793$ (30.54%) males and $|U^{\Phi,F}| = 10,734$ (69.46%) females (see Fig. S4 and SI for additional data). To understand whether this difference in the proportion of DDI per gender was due to *Pronto* having more female patients (59%), or because women tend to be prescribed more drugs in general [45], we first computed the *relative risk of co-administration* (*RRC*) for women. This measure is computed as the ratio of the conditional probabilities

of patients being dispensed at least one pair of drugs concomitantly given gender:

$$RRC^F = \frac{P(\Psi^u > 0 | u \in U^F)}{P(\Psi^u > 0 | u \in U^M)} = \frac{|U^{\Psi,F}|/|U^F|}{|U^{\Psi,M}|/|U^M|} = \frac{0.7689}{0.7218} = 1.0653 \quad (5)$$

Naturally, the same risk for males is computed as $RRC^M = 1/RRC^F$. We also similarly computed the *relative risk of interaction (RRI)* for women as:

$$RRI^F = \frac{P(\Phi^u > 0 | u \in U^F)}{P(\Phi^u > 0 | u \in U^M)} = \frac{|U^{\Phi,F}|/|U^F|}{|U^{\Phi,M}|/|U^M|} = \frac{0.1382}{0.0871} = 1.5867 \quad (6)$$

with $RRI^M = 1/RRI^F$. If the risks were equivalent for both genders, we would observe $RRC^M \approx RRC^F \approx 1$ and $RRI^M \approx RRI^F \approx 1$. Strikingly, these risk measures revealed instead that women are much more likely than men to be concomitantly dispensed drug pairs with a known DDI, even though they have only a small increased risk of concomitant drug co-administration over men. In other words, women in the Blumenau’s *Pronto* system have an almost 60% increased risk over men of being dispensed a DDI ($RRI^F = 1.5864$), but only a 6.5% increased risk of being dispensed drugs concomitantly ($RRC^F = 1.065$). If we look at the increased risk of interaction given both gender and severity level (RRI_s^F), the gender disparity is even greater. Women have an almost 90% increased risk of being dispensed a *major* DDI ($RRI_{major}^F = 1.8739$) while having an almost 20% decreased risk of a *minor* DDI ($RRI_{minor}^F = .8059$); see SI for more details, especially Table S18.

To understand the DDI phenomenon at large as well as which drugs are most responsible for the higher risk of DDI women face over men, we computed *DDI networks* that characterize drug pairs according to measures such as $|U_{i,j}^\Phi|$ (patient volume) and eq. 4 (DDI association strength) introduced in §1. One of these networks is shown in Figure 3 (others shown in SI, Figures S8 and S9). It is a weighted version of graph Δ (§1) where edge weights between drugs i, j (nodes in graph) are the values $\tau_{i,j}^\Phi$ obtained from eq. 4—yielding a proximity between drug pairs according to their co-occurrence in DDI co-administrations when either drug is administered (a symmetrical measure of strength of association/correlation [28], see §1). The 75 drug nodes involved in DDI are colored by their primary action class as retrieved from Drugs.com (see figure legend and SI). Node size represents the *probability of interaction* for drug i :

$$PI(i) = \frac{\sum_j \Phi_{i,j}}{\sum_j \Psi_{i,j}} \quad (7)$$

which denotes the propensity of drug i to be involved in a DDI with all drugs it is co-administered with in the data (see Table S23 for values); larger nodes thus identify more dangerous drugs in the sense that they most contribute to potential ADR from DDI in our data.

To better grasp gender differences in the DDI phenomenon, edges are colored according to the *relative risk of drug pair interaction for each gender*: $RRI_{i,j}^g$, where $g \in \{M, F\}$. These quantities are computed for each DDI pair (i, j) via eq. 6, but using $\Phi_{i,j}^u$ (number of co-administrations of known DDI pair (i, j) to patient u) instead of Φ^u . Naturally, $RRI_{i,j}^F = 1/RRI_{i,j}^M$. If $RRI_{i,j}^F > 1$, the edge is colored in red with intensity proportional to $RRI_{i,j}^F$, otherwise the edge is colored in blue with intensity proportional to $RRI_{i,j}^M$ (see legend). Therefore, increased DDI risk for women (men) is identified by darker red (blue) edges. Tables S14 and S15 in SI show the $RRI_{i,j}^g$ values for the top most gender imbalanced DDI pairs per gender.

The network representation allows us to integrate, summarize and visualize the DDI phenomenon as captured by the EHR data from Blumenau. We can easily visualize the drugs most involved in DDI by node size ($PI(i)$): Digoxin, Phenytoin, Haloperidol, Carbamazepine, Warfarin, Diltiazem, Biperiden, and others shown in Table S23 in SI. The analysis of the network itself also reveals nodes with largest degree, that is, drugs that participate in more known DDI. The top ones, participating in over 10 distinct DDI are: *Phenytoin*, *Carbamazepine*, Phenobarbital, Propranolol, *Warfarin*, Aminophylline, Fluoxetine, Fluconazole (see Table S23 in SI for others). Drugs in italic have both high degree and high PI , meaning they interact with many other drugs and are also more likely to interact with some other drug when dispensed. Note that drugs can have a high PI and low degree and vice-versa. For instance, $PI(\textit{Biperiden}) = 0.13$, but its degree is 1. So, even though 13% of the time that it is administered it is involved in a DDI, which




Figure 3: DDI network. A weighted version of network Δ where weights are defined by $\tau_{i,j}^\Phi$. **Nodes** denote drugs i involved in at least one co-administration known to be a DDI. Node size represents the highest level of primary action class, as retrieved from Drugs.com (see legend). Node size represents the probability of interaction $PI(i)$, as defined in text. **Edge weights** are the values of $\tau_{i,j}^\Phi$ obtained from eq. 4. **Edge colors** denote $RRI_{i,j}^g$, where $g \in \{M, F\}$, to identify DDI edges that are higher risk for females (blue) or males (red). Color intensity for $RRI_{i,j}^g$ varies in $[1, 5]$; that is, values are clipped at 5.

is high, the interaction is always with the same other drug (Haloperidol)—and 62% more often to males, $RRI_{Biperiden, Haloperidol}^M = 1.62$. Conversely, $PI(\text{Aminophylline}) = 0.01$ but it has a high degree of 10; Aminophylline interacts with 10 other drugs, but is rarely co-administered with them (only 1% of the time it is administered).

Of the $|\Delta| = 181$ DDI pairs we observed in the data (§2.1), 133 are associated with an increased risk for women (red edges), whereas only 48 denote an increased risk for men (blue edges)—a ratio of 2.8. To better visualize and study the DDI phenomenon per gender, the subgraphs of red and blue edges are also provided in Figure S9 in SI. The risk intensity is also more disadvantageous for women. For instance, if we look at DDI pairs with $RRI_{i,j}^g > 3$ (very gender-imbalanced pairs), we find 49 drugs in interactions that affected 3,327 women (4.28% of female Pronto population), but only 13 drugs that affected 64 men (0.01% of male Pronto population). The 65 (9) such interactions for women (men) have 16 (3) that are *major*. This is also clearly visible in the subgraph of *major* DDI edges shown in Figure S8 in SI, where almost all edges are red. All the top *major* DDI pairs discussed in §2.2 present a greater risk for females. For instance, $RRI_{Fluoxetine, Amitriptyline}^F = 3.55$, so women face a 255% risk increase over their male counterparts of being administered this *major* DDI—Fluoxetine-induced chronic Amitriptyline toxicity can be fatal with seizures and delirium reported as ADR [39].

Importantly, the DDI pairs with increased risk for women are not circumscribed to drugs commonly prescribed to women (such as estrogen contraceptives), but instead traverse all drug classes, ranging from

cardiovascular to central nervous systems agents. Indeed, removing female contraceptive drugs³ only slightly reduces the the number of DDI pairs associated with increased risk for women, from $133/181 = 73.48\%$ to $116/158 = 73.42\%$, which is still substantially higher than the number of DDI pairs associated with increased risk for men ($48/181 = 26.52\%$; $42/158 = 26.58\%$). Furthermore, removing these drugs only lowers the overall DDI risk for females RRI^F from 1.59 to 1.55 (eq. 6).

The network approach allows us to investigate the roles of an individual drugs and DDI pairs, in relation to others. For instance, Phenytoin, an anti-seizure medication, is the drug with largest degree in the DDI association network: it interacts with 24 other drugs, most of which have strong DDI association, granting it the highest total degree strength, $\sum_j \tau_{ij}^\Phi = 6.51$. When shortest paths are considered, it is also the most central node in the network, acting as a bridge between other nodes with a betweenness centrality of 0.30 [46]. Moreover, Phenytoin also has the second largest $PI(Phenytoin) = 0.2$ (node size), meaning that 1 in 5 times that Phenytoin is co-administered with another drug it leads to an interaction. So it interacts with many drugs and is very likely to be problematic when co-dispensed with other drugs. Carbamazepine, another CNS agent used in neuropathic pain and epilepsy treatment, has a similar behavior: it interacts with 18 other drugs and with a high $PI(Carbamazepine) = 0.18$. Digoxin, a drug used for heart rate and rhythm control, is the drug with the largest $PI(Digoxin) = 0.24$ (largest node in network). It interacts with other drugs almost 1 in 4 times it is co-administered with another drug—interacting with 9 other drugs in the *Pronto* data (see Table S23 SI for more cases).

The inferences above are made from the DDI association network in Figure 3, but inferences can also be made from the DDI volume network in Figure S8 in SI. For instance, the DDI pair co-administered to more patients in our data is (Omeprazole, Clonazepam) already discussed in §2.2. It is the thickest edge in the volume network as it affects 5,078 patients. Women also face a substantially higher risk of being administered this known (*moderate*) DDI than men: ($RRI_{Omeprazole,Clonazepam}^F = 2.28$), a 128% increase over men—thus it also appears as a red edge in Figure 3, with a reasonable association strength of $\tau_{Omeprazole,Clonazepam}^\Phi = 0.26$. The second most administered DDI pair is (Acetylsalicylic Acid (ASA), Ibuprofen): 2,117 patients (§2.2). This pair has a 42% ($RRI_{ASA,Ibuprofen}^F = 1.42$) increased risk of being co-administered to women.

Naturally, there are known DDI that present an increased risk for men. (Haloperidol, Biperiden) has a 62% ($RRI_{Haloperidol,Biperiden}^M = 1.62$) increased risk of being co-administered by men. This is a DDI between a psychotherapeutic and a central nervous system (CNS) agent. Haloperidol is an antipsychotic drug used in aggression reduction while Biperiden is usually used to treat Parkinson disease and drug-induced movement disorders. Similarly, (Digoxin, Furosemide) has a 64% ($RRI_{Digoxin,Furosemide}^M = 1.64$) increased risk for men. These often co-dispensed drugs are both cardiovascular agents, requiring special attention for possible electrolyte variations and arrhythmia [26].

$ U_{i,j}^{\Phi,F} $	i	j	$RRI_{i,j}^F$	$ U_{i,j}^{\Phi,M} $	i	j	$RRI_{i,j}^M$
13	Carbamazepine	Ethinyl Estradiol	∞	29	Digoxin	Amiodarone	1.78
13	Levonorgestrel	Carbamazepine	∞	11	Diclofenac	Warfarin	1.19
1,411	ASA	Ibuprofen	1.42	-	-	-	-
992	Amitriptyline	Fluoxetine	3.55	-	-	-	-
703	Fluconazole	Simvastatin	2.63	-	-	-	-
209	Imipramine	Fluoxetine	3.08	-	-	-	-
302	Diltiazem	Simvastatin	1.27	-	-	-	-
159	Fluoxetine	Lithium	1.79	-	-	-	-
122	Fluoxetine	Nortriptyline	2.70	-	-	-	-
28	Propranolol	Salbutamol	6.61	-	-	-	-

Table 4: Top 10 known *major* DDI pairs (i, j) with increased risk of co-administration per gender, $g \in \{M, F\}$, which affected at least 10 patients of each gender. Rows ordered by the rank product of the ranks of $RRI_{i,j}^g$, the relative gender risk of co-administration, and $|U_{i,j}^{\Phi,g}|$, the number of patients of given gender affected by the DDI. For men, only two DDI match the criteria. A complete list can be seen in Tables S14 and S15.

³drugs removed were Ethinyl Estradiol, Estradiol, Norethisterone, Levonorgestrel and Estrogens Conjugated.

2.4 Age Risk

It is known that age is also a factor in predicting the number of prescribed drugs [45], especially because of increased co-morbidity in older patients. To investigate the role of age in known DDI co-administration, we aggregated patients into age groups and computed the risk of specific age groups to be dispensed a known DDI for the amount of co-administrations observed for that age group. Thus, a *Risk of Interaction for age group* $[y_1, y_2]$ is calculated as

$$RI^{[y_1, y_2]} = \frac{P(\Phi^u > 0 \mid u \in U^{[y_1, y_2]})}{P(\Psi^u > 0 \mid u \in U^{[y_1, y_2]})}, \quad (8)$$

which can be interpreted as the probability of being dispensed a known DDI given the expected number of co-administrations for a patient in a specific age range $[y_1, y_2]$. If the number of DDI observed were proportional to the number of co-administrations, this quantity would be essentially flat across age groups. As shown in Figure 4, center, RI increases substantially for older age groups (see also Table S19 in SI), varying from near zero for younger age groups to 0.35 for groups over 70. A *Risk of Co-administration for age group* $[y_1, y_2]$, $RC^{[y_1, y_2]}$, is similarly computed, but using $\nu^u \geq 2$ —the number of patients with at least 2 drug administrations—instead of Ψ^u . This is interpreted as the probability of being concomitantly dispensed two or more drugs (co-administration), when a patient of a given age group is dispensed two or more drugs in the full observation period. While there is some variation, RC varies a lot less than RI —no more than 6% across all age groups as seen Figure 4, left (note the difference in scale.) This shows that risk of co-administration is largely proportional to number of dispensed drugs, while risk of interaction seems to grow more than the increase in co-administrations (polypharmacy) observed with age, a behavior we study in more detail below.




Figure 4: Left & center. Co-administration ($RC^{[y_1, y_2]}$; left) and interaction risk ($RI^{[y_1, y_2]}$; center) per age group, computed via eq. 8. Solid orange line is the cubic regression for $RC^{[y_1, y_2]}$ while solid red line is the cubic regression for $RI^{[y_1, y_2]}$ (linear and quadratic regressions in SI). **Right.** Absolute number of patients with at least one co-administration known to be a DDI. For all plots, age groups [90,94], [95,99] were aggregated into [90+]. Stars (*) depict values computed from the null model, H_0^{rnd} , with background filling denoting the 95% confidence interval based on 100 runs.

The risk of co-administration is overall quite high for all age groups ($RC^{[y_1, y_2]} \in [.92, .98]$), with increasing values as patients age. This means that patients dispensed at least two drugs are almost always being dispensed drugs concomitantly. Conversely, the risk of interaction starts from almost nonexistent at age [0-14] and reaches more than 25% after the age of 55. In other words, one in every four patients over 55 is likely to be dispensed a known DDI when co-administered two or more drugs.

One possible reason that RI grows much more than RC with age is that the two risk measures are related non-linearly, whereby a small increase in drug co-administration risk amplifies DDI risk. Another option is that factors other than increase in co-administration cause the increase of DDI risk with age. For instance, drugs dispensed to the elderly may have a higher propensity for interaction with other drugs, or even perhaps the medical establishment does not pay as much attention to known DDI when attending to older people, in comparison to children or younger patients?

Given the relationships among number of drugs dispensed (ν^u), co-administrations (Ψ^u), and interactions (Φ^u) for all users shown in Figure 5, the first option can be discarded. While there is a strong nonlinear (quadratic) relationship between ν^u and Ψ^u (Fig. 5, left), there is no evidence of a nonlinear relationship between Ψ^u and Φ^u (Fig. 5, right), which could explain the growth of RI with age (See SI for deeper




Figure 5: Patients plotted with number of drugs dispensed ν^u , co-administrations Ψ^u and interactions Φ^u . **Bottom row.** Each circle depicts a patient, with red (blue) circles denoting females (males). Color intensity denotes their age, with stronger red (blue) representing older women (men). To reduce circle overlay and enhance visualization, a uniform noise $\in [0, 1]$ was added to both coordinates. Green and orange lines denotes linear and quadratic regressions, respectively. Inserts with Hexagonal log-bins are included to better depict the density of patients close to the origin. **Top row.** Pareto fronts comparing regression results (R^2) at increasing regression model complexity. For example, complexity 1 and 2 denote a linear and quadratic regression, respectively.

analysis). While not related to first hypothesis, in contrast to previous reports [20], it is noteworthy that co-administrations (Ψ^u) predict interactions (Φ^u) better than number of drugs prescribed (ν^u), though neither do so particularly well (also see §2.5).

To investigate the second hypothesis—that factors other than increase in co-administration cause the increase of DDI risk with age—we developed a statistical null model, which also accounts for gender. The idea is to explore if the growth of RI^y is an expected phenomenon of increased polypharmacy with age, which necessarily results in a combinatorial increase of possible drug pairs that can interact. The null model, H_0^{rnd} , aims to capture the expected increase in RI^y with age, given the observed polypharmacy and gender for each specific age group. Thus, the model’s assumption is that all drugs that were in reality dispensed in a given age group are dispensed at random with same frequencies. Specifically, for each co-administration observed in the data for an age group $[y1, y2]$, the null model draws random drug pairs (i, j) from the set of all drugs observed for that age group $D^{[y1, y2]}$. The random drug pairs are subsequently checked for DDI status in *DrugBank*, just like the original analysis. This way, the null model has exactly the same number of co-administration occurrences for each age group and gender, but randomly shuffled drug pairs—and only the drugs dispensed for a certain age are randomly shuffled for that age group (details in SI §S5.6). Values reported for the null model are identified with a star (\star); e.g., $RI^{y\star}$ is the risk of interaction per age range derived from the null model.

The null model was not able to reproduce the observed behavior of RI^y , especially for older and younger ages (see Figures 4 and 6 and SI §S5.6 for details). Given the assumption of random drug dispensation, we expected $RI^{y\star}$ to be much higher than the real RI^y —as drugs are “dispensed” without medical knowledge in the null model. Indeed, this is what we observe for younger ages, where $RI^{[0, 29]}$ is much lower than the model’s prediction $RI^{[0, 29]\star}$; same for prediction of number of patients affected (Fig. 4, right). The largest discrepancies between model and real data occur in this age range, especially $[0, 4]$ and $[20, 24]$. However, this

expected behavior is inverted for ages [50+], with the transition occurring around age [40-44] (Fig. 4-center, right). For older ages, the largest discrepancies between model and reality occur for age groups in [50,70], where the predicted number of patients with DDI ($|U^{\Phi*}|$) for age group [60-64] is 16% lower than what is observed (see Fig. 4-right).

This analysis suggests that even though polypharmacy increase plays a role in the observed increase in RI and number affected patients with age (as the null model does predict an increase), other factors are at play in this behavior. It is very surprising, indeed shocking, that there are more cases (and increased risk) of DDI in older age than random (age-conditioned) dispensation of drugs would yield. Several factors may contribute to this observation, from the unavailability in the public system of alternative drugs with less risk of interaction, to insufficient attention to DDI risks of polypharmacy in the medical care of older patients.




Figure 6: Top left. Risk of co-administration per age group and gender, $RC^{[y_1, y_2], g}$. **Top center** Risk of interaction per age group and gender, $RI^{[y_1, y_2], g}$. **Top right.** Absolute number of patients with at least one known DDI co-administration, per age and gender $U^{\Phi, [y_1, y_2], g}$. **Bottom.** Female and male risk of interaction per age group and gender, $RI^{[y_1, y_2], F}$ (left) and $RI^{[y_1, y_2], M}$ (right). For all plots, age groups [90,94], [95,99], [90, 90+] were aggregated into [90+]. Stars (*) depict values computed from the null model, H_0^{nd} , with background filling denoting the 95% confidence interval based on 100 runs. Shaded areas identify specific age groups mentioned in the main manuscript.

We already showed that females overall have a 60% increased risk over men of being administered known DDI (§2.3). But an analysis of the DDI risk increase with age, parsed by gender, reveals additional insights. Specifically, we computed the $RI^{[y_1, y_2], g}$ for each gender $g \in \{M, F\}$ using eq. 8, but for users $u \in U^{[y_1, y_2], g}$,

shown in Figure 6-top-center. Similarly, the $RC^{[y_1, y_2], g}$ is computed for the risk of co-administration per age and gender and shown in Figure 6-top-left (see also Tables S20 and S21 in SI).

Both genders have overall similar risk of co-administration in all age groups. Even during childbearing age, the co-administration risk is similar for the numbers of drugs dispensed, even if slightly larger for females (see filling in Fig. 6-top-left). Interestingly, the story for DDI is quite different. For $RI^{[y_1, y_2], g}$ a clear difference between genders occurs *after* childbearing age, maximized between 50 and 69 years-old (see filling in Fig. 6-top-center and absolute number of patients in Fig. 6-top-right). The gender difference in RI appears after the age of 35, reaching more than a 9% difference for age group [60-64]. At this age, 1 in 3 women who are dispensed two or more drugs concomitantly, are dispensed a known DDI, whereas that ratio is less than 1 in 4 for men.

The random null model reveals additional gender differences. Bottom plots in Figure 6 show the expected gender risk of interaction $RI^{[y_1, y_2], g^*}$, in comparison to observed values, $RI^{[y_1, y_2], g}$, for women (left) and men (right), respectively (see absolute number of patients with DDI per gender in 6-top-right). For both genders, we still observe that the real RI for children and young adults ([0-34]) is well below the null model. However, the transition observed above for older age is much more pronounced for women. In fact, after age 40, observed male RI is largely consistent with the null model, while female risk is higher. This shows that deviation from the null model in older age is mostly explained by increased risk for females—though even matching the random null model is already an unexpected observed behavior as discussed above.

In summary, both genders have similar risk of drug co-administration overall (though 6% higher for women see §2.3), but women face an increased risk of DDI in comparison to men after 30 years of age, which is very pronounced after 50. Moreover, women after 50 face a *worse-than-random* risk of DDI, whereas men face a *same-as-random* risk, except for very few age groups after age 65. Younger groups of both genders, as expected, have a much *lower-than-random* risk of DDI. These facts further emphasize that the DDI phenomenon is not solely driven by increased polypharmacy, as men and women have very similar levels of co-administration risk per age group (see Fig. 6-left). Overall, this suggests that other factors of a social, biological, or medical-care nature are at play.

2.5 Prediction of Patients with DDI

In §2.4 the relationship among number of drugs dispensed (ν^u), co-administrations (Ψ^u), and interactions (Φ^u) for all users, was studied with linear regressions (see Fig. 5). It was shown that only 49% of the variance of Φ^u is predicted by a linear relationship with Ψ^u ($R^2 = 0.487$); and only 37% of variance of Φ^u is predicted by ν^u . Thus, the number of drugs dispensed is a worse predictor than the number of co-administrations of the number of known DDI a patient u is dispensed. More complex multiple regression (MR) models further show that the inclusion of additional variables does not improve much at all the prediction of the variance of Φ^u . For instance, a MR with both ν^u and Ψ^u as independent variables leads only to very marginal increase in the proportion of variance of Φ^u that is predicted: adjusted $R^2 = 0.492$. Adding higher order, nonlinear models also does not improve upon the original regression between Ψ^u and Φ^u . Even the inclusion of demographic variables in MR models does not lead to improvement of R^2 for Φ^u —we analyzed many neighborhood-level variables such as average income, robbery, theft, suicide, transit crime, trafficking and rape rates. Restricting the analysis to the subset of patients who reported education, and using education as an independent categorical variable also yields no improvement, even though completion of elementary school is a significant variable in the MR (see SI §S8.2 for MR and ANOVA details).

Interestingly, even the inclusion of gender as a categorical variable, does not improve R^2 for Φ^u . At first glance, this seems a somewhat counter intuitive result, given the observed high risk of DDI for females in comparison to males (§2.3,2.4). However, the MR analysis revealed that even though women certainly face a much greater risk of DDI, the number of DDI pairs they are administered (Φ^u) is on average similar to that of men, and both have large variance of Φ^u (see Fig. S5). Thus, while gender clearly is a very strong factor in the risk of DDI (risk of at least one interaction), it is not a good predictor of the *specific number* of interactions per patient, which is what the regression analysis above aims to predict.

These regression analysis results show that it is hard to predict the specific number of drug interactions (Φ^u) a patient u is likely to receive, given demographic variables and the numbers of drugs dispensed (ν^u) and drug co-administrations (Ψ^u). But can we use computational intelligence to flag patients who are at

greater risk of DDI with good confidence? Such prediction is certainly desirable both for patient well-being and to decrease the financial burden of DDI to the overall system. We already know that gender (§2.3) and age (§2.4) are very important factors in risk of DDI, but not sufficient for accurate prediction of patients likely to be at risk for being dispensed a known DDI. Next we demonstrate that machine learning methods allow us to predict patients with (at least one) DDI in a more fine-grained and accurate manner.

The prediction of patients with at least one DDI is a binary classification problem, thus we divided all $|U| = 132,722$ patients in two sets: those who were co-administered at least one DDI pair (positive class) and those who were not administered any DDI (negative class). This is an unbalanced classification problem as the two sets are of different size: $|U^\Phi| = 15,527$ (11.70%) in positive and $|\overline{U^\Phi}| = 117,195$ (88.30%) in the negative class. We trained linear kernel Support Vector Machine (SVM) [47] and Logistic Regression (LR) [48] classifiers using stratified 4-fold cross-validation to ensure generalization performance (see details in SI §S9). Age, gender, number of drugs (ν^u) and co-administrations (Φ^u) were used as demographic variables features. In addition, all $|D| = 122$ drugs in the data are used as binary features, whereby if patient u was administered drug i that feature is set to 1 and to 0 otherwise; this allows classifiers to be trained on which drugs, and drug combinations, are most likely to be involved in DDI—removing these features leads to significant reduction in performance (details in SI).

The trained classifiers are compared to two “coin-toss” null models, one unbiased where each class has equal probability, and a biased one based on estimated class frequency. A third, more elaborate null model classifier, finds the best age cutoff for each gender, from which all patients above the cutoff age are considered as having a DDI. This last “age-gender” null model represents a baseline comparison of the best we could do if only gender and age were given for each patient. To assess the performance of all classifiers, in SI §S9 we report several measures. Here, we focus on the Matthew’s Correlation Coefficient (MCC) [49], which is regarded as an ideal measure of the quality of binary classification in unbalanced scenarios such as this [50]. We also report two other measures widely used in machine learning classifier performance, the area under the receiver operating characteristic curve (AUC ROC), and the area under the precision and recall curve (AUC P/R). Both the SVM and LR classifiers reach very good performance, well above null models, with MCC ≈ 0.7 and excellent AUC scores: AUC ROC ≈ 0.97 and AUC P/R ≈ 0.83 . Given the unbalanced classification scenario, MCC and the AUC P/R measures are more informative, with the latter demonstrating that the probability our classifiers will assign a higher score to a randomly chosen DDI patient than to a randomly chosen patient without DDI is near 0.83. The high MCC also shows a strong positive correlation between classifier prediction and the real data. Other classifiers, feature selection and cross-validation techniques can be used to increase performance, but such gains when studying the DDI phenomenon do not typically lead to substantial performance increases [51], so such optimization is beyond the scope of this article.

3 Discussion

Our 18-month longitudinal analysis of EHR data of the entire city of Blumenau (§1) allowed us to study the DDI problem in primary and secondary care in greater detail and for a longer period of time than what has been hitherto possible. In summary, the analysis revealed that $\approx 12\%$ of all patients of the *Pronto* HIS where administered known DDI, which represents 5% of the entire Blumenau population. If we consider only the adult population, $\approx 15\%$ were dispensed a known DDI (more than 6% of the Blumenau adult population). Looking at the type of DDI, we observe that 4% of all patients (5% of adults) were dispensed a *major* DDI likely to result in a very serious ADR (per Drugs.com, see §1.2.1)—almost 2% of the city’s population. Comparing the 5% adult incidence of *major* DDI uncovered in Blumenau, to the 13% rate of “potentially serious” DDI found in (the only comparable but smaller study from) Tayside, Scotland in 2010 [20], suggests that the former region has less than half the rate of interactions than the latter—though a direct comparison is not possible as the list of “potentially serious” DDI from the British National Formulary used by Guthrie *et al* [20] is not publicly available (see §2.1).

We uncovered 181 DDI pairs (see Table 3 for top 20 and SI for complete list) that most likely could have been prevented [12]. These drugs known to interact were nonetheless co-administered to 15,527 people, including more than five thousand who were administered a *major* DDI, likely to require medical attention (§2.1.) In addition to the human suffering caused, patient hospitalization due to *major* DDI leads to a large

financial burden to health-care systems. The most conservative estimate of the cost of DDI to Blumenau during the eighteen months of observation is US\$1M. When extrapolated to the state of Santa Catarina, and Brazil as whole, the conservative estimate is US\$21M and US\$565M, respectively. But less conservative, reasonable estimates put this cost at US\$3.9M, US\$79M and US\$2.1B for city, state, and country, respectively. The range of assumptions pursued in our cost estimates are based on available clinical studies of the prevalence of DDI (see §2.1 for details.) While the field certainly needs more and larger pharmaco-epidemiological studies of the phenomenon, those are outside of the scope of our study. Nonetheless, based on the best available evidence, even our most conservative bound leads to a *per capita* cost of DDI that is more than double what has been previously reported in the literature. Thus, our large-scale longitudinal analysis suggests that previous estimates based on smaller studies likely underestimate the cost of the DDI phenomenon.

We provide comprehensive lists of the DDI pairs uncovered in the data, allowing others to look at specific drugs of interest. The data can be seen from different angles, such as the volume of people affected or the likelihood that certain drugs are co-administered. Some of the most common and important DDI uncovered are discussed in §2.2. They include common medications such as proton-pump inhibitors (Omeprazole), anti-depressants (Fluoxetine), or common analgesics (Ibuprofen), as well as not as common drugs (e.g. Erythromycin). It is noteworthy that often found in our results, was the DDI co-administration of CYP(3A4 and 2D6) inhibitors with their respective enzymes substrates. From our dataset CYP[3A4] inhibitors include Omeprazole, Fluconazole and Erythromycin and their respective substrate include Clonazepam, Simvastatin and Carbamazepine. Recently, the FDA included a comparison list [52] of *in vitro* and clinical inhibitors, inducers and substrates for CYP-mediated metabolisms. In agreement to the work of Molden et al. [16], who studied three primary pharmacies in Norway—comprising 43,500 patients in a 6 month period—, our analysis revealed several such DDI, including the most common DDI pair in our data (Omeprazole, Clonazepam) and several others listed as major and moderate in Tables 3 and S3.

Our characterization of the significant demographic factors in the DDI phenomenon, shows that women in Blumenau are at a greater risk of being dispensed known DDI than men, with a 1.6 risk multiplier (§2.3). When only *major* DDI are considered the risk multiplier is even higher: 1.9. That is, women have almost double the risk of men of being dispensed a *major* known DDI. The relative risk analysis was pursued for all age groups, showing that females face a greater or similar risk of DDI than males in all age groups, with substantially higher risk observed after 50 years of age. Therefore increased risk for females is not confounded by the larger number of women present in the data nor their age.

The risk of interaction for older age groups of both genders is also severe, reaching more than 30% for adults over 70 years of age in comparison to younger age groups (§2.4). While a greater risk for older age groups is expected due to increased polypharmacy with age, a comparison of the observed risk with a null model accounting for random polypharmacy shows that it does not explain the high levels of interactions older age groups face. The null model also revealed an additional gender bias, as older women have a *worse-than-random* and older men have a *same-as-random* risk of DDI. In contrast, younger age groups of both genders have much *better-than-random* risk of DDI (§2.3).

The observed gender and age risks suggest that the specific drugs dispensed to women or older populations are more dangerous and/or that not as much attention to DDI in primary care is reserved for these populations. This can be contrasted with the almost nonexistent number and risk of interactions in children, which are considerably lower than what the null model predicts for polypharmacy at that age. The fact that the specific drugs dispensed greatly improve DDI prediction (§2.5) favors the first hypothesis, but given the age and gender risks observed, it is also clear that the same DDI-prone drugs are administered differently between genders and across age groups. This second hypothesis is strengthened by the fact that removing female-specific hormone therapy from the the DDI network of Figure 3 (§2.3) barely reduces the DDI gender risk (from 60 to 50%). Indeed, the DDI pairs with increased risk for women traverse all drug classes, ranging from cardiovascular to central nervous systems agents that are not gender-specific. (see Figure 3 and Table 4, as well as Tables S11 and S12.) While it was already known that drugs withdrawn from the market for ADR presented greater risks for women [53], our study demonstrates that women also face a higher risk of being dispensed known DDI and that aging populations also require greater attention at the primary- and secondary-care levels. We can speculate that perhaps less concern for DDI is put in the health-care of females and older people, or there are fewer available medication options for the conditions that are more specific

to these sub-populations, forcing the prescription of known DDI. It could be that in older age groups (especially for women) there are fewer alternative drugs (with fewer adverse reactions) in the Blumenau public system, either because they are more expensive or simply because they are not available anywhere. These and other possibilities warrant further study outside the scope of the present article. For instance, would the introduction of newer and costlier drugs into the public system, overcome the financial and human burden of current DDI levels? Nonetheless, since medical care should in principle provide a *better-than-random* risk of DDI for all age groups and genders, this suggests that factors of a social, biological, or medical-care nature are at play.

Regarding additional demographic variables such as income and education, we observed that they do not play a role in the DDI phenomenon in Blumenau—they do not help in the regression analysis and DDI prediction (§2.5). Overall, the DDI phenomenon is stable across the city, and proportional to population size—demonstrating no major inequalities due to income, crime, or other neighborhood social factors (§2.5).

To better understand which drugs are most involved in the DDI phenomenon, including gender differences, we integrated all DDI information of the Blumenau population into easy to visualize DDI networks. The analysis of these networks identifies key drugs and interactions in the DDI phenomenon (§2.3). For instance, Phenytoin, Carbamazepine, and Warfarin have both high degree and high probability of interaction in the DDI Network. This means that they interact with many other drugs and are also likely to interact whenever they are dispensed. The network visualization further provides an easy-to-use formalism to integrate all the information extracted from the analysis: a birds-eye view of the DDI phenomenon we provide to the community. Furthermore, preliminary modularity analysis [54, 55] also shows that drugs form meaningful clusters, which seems to reflect co-administration patterns or comorbidities. For instance, one such module includes most hormone drugs and some CNS agents. Others, reflect drugs prescribed in broad psychological conditions, including either CNS or psychotherapeutic agents. Lastly, another cluster seems to represent heart related conditions, predominantly clustering cardiovascular agent drugs (see Table S23). We intent to pursue a more detailed network analysis in upcoming work.

Towards building patient-centered DDI warning systems, we also demonstrated that a machine learning approach is capable of accurately predicting, or classifying, patients likely to be administered at least one DDI (§2.5). The classification performance achieved demonstrates that standard machine learning methods can accurately identify patients likely to be administered known DDI. Using only their biographical and drug dispensation history, classification performance reaches $MCC = .7$, while simpler models considering only age and gender reach only $MCC = .28$. The most important factor is thus the specific drugs patients take, which is coherent with a patient-centered medicine approach. Other demographic variables such as education and neighborhood affluence do not to play a significant role in the risk for DDI in our data.

The performance achieved by our classifiers demonstrates that a useful computational intelligence pipeline is possible for the *Pronto* HIS to flag specific patients at high risk of DDI. Since the drugs involved in DDI can very well be prescribed by independent physicians who are not aware of (or do not check) what the patient has been already prescribed by other specialists, an accurate, personalized prediction of DDI risk may be more useful for those involved in integrating and managing the care of individual patients or the entire public-health system. Therefore, the automated classification of the type we demonstrate could be used for further assessment by a primary care physician, pharmacist, or public official to look closely at flagged patient records, or even to request a home visit from a community health agent. The personalized DDI alert system does not necessarily have be added to physician-level prescription systems, if another layer of alerts is deemed problematic in an already crowded alert system that physicians work with; those are decisions that each public-health system will have to weight. Still, our work demonstrates that a personalized alert system for DDI is accurate and can be used to reduce the DDI phenomenon not only in future versions of the *Pronto* HIS, but in other cities that have observed high levels of DDI (say as the Tayside region in Scotland [20]). Such personalized patient classification would aid doctors, pharmacists and public-health managers in safely prescribing and dispensing medication, as well as saving public health systems considerable expense. In future work we intend to add such a pipeline to *Pronto* as well as utilize additional sources of data, such as social media, since this HIS already includes such patient handles. Indeed, such data may allow early-warning signal detection of adverse events and DDI, improving patient-centered public health care outcomes [56, 57].

Large-scale analyses of EHR to establish the prevalence of known DDI are rare. Most studies are obtained

from small populations in hospital settings, so they vary by a large margin [6, 11, 12, 58]. Therefore, our study of the entire city of Blumenau at the primary- and secondary-care level offers an important new large-scale measurement of the DDI phenomenon in a public health-care system—a baseline that can be compared to other worldwide locations beyond Brazil, as EHR data becomes available. For instance, are the gender and age risk levels we observed similar in other primary- and secondary-care settings? Are there cultural or public/private differences? Will the health systems of other cities also prove to be unaffected by neighborhood and income levels, etc?

We present a much finer-grained characterization of the DDI phenomenon than previous studies. The analysis includes risk of severity, gender, and age, integrated via data- and network-science analytics that offer a full characterization of the DDI phenomenon, including the ability of DDI to be predicted per patient. Moreover, we used only open-source and public resources (e.g. DrugBank) for all inferences, which facilitate future comparisons to other EHR data; our risk measures, DDI pairs, and network data are provided to those who wish to study its associations further.

Our large-scale epidemiological analysis demonstrates that an integrated data- and network-science approach to public health can uncover biases in the DDI phenomenon as well as yield tools capable of issuing accurate DDI warnings. Both outcomes contribute to preventing ADR from DDI and thus may lead to a significant positive impact on the quality of life of patients and finances of public-health systems. Moreover, the gender and age risks of DDI we discovered, should inform physicians and other health professionals anywhere that such factors are important in the drug management of their patients. We expect the results to increase awareness of those risks we uncovered.

Acknowledgments. The authors would like to thank: The LDTT team, Ana Paula Zanette, David Wild, João Carlos, Jaqueline Elias, Johan Bollen, and Marijn ten Thij. We are also thankful for insightful reviewer comments on earlier versions of this manuscript. RBC is supported by CAPES Foundation grant 18668127, Instituto Gulbenkian de Ciência (IGC), and Indiana University Precision Health to Population Health (P2P) Study. LMR was partially funded by the National Institutes of Health, National Library of Medicine Program, grant 01LM011945-01, by a Fulbright Commission fellowship, and by NSF-NRT grant 1735095 “Interdisciplinary Training in Complex Networks and Systems.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- [1] S. J. C. Davies et al. “Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards”. In: *British Journal of Clinical Pharmacology* 57.4 (2004), pp. 464–472.
- [2] Hajjar ER et al. “Polypharmacy in elderly patients.” In: *Am J Geriatr Pharmacother* 5.4 (Dec. 2007), pp. 345–51.
- [3] Matthijs L Becker et al. “Hospitalisations and emergency department visits due to drug–drug interactions: a literature review”. In: *Pharmacoepidemiology and Drug Safety* 16.6 (2007), pp. 641–651.
- [4] Grace Pfaffenbach et al. “Drug adverse reactions leading to hospital admission”. In: *Rev. Assoc. Med. Bras.* 48.3 (Sept. 2002), pp. 237–241.
- [5] Aline Lins Camargo et al. “Adverse drug reactions: a cohort study in internal medicine units at a university hospital”. In: *Eur J Clin Pharmacol* 62 (2006), pp. 143–149.
- [6] Suely Rozenfeld. “Agravos provocados por medicamentos em hospitais do Estado do Rio de Janeiro, Brasil”. In: *Rev Saúde Pública* 41.1 (Feb. 2007), pp. 108–115.
- [7] Cristiano Moura et al. “Drug-Drug Interactions Associated with Length of Stay and Cost of Hospitalization”. In: *Journal of Pharmacy & Pharmaceutical Sciences* 12.3 (2009).
- [8] N.M.O. Silva et al. “Avaliação de potenciais interações medicamentosas em prescrições de pacientes internadas, em hospital público universitário especializado em saúde da mulher, em Campinas-SP”. In: *Rev Ciênc Farm Básica Apl* 31.2 (2010), pp. 171–176.

- [9] Chen Wu et al. “Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments: A Retrospective Study”. In: *Drug Safety* 35.9 (2012), pp. 769–781.
- [10] Meiry Fernanda Pinto Okuno et al. “Drug interaction in the emergency service”. In: *Einstein (São Paulo)* 11 (Dec. 2013), pp. 462–466.
- [11] Fabíola Giordani Cano and Suely Rozenfeld. “Adverse drug events in hospitals: a systematic review”. In: *Cadernos de Saúde Pública* 25.3 (2009), S360–S372.
- [12] Katja Hakkarainen et al. “Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis”. In: *PLoS ONE* 7.3 (2012), e33236.
- [13] Jane Grimson et al. “The SI Challenge in Health Care”. In: *Commun. ACM* 43.6 (June 2000), pp. 48–55.
- [14] B. Percha and R.B. Altman. “Informatics confronts drug-drug interactions”. In: *Trends in Pharmaceutical Sciences* 34.3 (2013), pp. 178–184.
- [15] Peter B. Jensen et al. “Mining electronic health records: towards better research applications and clinical care”. In: *Nature Reviews Genetics* 13 (May 2012), pp. 395–405.
- [16] Espen Molden et al. “Co-Prescription of Cytochrome P450 2d6/3a4 Inhibitor-Substrate Pairs in Clinical Practice. A Retrospective Analysis of Data From Norwegian Primary Pharmacies”. In: *Pharmacoeconomics and Prescription* 61.2 (2005), pp. 119–125.
- [17] Natália Balera Ferreira Pinto et al. “Drug interactions in prescriptions for elderly hypertensive patients: prevalence and clinical significance”. In: *Rev Enferm UERJ* 22.6 (Nov. 2014), pp. 735–741.
- [18] Srinivasan V Iyer et al. “Mining clinical text for signals of adverse drug-drug interactions”. In: *Journal of the American Medical Informatics Association* 21.2 (2014), pp. 353–362.
- [19] Henry J Lowe et al. “STRIDE –An Integrated Standards-Based Translational Research Informatics Platform”. In: *AMIA Annual Symposium Proceedings 2009* (2009), pp. 391–395.
- [20] Bruce Guthrie et al. “The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010”. In: *BMC medicine* 13.1 (2015), p. 74.
- [21] United Nations Development Programme et al. *Human Development Atlas in Brazil*. atlasbrasil.org.br/. Accessed on Mar 7. 2013.
- [22] United Nations Development Programme. *About human development*. hdr.undp.org/en/humandev/. Accessed on April 4.
- [23] Mauro Marcelo Mattos et al. “PRONTO System: integration between doctors and pharmacists in the basic health care”. In: *Int’l Conf. Software Eng. Research and Practice, SERP’15*. July 2015, pp. 177–180.
- [24] Laboratório de Desenvolvimento e Transferência de Tecnologia. *Pronto: nosso plano é atender você*. <http://www.furb.br/ldtt/>. 2015.
- [25] IBGE. *Instituto Brasileiro de Geografia e Estatística*. ibge.gov.br. 2018.
- [26] DS Wishart et al. “DrugBank: a knowledgebase for drugs, drug actions and drug targets.” In: *Nucleic Acids Res* 36.Database issue (Jan. 2008), pp. D901–6.
- [27] *Drugs.com*. <http://www.drugs.com>. Accessed on Oct 13. 2015.
- [28] Tiago Simas and Luis M. Rocha. “Distance closures on complex networks”. In: *Network Science* 3 (02 June 2015), pp. 227–268.
- [29] Centers for Disease Control and National Center for Health Statistics Prevention. *Multiple Cause of Death 1999-2017 on CDC WONDER Online Database*. <http://wonder.cdc.gov/mcd-icd10.html>. Accessed on Feb 18, 2019. 2019.
- [30] Ministério da Saúde. *Sistema de Informações Hospitalares – SIH/SUS*. datasus.gov.br. Accessed on Jan 6. 2018.

- [31] Anna Patrignani et al. “Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants”. In: *Giornale italiano di cardiologia (2006)* 19.1 (Jan. 2018), pp. 54–61. DOI: [10.1714/2852.28779](https://doi.org/10.1714/2852.28779).
- [32] Francisca González-Rubio et al. “Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study”. In: *Pharmacoepidemiology and drug safety* 20.12 (2011), pp. 1287–1294. DOI: [10.1002/pds.2172](https://doi.org/10.1002/pds.2172).
- [33] ML Ponte et al. “Drug-Drug Interactions: An Under-Estimated Problem”. In: *Drug Safety*. Vol. 33. 10. 2010, pp. 894–894.
- [34] Paulino A. Alvarez et al. “Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina”. In: *International Journal of Risk & Safety in Medicine* 25.3 (2013), pp. 185–192. DOI: [10.3233/JRS-130596](https://doi.org/10.3233/JRS-130596).
- [35] Nicholas P Tatonetti et al. “A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports”. In: *Journal of the American Medical Informatics Association* 19.1 (June 2012), pp. 79–85. DOI: [10.1136/amiajnl-2011-000214](https://doi.org/10.1136/amiajnl-2011-000214).
- [36] Y Caraco et al. “Interethnic difference in omeprazole’s inhibition of diazepam metabolism”. In: *Clin Pharmacol Ther* 58.1 (July 1995), pp. 62–72.
- [37] R T Kubacka et al. “Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects”. In: *Ann Pharmacother* 30.1 (Jan. 1996), pp. 20–6.
- [38] Joyce H S You et al. “Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects”. In: *Journal of clinical pharmacology* 50.10 (Oct. 2010), pp. 1151–8.
- [39] S H Preskorn et al. “Serious adverse effects of combining fluoxetine and tricyclic antidepressants”. In: *Am J Psychiatry* 147.4 (Apr. 1990), p. 532.
- [40] European Medicines Agency. *Updated advice on use of high-dose ibuprofen*. May 2015.
- [41] A Hadley and M P Cason. “Mania resulting from lithium-fluoxetine combination”. In: *Am J Psychiatry* 146.12 (Dec. 1989), pp. 1637–8.
- [42] Ministério da Saúde. *National Relation of Essential Medicines: RENAME 2015*. 9th ed. Brasília: <http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm>, 2015, p. 230.
- [43] U. S. Food and Drug Administration. *Drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury*. <http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm>. Accessed on Nov 7, 2017. 2011.
- [44] Haruka Itakura et al. “Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer”. In: *J Urol* 169.2 (Feb. 2003), p. 613.
- [45] L. Bjerrum et al. “Polypharmacy: correlations with sex, age and drug regimen. A prescription database study”. In: *European Journal of Clinical Pharmacology* 54.3 (1998), pp. 197–202.
- [46] Linton C. Freeman. “A Set of Measures of Centrality Based on Betweenness”. In: *Sociometry* 40.1 (1977), pp. 35–41. ISSN: 00380431.
- [47] Bernhard E. Boser et al. “A Training Algorithm for Optimal Margin Classifiers”. In: *Proceedings of the Fifth Annual Workshop on Computational Learning Theory*. COLT ’92. Pittsburgh, Pennsylvania, USA: ACM, 1992, pp. 144–152.
- [48] D.R. Cox. “Some procedures connected with the logistic qualitative response curve.” In: *Research Papers in Probability and Statistics (Festschrift for J. Neyman)*. Ed. by F.N. David. London: Wiley, 1966, pp. 55–71.
- [49] B.W. Matthews. “Comparison of the predicted and observed secondary structure of T4 phage lysozyme”. In: *Biochimica et Biophysica Acta (BBA) - Protein Structure* 405.2 (1975), pp. 442–451.
- [50] Pierre Baldi et al. “Assessing the accuracy of prediction algorithms for classification: an overview”. In: *Bioinformatics* 16.5 (2000), p. 412.

- [51] Artemy Kolchinsky et al. “Extraction of Pharmacokinetic Evidence of Drug-drug Interactions from the literature”. In: *PLoS ONE* 10.5 (2015), e0122199.
- [52] U. S. Food and Drug Administration. *Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers*. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm>. Accessed on Dec 14, 2017. 2016.
- [53] U.S. Gen. Accounting Office. *Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women*. Tech. rep. GAO-01-286R, Jan. 2001.
- [54] M. E. J. Newman and M. Girvan. “Finding and evaluating community structure in networks”. In: *Phys. Rev. E* 69 (Feb. 2004), p. 026113. DOI: [10.1103/PhysRevE.69.026113](https://doi.org/10.1103/PhysRevE.69.026113).
- [55] M. Rosvall et al. “The map equation”. In: *The European Physical Journal Special Topics* 178.1 (Nov. 2009), pp. 13–23. DOI: [10.1140/epjst/e2010-01179-1](https://doi.org/10.1140/epjst/e2010-01179-1).
- [56] Rion Brattig Correia et al. “Monitoring potential drug interactions and reactions via network analysis of Instagram user timeliness”. In: *Pacific Symposium on Biocomputing*. Vol. 21. 2016, pp. 492–503.
- [57] H. MacLeod et al. “Identifying Rare Diseases from Behavioural Data: A Machine Learning Approach”. In: *Proceedings of the First IEEE Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE 2016)*. 2016.
- [58] Vicente Codagnone Neto et al. “Possible pharmacological interactions in hypertensive and/or diabetic elderly in family health units at Blumenau (SC)”. en. In: *Brazilian Journal of Pharmaceutical Sciences* 46 (Dec. 2010), pp. 795–804.

Appendix A Pronto: academia, government and patients

This section explores some important details about the system that made the data presented in this paper possible and tries to enlighten for the broader impact of such projects.

Apart from systems nationally developed for specific health attention policies—vital statistics, mortality, epidemiology, diabetes, etc—Brazil has no universal electronic health record (EHR) country-wide [A1, A2]. Only secondary care (specialists) or high-cost procedures are fed into federal HIS that contains user identification with their national health card (*Cartão Nacional de Saúde*; CNS), even though the majority of services are performed at primary care [A1]. The CNS, initiated in 1999 [A3], was the initial step towards a unified EHR, but several difficulties were met along these now 19 years of the program [A4, A5, A6]. Thus, it is currently not possible to follow patients across systems—specially those that only access primary care—or request to the system their medical record. At the city level, most big cities have enough funds to buy specialized, private HIS, to develop and implement EHR along with a intra-city public health development plan for its citizens. On the other hand, the vast majority of small and mid-cities (there are 5,336 cities with less than 100.000 inhabitants [A7]) hardly have financial access to the same costly solutions, and most of the information still transits on paper. Still, the necessity to manage several primary care installations, hundreds of health professional agendas and input city-level information into federal HIS takes place.

To address this need in the city of Blumenau, southern Brazil, the municipal government and the regional university (*Universidade Regional de Blumenau*; FURB) joined forces to develop their own open-source HIS to collect and store EHR for its citizens. The system, named *Pronto*, was built by the Laboratory of Technology Development and Transfer (*Laboratório de Desenvolvimento e Transferência de Tecnologia*; LDTT [A8]), a small transdisciplinary [A9] team of professors and students from diverse fields of research—such as compute science, nursing, medicine, dentistry, psychology, communication, and others—at FURB. This enterprise, bridging academia, government and private sector [A10], spun off several scientific quests [A8, A11, A12, A13] in order to enhance the quality of life of patients in Blumenau, broadening FURB’s societal impact, and enabling patients to experience outcomes of scientific research first hand.

After development and deployment, the technology was transferred to the private sector under public bidding laws, and continues to this day to serve as Blumenau’s public health care system under municipal oversight. *Pronto* is currently used in all health institutions throughout the city. From primary to specialized care—hospitals have their own specialized system—and drug dispensing units. The system currently maintains health professional agendas, integrated medical and dental records, and drug prescription and dispensing across more than 30 health care units.

Doctors prescribe medications by selecting drug and dosage in the electronic system. Low-cost drugs can generally be directly dispensed at the primary-care facilities, whereas specialized and higher-cost medication are distributed in three central facilities across the city. All drugs are dispensed by pharmacists who must select in *Pronto* the drug and quantity to be dispensed, allowing the length of administration to be estimated. There is no pill manipulation as all drugs are dispensed in their original sealed packaging. The database also stores inventory information—in case of drug recall, for instance, patients can be contacted in regards to a specific drug lot.

Pronto runs on a custom built decentralized database model where each individual health unit has its own database and a master-to-master replication takes place asynchronously, a design feature due to the unreliable network infrastructure in rural areas. Included in the technical challenges faced by the developing team were also the heterogeneous data feed from multiple health professionals; the transformation from such data data into insightful knowledge to diverse stakeholders, and the constant adaptation to match city as well as state and federal regulations.

A city-wide unified EHR enables a variety of scientific research questions, but most importantly, it permits a holistic approach to public health care. Since patients may enter the system at different clinics throughout the city, the system enables their EHR to be present whenever they go. Moreover, since different health professionals have access to the EHR, health is not only seen at the individual level but also from the family social structure perspective, a government defined strategy for primary care [A14].

Another important system design concept, in line with recent international recommendations for HIS [A15], is that all data models are either patient- or family-centered. This means that all health professionals feed data into a model that enables information exchange to better support decisions focused either on the

individual or their family. For instance, leaving profession restriction on data privacy aside, let's say patient John D., a young teenager individual living with his/her parents, initiates a fluoxetine treatment prescribed by a local physician under complains of anxiety. From their conversations on a follow up examination, the doctor decides to ask the patient to check with a psychiatrist. The psychiatrist then detects traces of acute depression. Within the system the specialist accesses the community health agent notes (a type of family health specialist who monthly surveys households around a primary care health center) who, couple weeks back, checked on the family and reported the household provider lost his/her job. With better social and medical characterization of the problem, all three professionals are able to provide a more accurate, personalized and systematic treatment to the teenager. Furthermore, caring for the family well-being as a whole and the long-term health of other family members, they request a social worker be included to the case. This example, albeit simplistic, demonstrates the potential of a holistic approach to public health, focused on prevention, and enabled by a city-wide EHR.

References

- [A1] Jairnilson Paim et al. "The Brazilian health system: history, advances, and challenges". In: *The Lancet* 377.9779 (May 2011), pp. 21–27.
- [A2] Ministério da Saúde. "Final report of the 14th National Health Conference". In: *Conferência Nacional de Saúde*. Brasília, 2012. (Visited on 08/05/2015).
- [A3] Rosani Evangelista da Cunha. "National Health Card – the implementation and conception challenges of a national system used to extract information from health services". In: *Ciência e Saúde Coletiva* 7.4 (2002), pp. 869–878.
- [A4] Roberto A Hexsel et al. "Arquitetura do Sistema Cartão Nacional de Saúde". In: *VIII Congresso Brasileiro de Informática em Saúde*. Sept. 2002.
- [A5] Tulio Batista Franco. "Processos de trabalho e transição tecnologica na saude: um olhar a partir do Sistema Cartão Nacional de Saude". Doctorate. Campinas, SP: Faculdade de Ciências Médicas, 2003.
- [A6] Jorge Lorenzetti et al. "Gestão em Saúde no Brasil: Diálogo com Gestores Públicos e Privados". In: *Texto Contexto Enferm* 23.2 (Apr. 2014), pp. 417–425.
- [A7] IBGE. *Instituto Brasileiro de Geografia e Estatística*. ibge.gov.br. 2018.
- [A8] Laboratório de Desenvolvimento e Transferência de Tecnologia. *Pronto: nosso plano é atender você*. <http://www.furb.br/ldtt/>. 2015.
- [A9] Bernard C. K. Choi and Anita W. P. Pak. "Multidisciplinarity, interdisciplinarity and transdisciplinarity in health research, services, education and policy: 1. Definitions, objectives, and evidence of effectiveness." In: *Send to Clin Invest Med* 29.6 (Dec. 2006), pp. 351–64.
- [A10] H. Etkowitz. *The Triple Helix: University-Industry-Government Innovation in Action*. Taylor & Francis, 2010.
- [A11] Luciana Pereira de Araújo et al. "Using participatory design in designing phase of collaborative systems". In: *Proc. of the 2014 IEEE 18th Inte'l Conf. on Comp. Supported Cooperative Work in Design (CSCWD)*. Hsinchu, Taiwan, May 2014, pp. 633–637.
- [A12] Luciana Pereira de Araújo et al. "Mobile Application to Support Community Health Agents using GeneXus Smart Devices". In: *Proc. of the 2015 Inter'l Conf. on Innovative Mobile and Internet Services in Ubiquitous Computing (IMIS)*. Blumenau, Brazil, July 2015.
- [A13] Mauro Marcelo Mattos et al. "PRONTO System: integration between doctors and pharmacists in the basic health care". In: *Int'l Conf. Software Eng. Research and Practice, SERP'15*. July 2015, pp. 177–180.
- [A14] Ministério da Saúde. *National Primary Health Care Policy*. 1st ed. Brasília: Ministério da Saúde, 2012, p. 110. URL: <http://189.28.128.100/dab/docs/publicacoes/geral/pnab.pdf>.

[A15] The Lancet. “Making sense of our digital medicine Babel”. In: *The Lancet* 392.10157 (Nov. 2018), p. 1487. DOI: [10.1016/S0140-6736\(18\)32545-5](https://doi.org/10.1016/S0140-6736(18)32545-5).

Appendix B Notation and symbol reference

For quick reference, this appendix lists symbols used in the main manuscript and supplemental information.

symbol	description
U, u	Set of patients $u \in U \subset \mathbb{N}$ to whom at least one drug matched to DrugBank was dispensed.
D, i	Set of drugs $i \in D \subset \mathbb{N}$ available for dispensation in the public health care system of Blumenau; $D^u \subseteq D$ is the subset of drugs administered to patient u .
$A_i^u \equiv \{a_n^{i,u}\}$, $a_n = (i, t_s, t_f)_n$	Set of administration intervals a_n . Each interval is defined as a n-tuple comprised of drug i and its administration start t_s (the dispensation), end time t_f , and administration length $t_t = (t_f - t_s)$, where $t \in \mathbb{N}$ (in days).
α_i^u	Number of drug intervals a_n (dispensations) to patient u . $\alpha_i^u = A_i^u $
ν^u	Number of distinct drugs dispensed to patient u . $\nu^u \equiv D^u $
λ_i^u	Administration length (in days) of drug i (across possibly multiple dispensations) for patient u .
$\lambda_{i,j}^u$	Co-administration length (in days) of drug pair (i, j) (across possibly multiple dispensations) for patient u . See Eq. S2 for overlap computation.
$\Delta, \delta_{i,j}$	$\Delta : D \times D \rightarrow 0, 1$ is a symmetrical binary relation (symmetrical graph) on set D , denoting the drug pairs having ($\delta_{i,j} = 1$) a known DDI in DrugBank [B1], or not ($\delta_{i,j} = 0$); $\delta_{i,j} = \delta_{j,i}$, $\delta_{i,i} = 0$ (no self relation).
$\tau_{i,j}^u$	Normalized length of co-administration between drugs i and j for patient u . $\tau_{i,j}^u \in [0, 1]$ is a Jaccard measure between the number of days drug pair (i, j) was co-administered (intersection) divided by the number each drug, i and j was administered individually (union). $\tau_{i,j}^u = \lambda_{i,j}^u / (\lambda_i^u + \lambda_j^u - \lambda_{i,j}^u)$
Ω	The total city population. Also Ω^N and $\Omega^{y,g}$ are population numbers for a specific neighborhood N or for a certain age group y and gender g , respectively.

Table 5: Basic symbols used in the paper

symbol	description
g	Gender where $g \in \{M, F\}$.
y	Age where $y \in \mathbb{N}$. y can also be grouped into age intervals (e.g., $y^{[0-4]}$, $y^{[5-9]}$, ..., $y^{[95-99]}$, $y^{[>99]}$) following IBGE [B2] convention.
N	Neighborhood $N \in \mathbb{N}$ in the city of Blumenau.
E	Education levels $N \in \mathbb{N}$ following IBGE [B2] convention.
s	DDI severity based on Drugs.com [B3] classification. $s \in \{\text{major, moderate, minor, *, none}\}$

Table 6: Symbols used in indexing.

symbol	description
α	Total number of administration intervals dispensed. $\alpha = \sum_{u \in U, i \in D^u} \alpha_i^u$
$\psi_{i,j}^u$	Logical variable denoting whether drug pair (i, j) was co-administered by patient u . $\psi_{i,j}^u = (\lambda_{i,j}^u > 0)$
Ψ^u	Number of distinct co-administrations for patient u . $\Psi^u = \sum_{i,j \in D^u} \psi_{i,j}^u$
$\Psi_{i,j}$	Number of distinct co-administrations between drug pair (i, j) for all patients. $\Psi_{i,j} = \sum_{u \in D^u} \psi_{i,j}^u \equiv U_{i,j} $
Ψ	Total number of drug co-administrations. $\Psi = \sum_u \Psi^u = \sum_{i,j} \Psi_{i,j}$
$\varphi_{i,j}^u$	Logical variable denoting whether drug pair (i, j) was co-administered to patient u and the pair is listed in DrugBank as a known DDI. $\varphi_{i,j}^u = (\psi_{i,j}^u > 0 \wedge \delta_{i,j} = 1)$
Φ^u	Number of distinct co-administration for patient u known to be a DDI. $\Phi^u = \sum_{i,j \in D^u} \varphi_{i,j}^u$
$\Phi_{i,j}$	Number of distinct co-administrations known to be a DDI between drug pair (i, j) , for all patients. $\Phi_{i,j} = \sum_{u \in U} \varphi_{i,j}^u$
Φ	Total number of distinct drug interaction pairs. $\Phi = \sum_u \Phi^u = \sum_{i,j} \Phi_{i,j}$
$U^{\nu > x}$	Subset of patients who had at least $x \in \mathbb{N}$ distinct drugs administrations. $U^{\nu > x} = \{u \in U : \nu^u > x\}$.
U^Ψ	Subset of patients who had at least 1 drug co-administration. $U^\Psi = \{u \in U : \Psi^u > 0\}$.
$U_{i,j}^\Psi$	Subset of patients who were co-administered drug pair (i, j) . $U_{i,j}^\Psi \equiv \{u \in U : \psi_{i,j}^u = 1\}$.
U^Φ	Subset of patients who had at least 1 known DDI. $U^\Phi = \{u \in U : \Phi^u > 0\}$.
$U_{i,j}^\Phi$	Subset of patients who were co-administered known DDI pair (i, j) . $U_{i,j}^\Phi \equiv \{u \in U : \varphi_{i,j}^u = 1\}$.
U^g	Subset of patients per gender g . $U^g \equiv \{u \in U : \text{gender}(u) = g\}$.
$U^{[y_1, y_2]}$	Subset of patients per age bracket $[y_1, y_2]$. $U^{[y_1, y_2]} \equiv \{u \in U : \text{age}(u) \in [y_1, y_2]\}$.
U^N	Subset of patients per neighborhood N . $U^N \equiv \{u \in U : \text{neighborhood}(u) \in \mathbb{N}\}$.
U^E	Subset of patients per education level E . $U^{E=\emptyset}$ is the subset of patients who did not report their education level.
$\gamma_{i,j}^\Psi, \gamma_{j,i}^\Psi$	Normalized number of patients that were co-administering drug pair (i, j) . $\gamma_{i,j}^\Psi = U_{i,j}^\Psi / U_i $ and $\gamma_{j,i}^\Psi = U_{i,j}^\Psi / U_j $. Note $\gamma_{i,j}^\Psi \neq \gamma_{j,i}^\Psi$.
$\gamma_{i,j}^\Phi, \gamma_{j,i}^\Phi$	Normalized number of patients that were co-administering drug pair (i, j) , known to be a DDI. $\gamma_{i,j}^\Phi = U_{i,j}^\Phi / U_i $ and $\gamma_{j,i}^\Phi = U_{i,j}^\Phi / U_j $. Note $\gamma_{i,j}^\Phi \neq \gamma_{j,i}^\Phi$.
$\tau_{i,j}^\Psi$	Normalized length of co-administration of drug pair (i, j) , for all patients. $\tau_{i,j}^\Psi = \sum_{u \in U_{i,j}^\Psi} \tau_{i,j}^u / U_{i,j}^\Psi $
$\tau_{i,j}^\Phi$	Normalized length of co-administration of drug pair (i, j) , known to be a DDI, for all patients. $\tau_{i,j}^\Phi = \tau_{i,j}^\Psi \times \delta_{i,j}$

Table 7: Administration, co-administration and interaction symbols

symbol	description
RRC^F, RRC^M	Relative risk of co-administration for women and men, respectively. For computation details see §S5.
RRI^F, RRI^M	Relative risk of interaction for women and men, respectively. For computation details see §S5.
$PI(i)$	Probability of interaction, or the propensity of a drug i to be involved in a DDI with all drugs it is co-administered with in the data. $PI(i) = \sum_j \Phi_{i,j} / \sum_j \Psi_{i,j}$

Table 8: Relative Risks and Probabilities

References

- [B1] DS Wishart et al. “DrugBank: a knowledgebase for drugs, drug actions and drug targets.” In: *Nucleic Acids Res* 36.Database issue (Jan. 2008), pp. D901–6.
- [B2] IBGE. *Instituto Brasileiro de Geografia e Estatística*. ibge.gov.br. 2018.
- [B3] *Drugs.com*. <http://www.drugs.com>. Accessed on Oct 13. 2015.

Supplemental Materials

S1 Blumenau, Santa Catarina, Brazil	2
S2 Computation details	2
S3 Pronto Dataset	4
S3.1 Patient education	4
S3.2 Public health care system dispensation	5
S4 Drug Interactions	6
S4.1 Interactions per severity	13
S4.2 Interactions per gender	13
S4.3 Interactions per age	14
S4.4 Interaction per age and gender	14
S5 Risk and Relative Risk measures	16
S5.1 Relative Risk per gender	16
S5.2 Relative Risk per severity	20
S5.3 Risk Measures per age	20
S5.4 Risk Ratios per number of drug	21
S5.5 DDI Networks	22
S5.6 Null Model for RI^y	31
S6 Neighborhood Results	32
S7 Projected Cost of DDI in hospitalizations	35
S8 Statistical modeling	38
S8.1 Simple Regression (SR) models	39
S8.2 Multiple Regression (MR) models	42
S8.3 Linear Mixed-Effect (LMM) models	47
S9 Patient classification	49
S9.1 Simple model	50
S9.2 Complete model	51
S9.3 No Drugs model	51
S9.4 Precision & Recall and Receiver Operating Characteristic curves	51
S9.5 Feature loadings	51

S1 Blumenau, Santa Catarina, Brazil

In order to provide readers some geographical context, Figure S1 shows the location of Blumenau in Brazil as well as the city neighborhoods with their individual population density.




Figure S1: (left) Political map of Brazil with state borders. Arrow denotes city of *Blumenau* in the state of *Santa Catarina*. (right) Political map of *Blumenau* with neighborhoods (N) annotated and mapped to city population, $P(\Omega^N)$. Data from IBGE[S1].

S2 Computation details

This section describes variables used in the main manuscript. It also details computations in order to facilitate replication. A quick symbol reference can be seen in Appendix B. All computations were done in python using custom built scripts.

In our analysis, patients are denoted by $u \in U$ and drugs by $i, j \in D$; $U_i \in U$ is the subset of users who were dispensed drug i , $D^u \subseteq D$ is the subset of drugs dispensed to patient u , and $\nu^u \equiv |D^u|$ is the number of distinct drugs dispensed to patient u . Drugs are dispensed to patients in administration intervals $a = (i, t_s, t_f)$, where t_s and t_f are the start and end times (in days; $t \in \mathbb{N}$) of drug administration, and $(t_f - t_s)$ represents the total length of administration, respectively. The total number of drug i intervals dispensed to patient u is $\alpha_i^u = |A_i^u|$, where $A_i^u \equiv \{a_n^{i,u}\}$ is the set of administration intervals for patient u of drug i in the data, with $n = 1, \dots, \alpha_i^u$.

Administration length. The total number of days patient u administered drug i (possibly over n distinct dispensations) is then computed as

$$\lambda_i^u = \sum_1^n a_n^{i,u} . \quad (\text{S1})$$

Co-administration length. For each drug pair (i, j) administered to patient u , $\forall i, j \in D^u$, we identify the possible length of administration overlap between administrations of both drugs, $A_i^u \equiv \{a_n^{i,u}\}$ and $A_j^u \equiv \{a_m^{j,u}\}$, assuming without loss of generality that $t_{s,n} \leq t_{s,m}$, as

$$\lambda_{i,j}^u = \sum_{\substack{a_n \in A_i^u \\ a_m \in A_j^u}} \begin{cases} (t_{f,n} - t_{s,m}) , & \text{iff } (t_{f,n} < t_{f,m}) \\ (t_{f,m} - t_{s,m}) , & \text{otherwise} \end{cases} . \quad (\text{S2})$$

Co-administrations. To be able to discriminate patients with a specific co-administration, and to compute how many were prescribed such co-administration, we define

$$\psi_{i,j}^u = (\lambda_{i,j}^u > 0) \quad , \quad (\text{S3})$$

a logical variable measuring whether patient u had at least one day of co-administration between drug pair (i, j) ; $\psi_{i,j}^u \in \{0, 1\}$. Then, the total number of co-administrations, per patient u or drug pair (i, j) is calculated as

$$\Psi^u = \sum_{i,j \in D^u} \psi_{i,j}^u \equiv |U^\Psi| \quad , \quad \Psi_{i,j} = \sum_{u \in U} \psi_{i,j}^u \equiv |U_{i,j}^\Psi| \quad . \quad (\text{S4})$$

Interactions. Next, we define a symmetrical binary map, also known as a symmetrical graph, $\Delta : D \times D \rightarrow \{0, 1\}$ on set D indicating if a drug pair $(i, j) \in D \times D$ has $(\delta_{i,j} = 1)$ a known DDI in DrugBank, or not $(\delta_{i,j} = 0)$. Then, to discriminate patients with a known DDI we define

$$\varphi_{i,j}^u = (\psi_{i,j}^u = 1 \wedge \delta_{i,j} = 1) \quad , \quad (\text{S5})$$

a logical variable measuring whether patient u had at least one day of co-administration between drug pair (i, j) and this drug pair is listed in DrugBank as a known DDI; $\varphi_{i,j}^u \in \{0, 1\}$. The total number of co-administrations of known DDI, per patient u or drug pair (i, j) is calculated as

$$\Phi^u = \sum_{i,j \in D^u} \varphi_{i,j}^u \equiv |U^\Phi| \quad , \quad \Phi_{i,j} = \sum_{u \in U} \varphi_{i,j}^u \equiv |U_{i,j}^\Phi| \quad . \quad (\text{S6})$$

Normalized interactions. To identify the drug pairs (i, j) with the largest ‘‘footprint’’ in the population, we compute the pairs that are most co-administered in the population: those pairs that maximize $|U_{i,j}^\Psi|$. Out of these, we are naturally most interested in the drug pairs that are known DDI and are most co-administered: those that maximize $|U_{i,j}^\Phi|$. Two asymmetrical normalized versions of this measure are computed as

$$\gamma_{i,j}^\Phi = \frac{|U_{i,j}^\Phi|}{|U_i|} \quad , \quad \gamma_{j,i}^\Phi = \frac{|U_{i,j}^\Phi|}{|U_j|} \quad , \quad (\text{S7})$$

which conditions the number of users co-administered drug pair (i, j) on the number of users that are administering either drug, i or j .

Normalized lengths. To obtain a normalized value of co-administration length, we also define

$$\tau_{i,j}^u = \frac{\lambda_{i,j}^u}{\lambda_i^u + \lambda_j^u - \lambda_{i,j}^u} \quad , \quad (\text{S8})$$

where $\tau_{i,j}^u \in [0, 1]$, and can be thought of a probability—or a Jaccard measure where values indicate a proximity [S2, S3, S4]—of having drug pair (i, j) co-administered in relation to each drug’s individual length of administration, for patient u .

Intuitively, if patient u always administers drugs i and j simultaneously, $\tau_{i,j}^u \rightarrow 1$. Conversely, drug pairs with small co-administration overlap have $\tau_{i,j}^u \rightarrow 0$. A normalized measure for the entire population is computed as

$$\tau_{i,j}^\Psi = \frac{\sum_{u \in U_{i,j}^\Psi} \tau_{i,j}^u}{|U_{i,j}^\Psi|} \quad , \quad (\text{S9})$$

where this proximity measure defines a weighted graph T^Ψ [S3] on set D where edges are $\tau_{i,j}^\Psi \in [0, 1]$ and link drugs that were co-administered in the population. $\tau_{i,j}^\Psi$ is larger when drug pairs (i, j) tend to be co-administered when either i or j is administered (correlated), and smaller otherwise (independent). To obtain a subgraph T^Φ , restricted to known DDI pairs, we compute $\tau_{i,j}^\Psi \times \delta_{i,j}$; thus T^Φ is a weighted version of Δ . In practice, due to computational complexity, we only compute $\tau_{i,j}^\Psi$ for drug pairs known to be a DDI

($\varphi_{i,j}^u > 0$).

Drug classes. For drug pairs co-administered and known to be DDI, we gathered their respective drug class hierarchy from Drugs.com [S5]. In the main manuscript we used the top level of this hierarchy to distinguish different types of drugs (i.e., cardiovascular agents, hormones, etc). For example, Fluoxetine⁴ has the following hierarchy: “Psychotherapeutic agents”, “Antidepressants”, and “Selective serotonin reuptake inhibitors”, where the base class used was “Psychotherapeutic agents”.

S3 Pronto Dataset

This section summarizes demographic information of patients in the *Pronto* dataset.

S3.1 Patient education

To place the education numbers acquired via *Pronto* system in perspective, we gathered data from the Atlas Brasil Blumenau⁵, a United Nations Program for the Development of Brazil (PNUD).

In 2010 the city of Blumenau reported that the proportion of children age 5-6 in school was 88.41%. For the same year the proportion of children age 11-13 attending the last years of elementary school was 90.41%. The proportion of teenagers age 15-17 having completed elementary school was 72,34%. And the proportion of young adults age 18-20 who completed high school was 51.38%. Nationally these number were 91.12%, 84,86%, 57.24% and 41.01%, respectively. The average length of study for children in school age was 10.81 years for Blumenau and 9.97 for the state of Santa Catarina. The number of adults, age 18 or older, who completed elementary school was 65.88% for Blumenau and 54.92% for the state. Considering adults age 25 or older: 2,13% were illiterate, 61,55% completed elementary school, 41,22% completed high school and 15,49%, completed college. Nationally, these proportions are 11,82%, 50,75%, 35,83% and 11,27%, respectively.

Below is the self-reported education distribution for unique patients of *Pronto*. Education level is requested upon registration or profile update and no documents are required. However, staff in health centers are trained to retrieve the best response from patients without their embarrassment—by displaying a card with enumerated answers asking them to respond the according letter.

<i>E</i>	U^E	%	Ac. %	%	Ac. %
Cant read/write	4,720	0.0356	0.0356	0.0773	0.0773
Can read/write a note	3,104	0.0234	0.0590	0.0508	0.1281
Incomplete elementary	28,557	0.2152	0.2741	0.4677	0.5958
Complete elementary	7,516	0.0566	0.3307	0.1231	0.7189
Incomplete high school	4,650	0.0350	0.3658	0.0762	0.7951
Complete high school	8,797	0.0663	0.4321	0.1441	0.9391
Incomplete college	1,654	0.0125	0.4445	0.0271	0.9662
Complete college	1,823	0.0137	0.4583	0.0299	0.9961
Espec./Residency	192	0.0014	0.4597	0.0031	0.9992
Masters	26	0.0002	0.4599	0.0004	0.9997
Doctoral	21	0.0002	0.4601	0.0003	1.0000
Not reported	71,662	0.5399	1.0000		
Total	132,722	1.0000			

Table S1: Education level of *Pronto* patients

⁴<https://www.drugs.com/fluoxetine.html>

⁵http://atlasbrasil.org.br/2013/pt/perfil_m/blumenau_sc

E	U^E	%	Ac. %	%	Ac. %
Cant read/write	1,245	0.0134	0.0134	0.0257	0.0257
Can read/write a note	2,552	0.0274	0.0408	0.0528	0.0785
Incomplete elementary	23,983	0.2577	0.2985	0.4957	0.5742
Complete elementary	6,733	0.0723	0.3708	0.1392	0.7134
Incomplete high school	3,126	0.0336	0.4044	0.0646	0.7780
Complete high school	7,544	0.0811	0.4855	0.1559	0.9340
Incomplete college	1,233	0.0132	0.4987	0.0255	0.9594
Complete college	1,732	0.0186	0.5173	0.0358	0.9952
Espec./Residency	187	0.0020	0.5194	0.0039	0.9991
Masters	25	0.0003	0.5196	0.0005	0.9996
Doctoral	18	0.0002	0.5198	0.0004	1.0000
Not reported	44,690	0.4802	1.0000		
Total	93,068	1.0000			

Table S2: Education level of *Pronto* patients age 25 or older

S3.2 Public health care system dispensation

The monthly drug dispensation in the city of Blumenau can be seen in Figure S2. We conjecture that the smaller number of dispensed medication during summer months (Dec-Feb) are due to a difference portion of the city population taking mandatory 30-days vacations yearly, which are usually split in two 10-days vacations during the summer months, and another 10-days during the winter months. The Atlantic Ocean coast, only a 40 minutes drive east, is a common destination for Blumenau citizens on weekends and holidays. Carnival (*Carnaval*), which is usually held at the end of February, also draws many citizens for a 1 week vacation on the coast.




Figure S2: Total number (in thousands) of drug intervals dispensed (α) monthly in the city of Blumenau. Orange fill shows average temperature range in Blumenau (in $^{\circ}\text{C}$). There is no correlation (0.06) between drug dispensation (in non shaded area) and average temperature in the same period. Grey area shows months in which the *Pronto* HIS was under field deployment.

Since Brazil also has private health care and pharmaceutical systems, patients of the public system are often thought to be from lower economical classes, a hypothesis we investigated.

Indeed, the proportion of *Pronto* patients for most age brackets in the four richest neighborhoods—namely *Jardim Blumenau*, *Bom Retiro*, *Victor Konder* and *Vila Formosa*—are significantly smaller than in other neighborhoods (t -test, $p < 3^{-20}$). This strongly suggests that patients from the richest neighborhoods use the public drug dispensation system much less than equivalent groups from other areas (see Figure S3).

The only exception to this pattern was found for females age 45-74 from *Bom Retiro* and *Victor Konder* (2nd and 3rd richest neighborhoods, respectively), who, while using the system less than the same group in other neighborhoods, do use it significantly more than those from the richest neighborhood, *Jardim Blumenau* (t -test, $p < 2^{-6}$). This suggests that these two higher-income neighborhoods have a population of older women who uses the public health care system. This may be an interesting phenomenon warranting further sociological studies.




Figure S3: Top. Neighborhood average income in Brazilian Reais (R\$) [S1]. **Middle & bottom.** Age-neighborhood bins of male (middle; $U^{N,y,g=M}/\Omega^{N,y,g=M}$) and female (bottom; $U^{N,y,g=F}/\Omega^{N,y,g=F}$) patients registered in *Pronto* with at least one drug dispensed and matched to DrugBank. Each bin is a probability-like value of patients normalized by official census population data collected and defined by IBGE [S1]. Green bins represent values above 1, meaning our data has more patients than IBGE[S1] census data. Conversely, cyan bins represent values where our data contains no patient.

S4 Drug Interactions

This section lists DDI found in the analysis. Data source for these interactions were retrieved from <http://wifo5-04.informatik.uni-mannheim.de/drugbank/>. This dataset was last updated in 2011 and it contains the DrugBank ID for each pair of drugs and a textual description of the interaction. The latest (version 5.0) version of the DrugBank database includes a much larger number of interaction although much of the interaction at the top of the list could not be validated from a second source, namely Drugs.com [S5]. Thus we opted for a more conservative approach with fewer number of overall unique interaction that we could attribute a severity score from a second data source.

From Drugs.com [S5], the description of each severity score is as follow:

- *Major*: Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
- *Moderate*: Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.

- *Minor*: Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Note that some interactions present in DrugBank were not found in Drugs.com. These are marked as *None*.

rank Φ	$ U_{i,j}^\Phi $	$\gamma_{i,j}^\Phi$	$\tau_{i,j}^\Phi$	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRR_{i,j}^F$	severity	interaction
1	5078	0.19	0.26	102 ± 95	Omeprazole	Clonazepam	2.28	Moderate	Omeprazole increases the effect of benzodiazepine
2	2117	0.18	0.23	54 ± 74	ASA	Ibuprofen	1.42	Major	Both of them reduces ASA cardioprotective effects
3	1466	0.20	0.21	58 ± 77	ASA	Ibuprofen	1.88	Moderate	Risk of inhibition of renal prostaglandin
4	1249	0.10	0.60	141 ± 124	ASA	Glyburide	0.89	Moderate	The salicylate increases the effect of sulfonylureas
5	1190	0.10	0.45	127 ± 127	Amitriptyline	Fluoxetine	3.35	Major	Fluoxetine increases the effect and toxicity of tricyclics
6	989	0.04	0.27	87 ± 86	Omeprazole	Diazepam	1.21	Moderate	Omeprazole increases the effect of benzodiazepine
7	892	0.14	0.20	56 ± 61	Flucanazole	Sildenafil	2.63	Major	Increased risk of hypotension/rhabdomyolysis
8	752	0.06	0.12	30 ± 50	ASA	Dexamethasone	1.30	Moderate	The corticosteroid weakens the effect of salicylates
9	627	0.10	0.16	46 ± 81	Prednisone	Clonazepam	3.40	None	Increases the effect of benzodiazepine
10	609	0.07	0.19	48 ± 93	Atenolol	ASA	0.94	Moderate	The corticosteroid decreases the effect of salicylates
11	535	0.07	0.58	152 ± 132	Atenolol	Glyburide	1.22	Moderate	The beta-blocker decreases the symptoms of hypoglycemia
12	524	0.50	0.20	243 ± 188	Haloperidol	Ibuprofen	0.62	Moderate	Anticholinergic inc. risk of psychosis and tardive dyskinesia
13	504	0.21	0.25	44 ± 62	Proparanolol	Ibuprofen	3.42	Moderate	Risk of inhibition of renal prostaglandin
14	500	0.15	0.40	52 ± 75	Furosemide	Ibuprofen	1.93	Moderate	NSAID decreases diuretic and antihypertensive effects of loop diuretic
15	496	0.04	0.36	103 ± 87	Diltiazem	Gliclazide	0.78	None	The salicylate increases the effect of sulfonylureas
16	470	0.63	0.55	160 ± 133	Digoxin	Simvastatin	1.27	Major	Increases the effect and toxicity of sulfonylureas
17	385	0.59	0.60	155 ± 125	Fluoxetine	Furosemide	0.61	Moderate	Possible electrolyte variations and arrhythmias
18	377	0.03	0.50	143 ± 138	Fluoxetine	Carbamazepine	0.98	Moderate	Increases the effect of carbamazepine
19	364	0.17	0.28	110 ± 106	Carbamazepine	Simvastatin	0.94	Moderate	Decreases the effect of the statin
20	355	0.03	0.26	86 ± 84	Fluoxetine	Proparanolol	4.76	Moderate	The SSRI increases the effect of the beta-blocker
21	284	0.04	0.42	66 ± 57	Levothyroxine	Iron (II) Sulfate	4.59	Moderate	Iron decreases absorption of levothyroxine
22	272	0.42	0.55	140 ± 114	Digoxin	Fluoxetine	3.08	Minor	Increased digoxin levels and decreased effect with spironolactone
23	257	0.16	0.42	123 ± 130	Imipramine	Fluoxetine	3.08	Major	Fluoxetine increases the effect and toxicity of tricyclics
24	244	0.01	0.19	42 ± 40	Fluconazole	Amitriptyline	4.25	Moderate	The imidazole increases the effect and toxicity of the tricyclic
25	244	0.04	0.22	57 ± 77	Acetaminophen	Warfarin	1.07	Minor	Acetaminophen increases the anticoagulant effect
26	222	0.02	0.49	151 ± 145	Amitriptyline	Carbamazepine	0.99	Moderate	The tricyclics increases the effect of carbamazepine
27	222	0.02	0.47	148 ± 139	Fluoxetine	Lithium	1.79	Major	The SSRI increases serum levels of lithium
28	201	0.03	0.34	107 ± 95	Atenolol	Gliclazide	1.09	None	The beta-blocker decreases the symptoms of hypoglycemia
29	186	0.18	0.43	142 ± 156	Haloperidol	Carbamazepine	0.62	Moderate	Carbamazepine decreases the effect of haloperidol
30	179	0.08	0.09	10 ± 6	Ethinyl Estradiol	Amoxicillin	126.09	Moderate	Anti-infectious agent could decrease effect of oral contraceptive
31	173	0.27	0.41	109 ± 96	Digoxin	Carvedilol	0.53	Moderate	Carvedilol increases levels/effect of digoxin
32	155	0.02	0.22	68 ± 80	Amitriptyline	Salbutamol	2.83	Moderate	The tricyclic increases the sympathomimetic effect
33	154	0.02	0.45	144 ± 122	Levothyroxine	Warfarin	1.05	Moderate	Thyroid hormones increase the anticoagulant effect
34	154	0.01	0.33	94 ± 92	Fluoxetine	Norriptyline	2.70	Major	Fluoxetine increases the effect and toxicity of tricyclics
35	149	0.28	0.32	115 ± 109	Phenylethanolamine	Omeprazole	0.80	Moderate	Omeprazole increases the effect of hydantoin
36	148	0.14	0.49	168 ± 160	Haloperidol	Lithium	1.31	Major	Possible extrapyramidal effects and neurotoxicity
37	147	0.02	0.23	60 ± 76	Atenolol	Salbutamol	1.37	Moderate	Antagonism
38	130	0.00	0.08	27 ± 45	Ibuprofen	Lithium	2.08	Moderate	The NSAID increases serum levels of lithium
39	123	0.00	0.16	31 ± 43	Ibuprofen	Carvedilol	0.88	Moderate	Risk of inhibition of renal prostaglandins
40	117	0.18	0.46	126 ± 127	Digoxin	Hydrochlorothiazide	0.95	Moderate	Possible electrolyte variations and arrhythmias
41	116	0.02	0.14	9 ± 7	Nerifloxacin	Iron (II) Sulfate	6.14	Moderate	Formation of non-absorbable complexes
42	103	0.16	0.43	113 ± 110	Digoxin	Levothyroxine	1.50	Moderate	The thyroid hormones decreases the effect of digoxin
43	102	0.01	0.23	76 ± 80	Fluoxetine	Carvedilol	1.50	Moderate	The SSRI increases the effect of the beta-blocker
44	102	0.01	0.04	4 ± 4	Diclofenac	Alendronate	9.61	Moderate	Increased risk of gastric toxicity
45	101	0.01	0.25	92 ± 81	Fluoxetine	Warfarin	1.46	Moderate	The SSRI increases the effect of anticoagulant
46	95	0.04	0.57	140 ± 126	Proparanolol	Glyburide	1.61	Moderate	The beta-blocker decreases the symptoms of hypoglycemia
47	91	0.01	0.52	154 ± 142	Atenolol	Diltiazem	1.19	Major	Increased risk of bradycardia
48	90	0.06	0.50	161 ± 157	Imipramine	Carbamazepine	1.35	Moderate	The tricyclic increases the effect of carbamazepine
49	89	0.01	0.17	36 ± 32	Fluconazole	Diazepam	2.16	Moderate	Increases the effect of benzodiazepine
50	84	0.01	0.09	15 ± 26	Prednisone	Ethinyl Estradiol	58.79	Moderate	The estrogenic agent increases the effect of corticosteroid

Table S3: DDI list 1-50. Complete list of known DDI pairs (i, j) by rank of $U_{i,j}^\Phi$, the number of patients affected by the DDI (1st and 2nd columns, respectively). The normalized drug pair footprint in the population $(\gamma_{i,j}^\Phi)$ as well as the normalized co-administration length $(\tau_{i,j}^\Phi)$, are shown in columns 3 and 4, respectively. Mean $(\pm$ s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 5 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative gender risk of DDI pair co-administration, $RRR_{i,j}^F$, shown in column 8. DDI severity classification, according to *Drugs.com*, shown in column 9; DDIs or drugs not found in *Drugs.com* are labeled as *None* or ***, respectively. Drug pair interaction, according to *DrugBank*, shown in column 10. Continues on Table S4.

rank _{Φ}	$ U_{i,j}^{\Phi} $	$\gamma_{i,j}^{\Phi}$	$\tau_{i,j}^{\Phi}$	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRI F_{i,j}$	severity	interaction
51	71	0.13	0.47	169 ± 151	Phenytoin	Fluoxetine	0.73	Moderate	Fluoxetine increases the effect of phenytoin
51	51	0.01	0.08	15 ± 19	Atenolol	Fenofibrate	2.64	*	Antagonism
53	69	0.02	0.16	10 ± 8	Ciprofloxacin	Iron (II) Sulfate	4.18	Moderate	Formation of non-absorbable complexes
54	63	0.17	0.34	33 ± 28	Methyldopa	Iron (II) Sulfate	21.60	Moderate	Iron decreases the absorption of dopa derivatives
54	63	0.08	0.35	110 ± 118	Diltiazem	Amlodipine	1.52	Moderate	Increases the effect and toxicity of amlodipine
56	60	0.01	0.19	49 ± 95	Prednisone	Warfarin	0.76	Moderate	The corticosteroid alters the anticoagulant effect
56	60	0.01	0.12	28 ± 43	Amtripyline	Fenofibrate	2.83	*	The tricyclic increases the sympathomimetic effect
58	59	0.01	0.15	34 ± 34	Fluconazole	Carbamazepine	1.03	Moderate	Increases the effect of carbamazepine
58	59	0.05	0.03	5 ± 10	Hydrocortisone	ASA	1.35	Moderate	The corticosteroid decreases the effect of salicylates
60	57	0.01	0.15	50 ± 48	Fluconazole	Imipramine	7.37	Moderate	The imidazole increases the effect and toxicity of the tricyclic
60	57	0.02	0.35	96 ± 96	Glyburide	Carvedilol	0.73	Moderate	The beta-blocker decreases the symptoms of hypoglycemia
62	52	0.08	0.49	118 ± 114	Digoxin	Amiodarone	0.56	Major	Amiodarone increases the effect of digoxin
63	51	0.00	0.23	93 ± 90	Hydrochlorothiazide	Lithium	2.90	Major	The thiazide diuretic increases serum levels of lithium
64	48	0.00	0.16	65 ± 74	Enalapril	Lithium	1.91	Moderate	The ACE inhibitor increases serum levels of lithium
65	47	0.04	0.46	135 ± 109	Allopurinol	Warfarin	0.19	Moderate	Allopurinol increases the anticoagulant effect
66	44	0.03	0.16	51 ± 61	Imipramine	Salbutamol	3.19	Moderate	The tricyclic increases the sympathomimetic effect
67	43	0.08	0.40	144 ± 153	Phenytoin	Diazepam	0.62	Moderate	Possible increased levels of the hydantoin, decrease of benzodiazepine
68	41	0.00	0.21	82 ± 74	Losartan	Lithium	4.13	Moderate	Losartan increases serum levels of lithium
69	39	0.04	0.42	82 ± 64	Gliclazide	Carvedilol	0.67	None	The beta-blocker decreases the symptoms of hypoglycemia
69	39	0.14	0.15	30 ± 46	Timolol	Ibuprofen	1.42	None	Risk of inhibition of renal prostaglandins
69	39	0.06	0.42	130 ± 122	Nortriptyline	Carbamazepine	1.26	Moderate	The tricyclic increases the effect of carbamazepine
72	36	0.05	0.05	15 ± 14	Phenobarbital	Dexamethasone	1.11	Moderate	The barbiturate decreases the effect of the corticosteroid
73	31	0.01	0.04	9 ± 8	Prednisone	ASA	2.95	Moderate	The corticosteroid decreases the effect of salicylates
73	31	0.01	0.20	48 ± 66	Propranolol	Salbutamol	6.61	Major	Antagonism
75	30	0.00	0.09	10 ± 3	Clavulanate	Ethinyl Estradiol	inf	None	Anti-infectious agent could decrease effect of oral contraceptive
76	28	0.04	0.22	83 ± 86	Digoxin	Diazepam	1.09	Moderate	The benzodiazepine increases the effect of digoxin
77	27	0.01	0.30	81 ± 73	Propranolol	Gliclazide	2.02	None	The beta-blocker decreases the symptoms of hypoglycemia
77	27	0.03	0.19	11 ± 6	Doxycycline	Ethinyl Estradiol	inf	Moderate	Anti-infectious agent could decrease effect of oral contraceptive
77	27	0.05	0.05	10 ± 6	Phenytoin	Ciprofloxacin	0.49	Moderate	Ciprofloxacin decreases the hydantoin effect
77	27	0.01	0.05	7 ± 3	Carbamazepine	Metronidazole	1.68	Moderate	Metronidazole increases the effect of carbamazepine
77	27	0.01	0.07	8 ± 7	Prednisone	Estradiol	inf	Moderate	The estrogenic agent increases the effect of corticosteroid
82	26	0.00	0.20	44 ± 70	Fluconazole	Nortriptyline	5.43	Moderate	The imidazole increases the effect and toxicity of the tricyclic
82	26	0.05	0.07	14 ± 12	Phenytoin	Dexamethasone	1.13	Moderate	The enzyme inducer decreases the effect of the corticosteroid
84	25	0.03	0.56	157 ± 136	Diltiazem	Amiodarone	1.26	Major	Increased risk of cardiotoxicity and arrhythmias
85	24	0.01	0.17	15 ± 10	Propranolol	Fenofibrate	3.54	Major	Antagonism
85	24	0.01	0.29	100 ± 85	Carbamazepine	Warfarin	0.99	Moderate	Decreases the anticoagulant effect
85	24	0.00	0.05	3 ± 2	Diclofenac	Warfarin	0.84	Major	The NSAID increases the anticoagulant effect
85	24	0.04	0.15	29 ± 45	Phenytoin	Prednisone	1.72	Moderate	The enzyme inducer decreases the effect of the corticosteroid
89	23	0.03	0.47	152 ± 143	Diltiazem	Propranolol	2.01	Major	Increased risk of bradycardia
89	23	0.00	0.16	36 ± 44	Fluconazole	Haloperidol	1.33	Major	The imidazole increases the effect and toxicity of haloperidol
91	22	0.05	0.20	19 ± 28	Estrogens Conj.	Prednisone	inf	Moderate	The estrogenic agent increases the effect of corticosteroid
91	22	0.00	0.07	9 ± 4	Ciprofloxacin	Warfarin	1.02	Major	The quinolone increases the anticoagulant effect
93	21	0.01	0.08	10 ± 6	Tobramycin	Furosemide	3.01	Major	Increased ototoxicity
93	21	0.02	0.33	94 ± 116	Chlorpromazine	Propranolol	1.77	Moderate	Increased effect of both drugs
95	19	0.00	0.07	26 ± 35	Prednisone	Phenobarbital	1.53	Moderate	The barbiturate decreases the effect of the corticosteroid
95	19	0.00	0.07	10 ± 7	Ciprofloxacin	Aminophylline	1.21	Major	The quinolone increases the effect of theophylline
97	18	0.00	0.13	33 ± 44	Fluconazole	Warfarin	0.89	Major	Increases the anticoagulant effect
98	17	0.03	0.24	50 ± 48	Nortriptyline	Salbutamol	1.01	Moderate	The tricyclic increases the sympathomimetic effect
98	17	0.01	0.26	107 ± 85	Propranolol	Phenobarbital	1.70	Moderate	The barbiturate decreases the effect of metabolized beta-blocker
100	16	0.02	0.24	46 ± 29	Haloperidol	Propranolol	1.56	Moderate	Increased effect of both drugs

Table S4: DDI list 51-100. See Table S3 for column description. Continues on Table S5.

rank _Φ	$ U_{t,j}^{\Phi} $	$\chi_{t,j}^{\Phi}$	$\tau_{t,j}^{\Phi}$	$\langle \lambda_{t,j}^{\Phi} \rangle$	i	j	$RRI_{t,j}^{\Phi}$	severity	interaction
100	16	0.00	0.07	6 ± 3	Azithromycin	Warfarin	1.18	Moderate	Increases the anticoagulant effect
100	16	0.00	0.08	16 ± 21	Metronidazole	Lithium	4.96	Moderate	Metronidazole increases the effect and toxicity of lithium
100	16	0.03	0.31	94 ± 83	Phenytoin	Furosemide	0.55	Minor	The hydantoin decreases the effect of furosemide
104	15	0.01	0.13	20 ± 17	Carvedilol	Fenoterol	0.47	Antagonism	Possible antagonism of action
105	14	0.02	0.21	5 ± 3	Doxycycline	Amoxicillin	0.53	Moderate	Increased ototoxicity
105	14	0.00	0.12	9 ± 7	Furosemide	Gentamicin	0.71	Major	Increases the effect of hydantoin
105	14	0.00	0.23	63 ± 59	Fluonazole	Phenytoin	1.28	Moderate	Increased hydantoin levels and risk of bleeding
105	14	0.03	0.23	88 ± 71	Phenytoin	Warfarin	0.94	Moderate	This product might cause a slight decrease of contraceptive effect
109	13	0.01	0.14	35 ± 26	Carbamazepine	Ethinyl Estradiol	inf	Major	Carbamazepine decreases the contraceptive effect
109	13	0.01	0.14	35 ± 26	Levonorgestrel	Carbamazepine	inf	Major	Carbamazepine decreases the contraceptive effect
109	13	0.05	0.19	122 ± 113	Propranolol	Methylodopa	8.50	Major	Possible hypertensive crisis
109	13	0.01	0.18	55 ± 59	Timolol	Glyburide	1.13	Moderate	The beta-blocker decreases the symptoms of hypoglycemia
113	12	0.01	0.18	72 ± 98	Captopril	Lithium	1.42	Moderate	The ACE inhibitor increases serum levels of lithium
114	11	0.01	0.08	33 ± 63	Imipramine	Fenoterol	7.08	None	The tricyclic increases the sympathomimetic effect
114	11	0.01	0.24	57 ± 46	Methylphenidate	Carbamazepine	0.07	None	The quinolone could reduce the effect of methylphenidate
114	11	0.00	0.15	14 ± 21	Noxflaxacin	Aminophylline	7.08	Moderate	The macrolide increases the effect of theophylline
117	10	0.02	0.04	11 ± 4	Erythromycin	Simvastatin	2.83	Major	The macrolide possibly increases the statin toxicity
118	9	0.00	0.03	7 ± 1	Prednisolone	Phenobarbital	0.89	Moderate	The barbiturate decreases the levels of hydantoin
118	9	0.00	0.29	62 ± 46	Folic acid	Phenytoin	1.42	Moderate	Folic acid decreases the levels of hydantoin
118	9	0.00	0.11	16 ± 9	Metoclopramide	Levodopa	5.67	Moderate	Levodopa decreases the effect of metoclopramide
118	9	0.03	0.15	72 ± 128	Carbamazepine	Norethisterone	inf	Major	This product may cause a slight decrease of contraceptive effect
123	8	0.01	0.22	51 ± 91	Timolol	Salbutamol	0.89	Major	Antagonism
123	8	0.00	0.04	67 ± 36	Diltiazem	Carbamazepine	0.71	Major	Increases the effect of carbamazepine
123	8	0.02	0.33	6 ± 2	Metronidazole	Phenobarbital	1.18	Moderate	The barbiturate decreases the effect of metronidazole
123	8	0.02	0.35	53 ± 40	Methylodopa	Salbutamol	4.96	Moderate	Increased arterial pressure
123	8	0.00	0.25	82 ± 54	Carbamazepine	Aminophylline	0.71	Moderate	Increases or decreases the effect of theophylline
127	7	0.01	0.16	62 ± 97	Phenytoin	Trimethoprim	0.94	Moderate	Trimethoprim increases the effect of hydantoin
127	7	0.00	0.23	122 ± 123	Propranolol	Maprotiline	4.25	Minor	Propranolol increases the serum levels of cisapride
127	7	0.01	0.11	25 ± 15	Nortriptyline	Fenoterol	1.77	None	The tricyclic increases the sympathomimetic effect
127	7	0.02	0.09	13 ± 8	Methylodopa	Fenoterol	4.25	None	Increased arterial pressure
127	7	0.01	0.20	11 ± 4	Doxycycline	Iron (II) Sulfate	inf	Moderate	Formation of non-absorbable complexes
132	5	0.00	0.55	82 ± 86	Propranolol	Aminophylline	1.06	Major	Antagonism of action and increased effect of theophylline
132	5	0.04	0.45	221 ± 207	Propylthiouracil	Warfarin	1.06	Moderate	The anti-thyroid agent causes variations in the anticoagulant effect
132	5	0.01	0.09	9 ± 4	Doxycycline	Carbamazepine	2.83	Moderate	The anticonvulsant decreases the effect of doxycycline
132	5	0.02	0.22	34 ± 26	Timolol	Gliclazide	1.06	None	The beta-blocker decreases the symptoms of hypoglycemia
132	5	0.00	0.17	10 ± 6	Prednisolone	Ethinyl Estradiol	inf	Moderate	The estrogenic agent increases the effect of hormones
132	5	0.00	0.31	162 ± 120	Medroxyprogesterone Ac.	Phenobarbital	inf	Moderate	The enzyme inducer increases the effect of hydantoin
132	5	0.01	0.35	107 ± 123	Phenytoin	Amiodarone	0.18	Moderate	The enzyme inducer decreases the effect of hydantoin
132	5	0.00	0.21	104 ± 153	Folic acid	Phenobarbital	2.83	Moderate	Folic acid decreases the effect of anticonvulsant
140	4	0.00	0.16	40 ± 29	Levonorgestrel	Phenobarbital	inf	Major	Phenobarbital decreases the effect of levonorgestrel
140	4	0.00	0.26	72 ± 61	Atenolol	Verapamil	0.00	Major	Increased effect of both drugs
140	4	0.01	0.14	10 ± 2	Estrogens Conj.	Prednisolone	inf	Moderate	The estrogenic agent increases the effect of corticosteroid
140	4	0.00	0.14	4 ± 3	Doxycycline	Clavulanate	0.71	None	Possible antagonism of action
140	4	0.00	0.17	62 ± 44	Phenobarbital	Aminophylline	0.24	Moderate	The enzyme inducer decreases the effect of theophylline
145	3	0.01	0.18	97 ± 94	Estrogens Conj.	Phenobarbital	inf	Moderate	The enzyme inducer decreases the effect and toxicity of theophylline
145	3	0.00	0.32	136 ± 117	Ethinyl Estradiol	Aminophylline	inf	Major	This product may cause a slight decrease of contraceptive effect
145	3	0.00	0.20	53 ± 16	Medroxyprogesterone Ac.	Phenobarbital	inf	None	The agent increases the effect of anticonvulsant
145	3	0.00	0.22	45 ± 43	Hydrocortisone	Warfarin	1.42	Moderate	The barbiturate decreases the effect of the corticosteroid
145	3	0.00	0.01	2 ± 0	Doxycycline	Warfarin	1.42	Moderate	The tetracycline increases the anticoagulant effect

Table S5: DDI list 101-150. See Table S3 for column description. Continues on Table S6.

rank Φ	$ U_{k,j}^{\Phi} $	$\gamma_{k,j}^{\Phi}$	$\tau_{k,j}^{\Phi}$	$\langle \lambda_{k,j}^u \rangle$	i	j	$RR_{k,j}^F$	severity	interaction
145	3	0.01	0.12	23 ± 13	Phenytoin	Aminophylline	1.42	Moderate	Decreased effect of both products
145	3	0.01	0.43	40 ± 57	Methyldopa	Levodopa	inf	Minor	Methyldopa increases the effect and toxicity of levodopa
145	3	0.00	0.12	40 ± 19	Digoxin	Verapamil	inf	Moderate	Verapamil increases the effect of digoxin
145	3	0.00	0.15	58 ± 56	Aminophylline	Lithium	1.42	Moderate	Theophylline decreases serum levels of lithium
145	3	0.01	0.10	9 ± 4	Phenytoin	Prednisolone	0.35	Moderate	The enzyme inducer decreases the effect of the corticosteroid
145	3	0.01	0.43	185 ± 98	Phenytoin	Levodopa	0.00	Moderate	The hydantoin decreases the effect of levodopa
157	2	0.00	0.06	6 ± 1	Estradiol	Prednisolone	inf	Moderate	The estrogenic agent increases the effect of corticosteroid
157	2	0.01	0.13	31 ± 0	Timolol	Aminophylline	inf	Major	Antagonism of action and increased effect of theophylline
157	2	0.00	0.24	62 ± 53	Phenytoin	Estradiol	inf	Moderate	The enzyme inducer decreases the effect of theophylline
157	2	0.00	0.08	23 ± 11	Doxycycline	Phenobarbital	inf	Moderate	The anticonvulsant decreases the effect of the hormones
157	2	0.00	0.20	79 ± 30	Norethisterone	Phenobarbital	inf	Major	This product may cause a slight decrease of doxycycline
157	2	0.00	0.20	79 ± 30	Estradiol	Phenobarbital	inf	Moderate	The enzyme inducer decreases the effect of hormones
157	2	0.00	0.42	102 ± 110	Propranolol	Verapamil	0.71	Major	Increased effect of both drugs
157	2	0.01	0.03	2 ± 0	Timolol	Fenoterol	inf	Major	Antagonism
157	2	0.00	0.02	2 ± 0	Phenytoin	Hydrocortisone	0.71	Moderate	The enzyme inducer decreases the effect of the corticosteroid
157	2	0.00	0.53	288 ± 213	Phenytoin	Med-roxyprogesterone, Ac.	inf	Moderate	The enzyme inducer decreases the effect of the hormones
157	2	0.00	0.24	62 ± 53	Phenytoin	Norethisterone	inf	Major	This product may cause a slight decrease of contraceptive effect
157	2	0.00	0.42	274 ± 218	Digoxin	Propylthiouracil	0.71	Moderate	The antithyroid agent increases the effect of digoxin
169	1	0.00	0.00	2 ± 0	Atenolol	Epinephrine	inf	Moderate	Hypertension, then bradycardia
169	1	0.00	0.49	179 ± 0	Phenytoin	Ethinyl Estradiol	inf	Major	This product may cause a slight decrease of contraceptive effect
169	1	0.00	0.30	117 ± 0	Haloperidol	Methyldopa	inf	Moderate	Methyldopa increases haloperidol effect or risk of psychosis
169	1	0.00	0.49	179 ± 0	Phenytoin	Levonorgestrel	inf	Major	Phenytoin decreases the contraceptive effect
169	1	0.00	0.51	31 ± 0	Phenytoin	Sulfadiazine	0.00	Moderate	The sulfonamide increases the effect of hydantoin
169	1	0.00	0.02	4 ± 0	Erythromycin	Aminophylline	inf	Moderate	The macrolide increases the effect and toxicity of theophylline
169	1	0.00	0.24	12 ± 0	Timolol	Methyldopa	inf	Major	Possible hypertensive crisis
169	1	0.00	0.05	6 ± 0	Erythromycin	Carbamazepine	0.00	Major	The macrolide increases the effect of carbamazepine
169	1	0.00	0.06	2 ± 0	Erythromycin	Diazepam	inf	Moderate	The macrolide increases the effect of the benzodiazepine
169	1	0.00	0.03	9 ± 0	Erythromycin	Fluoxetine	inf	Moderate	Possible serotonergic syndrome with this combination
169	1	0.00	0.25	15 ± 0	Phenytoin	Doxycycline	inf	Moderate	The anticonvulsant decreases the effect of doxycycline
169	1	0.00	0.06	29 ± 0	Phenytoin	Estrogens Conj.	inf	Moderate	The enzyme inducer decreases the effect of the hormones
169	1	0.00	0.31	124 ± 0	Carbamazepine	Verapamil	0.00	Major	Verapamil increases the effect of carbamazepine

Table S6: DDI list 151-181. See Table S3 for column description.

rank $_{\Phi}$	$ U_{i,j}^{\Phi} $	$\gamma_{i,j}^{\Phi}$	$\tau_{i,j}^{\Phi}$	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRI_{i,j}^F$	severity
2	2117	0.18	0.23	53 \pm 74	ASA	Ibuprofen	1.42	Major
5	1190	0.19	0.45	127 \pm 127	Amitriptyline	Fluoxetine	3.55	Major
7	892	0.14	0.20	56 \pm 61	Fluconazole	Simvastatin	2.63	Major
16	470	0.63	0.55	160 \pm 133	Diltiazem	Simvastatin	1.27	Major
23	257	0.16	0.42	123 \pm 130	Imipramine	Fluoxetine	3.08	Major
27	222	0.02	0.47	148 \pm 139	Fluoxetine	Lithium	1.79	Major
33	154	0.01	0.33	94 \pm 92	Fluoxetine	Nortriptyline	2.70	Major
36	148	0.14	0.49	168 \pm 160	Haloperidol	Lithium	1.31	Major
47	91	0.01	0.52	154 \pm 142	Atenolol	Diltiazem	1.19	Major
62	52	0.08	0.49	118 \pm 114	Digoxin	Amiodarone	0.56	Major
63	51	0.00	0.23	93 \pm 90	Hydrochlorothiazide	Lithium	2.90	Major
73	31	0.01	0.20	48 \pm 66	Propranolol	Salbutamol	6.61	Major
84	25	0.03	0.56	157 \pm 136	Diltiazem	Amiodarone	1.26	Major
85	24	0.00	0.05	3 \pm 2	Diclofenac	Warfarin	0.84	Major
89	23	0.03	0.47	152 \pm 143	Diltiazem	Propranolol	2.01	Major
89	23	0.00	0.16	36 \pm 44	Fluconazole	Haloperidol	1.33	Major
91	22	0.00	0.07	9 \pm 4	Ciprofloxacin	Warfarin	1.02	Major
93	21	0.01	0.08	10 \pm 6	Tobramycin	Furosemide	3.01	Major
95	19	0.00	0.07	10 \pm 7	Ciprofloxacin	Aminophylline	1.21	Major
97	18	0.00	0.13	33 \pm 44	Fluconazole	Warfarin	0.89	Major

Table S7: Top 20 *major* DDI pairs (i, j) by rank of $|U_{i,j}^{\Phi}|$, the number of patients affects by the DDI (1st and 2nd columns, respectively). The normalized drug pair footprint in the population ($\gamma_{i,j}^{\Phi}$) as well as the normalized co-administration length ($\tau_{i,j}^{\Phi}$), are shown in columns 3 and 4, respectively. Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 5 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative gender risk of DDI pair co-administration, $RRI_{i,j}^F$, is shown in column 8. DDI severity classification, according to *Drugs.com*, shown in column 9.

rankp(γ)	$\gamma_{i,j}^{\Phi}$	$\gamma_{j,i}^{\Phi}$	$ U_{i,j}^{\Phi} $	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRI_{i,j}^F$	severity
1	0.50	0.61	524	243 \pm 188	Haloperidol	Biperiden	0.62	Moderate
2	0.59	0.12	385	155 \pm 125	Digoxin	Furosemide	0.61	Moderate
3	0.19	0.36	5078	102 \pm 95	Omeprazole	Clonazepam	2.28	Moderate
4	0.10	0.50	1249	141 \pm 124	ASA	Glyburide	0.89	Moderate
5	0.42	0.14	272	140 \pm 114	Digoxin	Spironolactone	0.58	Minor
6	0.63	0.02	470	160 \pm 133	Diltiazem	Simvastatin	1.27	Major
7	0.27	0.15	173	109 \pm 96	Digoxin	Carvedilol	0.53	Moderate
8	0.04	0.44	496	103 \pm 87	ASA	Gliclazide	0.78	None
9	0.04	0.31	999	87 \pm 86	Omeprazole	Diazepam	1.21	Moderate
9	0.19	0.09	1190	127 \pm 127	Amitriptyline	Fluoxetine	3.55	Major
11	0.14	0.16	148	168 \pm 160	Haloperidol	Lithium	1.31	Major
12	0.07	0.22	535	152 \pm 132	Atenolol	Glyburide	1.22	Moderate
13	0.18	0.08	186	142 \pm 156	Haloperidol	Carbamazepine	0.62	Moderate
14	0.18	0.06	2117	53 \pm 74	ASA	Ibuprofen	1.42	Major
14	0.20	0.04	1460	54 \pm 77	Atenolol	Ibuprofen	1.88	Moderate
16	0.02	0.24	222	148 \pm 139	Fluoxetine	Lithium	1.79	Major
17	0.03	0.18	201	107 \pm 95	Atenolol	Gliclazide	1.09	None
18	0.01	0.26	154	94 \pm 92	Fluoxetine	Nortriptyline	2.70	Major
19	0.28	0.00	149	115 \pm 109	Phenytoin	Omeprazole	0.80	Moderate
20	0.03	0.17	377	143 \pm 138	Fluoxetine	Carbamazepine	0.98	Moderate

Table S8: Top 20 known DDI pairs (i, j) by rank product (1st column) of the ranks of $\gamma_{i,j}^{\Phi}$ and $\gamma_{j,i}^{\Phi}$, the normalized drug pair footprint in the population (1st, 2nd and 3rd columns, respectively). The number of patients affected by the drug pair, $|U_{i,j}^{\Phi}|$, is shown in column 4. Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 5 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 6 and 7. The relative gender risk of DDI pair co-administration, $RRI_{i,j}^F$, is shown in column 8. DDI severity classification, according to *Drugs.com*, shown in column 9; DDIs or drugs not found in *Drugs.com* are labeled as *None* or ***, respectively.

rank _{τ}	$\tau_{i,j}^\Phi$	$ U_{i,j}^\Phi $	$\langle \lambda_{i,j}^u \rangle$	i	j	$RRI_{i,j}^F$	severity
1	0.70	524	243 ± 188	Haloperidol	Biperiden	0.62	Moderate
2	0.60	1249	141 ± 124	ASA	Glyburide	0.89	Moderate
3	0.60	385	155 ± 125	Digoxin	Furosemide	0.61	Moderate
4	0.58	535	152 ± 132	Atenolol	Glyburide	1.22	Moderate
5	0.57	95	140 ± 126	Propranolol	Glyburide	1.61	Moderate
6	0.56	25	157 ± 136	Diltiazem	Amiodarone	1.26	Major
7	0.56	13	122 ± 113	Propranolol	Methyldopa	8.50	Major
8	0.55	470	160 ± 133	Diltiazem	Simvastatin	1.27	Major
9	0.55	5	82 ± 86	Propranolol	Aminophylline	1.06	Major
10	0.55	272	140 ± 114	Digoxin	Spironolactone	0.58	Minor
11	0.53	2	288 ± 213	Phenytoin	Medroxyproges. Ac.	inf	Moderate
12	0.52	91	154 ± 142	Atenolol	Diltiazem	1.19	Major
13	0.51	1	31 ± 0	Phenytoin	Sulfadiazine	0.00	Moderate
14	0.50	90	161 ± 157	Imipramine	Carbamazepine	1.35	Moderate
15	0.50	377	143 ± 138	Fluoxetine	Carbamazepine	0.98	Moderate
16	0.49	226	151 ± 145	Amitriptyline	Carbamazepine	0.99	Moderate
17	0.49	52	118 ± 114	Digoxin	Amiodarone	0.56	Major
18	0.49	1	179 ± 0	Phenytoin	Levonorgestrel	inf	Major
18	0.49	1	179 ± 0	Phenytoin	Ethinyl Estradiol	inf	Major
20	0.49	148	168 ± 160	Haloperidol	Lithium	1.31	Major

Table S9: Top 20 known DDI pairs (i, j) by rank of $\tau_{i,j}^\Phi$, the normalized co-administration length (1st and 2nd columns, respectively). The number of patients affected by the drug pair, $|U_{i,j}^\Phi|$, is shown in column 3. Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 5 and 6. The relative gender risk of DDI pair co-administration, $RRI_{i,j}^F$, shown in column 7. DDI severity classification, according to *Drugs.com*, shown in column 8; DDIs or drugs not found in *Drugs.com* are labeled as *None* or ***, respectively.

S4.1 Interactions per severity

In this section, Table S10 shows the number of individual interactions and unique users, both per severity of interaction.

Note that some interactions present in DrugBank were not found in Drugs.com. These are marked as *None*. The drug *Fenoterol* (brand name *Berotec* in Brazil) was not found in Drugs.com. These interactions were summed separately and are shown with an asterisk (*).

severity s	Φ_s	$ U_s^\Phi $	$ U_s^\Phi / U $	$ U_s^\Phi / \Omega $
<i>Major</i>	5,968 (22.50%)	5,224	3.94%	1.54%
<i>Moderate</i>	18,335 (69.13%)	12,711	9.58%	3.75%
<i>Minor</i>	542 (02.04%)	528	0.40%	0.16%
<i>None</i>	1,489 (05.61%)	1,314	0.99%	0.39%
*	190 (00.72%)	179	0.13%	0.05%
Total	26,524 (100%)	19,956	-%	-%

Table S10: The 2nd column lists the numbers of interactions, Φ_s , per DDI severity class (1st column); percentages of interactions per class are shown in parenthesis. Drugs or interactions identified in *DrugBank* but not present in Drugs.com are tallied as *None*. Interactions for *Berotec* tallied as *. The 3rd column lists the number of patients affected by at least one interaction $|U_s^\Phi|$, per DDI severity. Fourth and fifth columns lists the proportion of patients in each DDI severity class for the *Pronto* system and the entire Blumenau populations, respectively. Notice that the same patient may have been administered DDI of more than one severity type.

S4.2 Interactions per gender

In this section, Table S11 shows the number of individual interactions and unique users per gender.

gender g	Φ^g	$ U^{\Phi,g} $	$ U^{\Phi,g} / U $	$ U^{\Phi,g} / \Omega $
Male	8,100 (30.54%)	4,793	3.61%	1.41%
Female	18,424 (69.46%)	10,734	8.09%	3.17%
Total	26,524 (100%)	15,527	11.70%	4.58%

Table S11: The 2nd column lists the numbers of interactions, Φ , per gender (1st column); percentages of interactions per gender shown in parenthesis. The 3rd column lists the number of patients affected by at least one interaction per gender, $|U^{\Phi,g}|$. The 4th and 5th columns show the proportion of patients in each gender for the *Pronto* system and entire Blumenau populations, respectively.

S4.3 Interactions per age

Table S12 shows the number of individual interaction and unique users per age group.

age y	Φ^y	$ U^{\Phi,y} $	$ U^{\Phi,y} / U $	$ U^{\Phi,y} / \Omega $
00-04	23 (0.09%)	20	0.02%	0.01%
05-09	7 (0.03%)	7	0.01%	0.00%
10-14	29 (0.11%)	25	0.02%	0.01%
15-19	172 (0.65%)	139	0.10%	0.04%
20-24	311 (1.17%)	237	0.18%	0.07%
25-29	433 (1.63%)	301	0.23%	0.09%
30-34	771 (2.91%)	525	0.40%	0.15%
35-39	1,097 (4.14%)	687	0.52%	0.20%
40-44	1,581 (5.96%)	1,023	0.77%	0.30%
45-49	2,332 (8.79%)	1,426	1.07%	0.42%
50-54	3,128 (11.79%)	1,868	1.41%	0.55%
55-59	3,447 (13.00%)	1,956	1.47%	0.58%
60-64	3,508 (13.23%)	2,006	1.51%	0.59%
65-69	3,254 (12.27%)	1,794	1.35%	0.53%
70-74	2,417 (9.11%)	1,311	0.99%	0.39%
75-79	1,978 (7.46%)	1,057	0.80%	0.31%
80-84	1,143 (4.31%)	638	0.48%	0.19%
85-89	620 (2.34%)	349	0.26%	0.10%
90-94	205 (0.77%)	117	0.09%	0.03%
95-99	49 (0.18%)	27	0.02%	0.01%
>99	19 (0.07%)	14	0.01%	0.00%
Total	26,524 (100%)	15,527	11.70%	4.58%

Table S12: The 2nd column lists the numbers of interactions, Φ^y , per age range (1st column); percentages of interactions per age range shown in parenthesis. The 3rd column lists the number of patients affected by at least one interaction per age range, $|U^{\Phi,y}|$. The 4th and 5th columns show the proportion of patients in each age range from the *Pronto* system and entire Blumenau populations, respectively.

S4.4 Interaction per age and gender




Figure S4: The joint probability a patient was dispensed at least one drug $P(U^{\nu>0,y,g})$, had co-administrations $P(U^{\Psi,y,g})$, or had a DDI $P(U^{\Phi,y,g})$, given age range $[y_1, y_2]$ and gender (g) , are shown in blue, orange and red lines, respectively. Values for age group $y \geq 90$ were aggregated for plotting. Population distribution for Blumenau $P(\Omega^{y,g})$ is shown as a green fill. A Kolmogorov-Smirnov test cannot reject the hypothesis that both the female and male distribution of patients with at least one co-administration known to be DDI ($U^{\Phi,y,g}$) are drawn from the same underlying continuous distribution ($KS = .3810$, $p\text{-value} = .0706$).




Figure S5: **Left.** Mean number of drugs dispensed (ν^u) to patients in each age group. **Middle.** Mean number of drug pairs co-administered (Ψ^u) by patients in each age group. **Right.** Mean number of drug pairs known to be a DDI (Φ^u) co-administered by patients in each age group. Numbers for male and female patients shown in lighter and darker colors, respectively. In all plots vertical bars denote the standard deviation.




Figure S6: **Left.** Absolute number of patients with at least one co-administration per age group, $|U^{\Psi,[y_1,y_2]}|$. **Right.** Absolute number of patients with at least one co-administration per age group and gender, $|U^{\Psi,[y_1,y_2],g}|$.

S5 Risk and Relative Risk measures

Risk and Relative Risk measures are computed based on the number of patients in specific groups. Here we detail the computation of all measures used throughout the main manuscript.

The relative risk of co-administration and interaction for women, are computed as

$$RRC^F = \frac{P(\Psi^u > 0 | u \in U^F)}{P(\Psi^u > 0 | u \in U^M)} = \frac{|U^{\Psi,F}|/|U^F|}{|U^{\Psi,M}|/|U^M|}; \quad RRI^F = \frac{P(\Phi^u > 0 | u \in U^F)}{P(\Phi^u > 0 | u \in U^M)} = \frac{|U^{\Phi,F}|/|U^F|}{|U^{\Phi,M}|/|U^M|}. \quad (S10)$$

Similarly, $RRC^M = 1/RRC^F$ and $RRI^M = 1/RRI^F$. In the main manuscript we mentioned the computation of RRI^F without contraceptive drugs. The drug removed in this computation were *Ethinyl Estradiol*, *Estradiol*, *Norethisterone*, *Levonorgestrel* and *Estrogens Conjugated*.

The relative risk of an interaction at a certain DDI severity level, $s \in \{\text{major, moderate, minor, none, *}\}$, given gender, is computed as

$$RRI_s^F = \frac{P(\Phi_s^u > 0 | u \in U^F)}{P(\Phi_s^u > 0 | u \in U^M)} = \frac{|U_s^{\Phi,F}|/|U^F|}{|U_s^{\Phi,M}|/|U^M|}. \quad (S11)$$

The relative risk of an interaction between two drugs, given gender, is computed as

$$RRI_{i,j}^F = \frac{P(\Phi_{i,j}^u > 0 | u \in U^F)}{P(\Phi_{i,j}^u > 0 | u \in U^M)} = \frac{|U_{i,j}^{\Phi,F}|/|U^F|}{|U_{i,j}^{\Phi,M}|/|U^M|}. \quad (S12)$$

The relative risk of co-administration and interaction, given number of dispensed drugs, are computed as

$$RRC^{\nu=x} = \frac{P(\Psi^u | u \in U^{\nu=x})}{P(\Psi^u | u \in U^{\nu=2})} = \frac{|U^{\Psi,\nu=x}|/|U^{\nu=x}|}{|U^{\Psi,\nu=2}|/|U^{\nu=2}|}; \quad RRI^{\nu=x} = \frac{P(\Phi^u | u \in U^{\nu=x})}{P(\Phi^u | u \in U^{\nu=2})} = \frac{|U^{\Phi,\nu=x}|/|U^{\nu=x}|}{|U^{\Phi,\nu=2}|/|U^{\nu=2}|}. \quad (S13)$$

The risk of co-administration and interaction, given age group, are computed as

$$RC^{[y_1,y_2]} = \frac{P(\Psi^u > 0 | u \in U^{[y_1,y_2]})}{P(\nu \geq 2 | u \in U^{[y_1,y_2]})} = \frac{|U^{\Psi,[y_1,y_2]}|}{|U^{\nu \geq 2,[y_1,y_2]}|}; \quad RI^{[y_1,y_2]} = \frac{P(\Phi^u > 0 | u \in U^{[y_1,y_2]})}{P(\Psi^u > 0 | u \in U^{[y_1,y_2]})} = \frac{|U^{\Phi,[y_1,y_2]}|}{|U^{\Psi,[y_1,y_2]}|}. \quad (S14)$$

Note $RC^{[y_1,y_2]}$ and $RI^{[y_1,y_2]}$ can be also interpreted as probabilities. Similarly, we also compute the risk of co-administration and interaction, per age group and gender as

$$RC^{g,[y_1,y_2]} = \frac{P(\Psi^u > 0 | u \in U^{g,[y_1,y_2]})}{P(\nu \geq 2 | u \in U^{g,[y_1,y_2]})} = \frac{|U^{\Psi,g,[y_1,y_2]}|}{|U^{\nu \geq 2,g,[y_1,y_2]}|}; \quad RIG^{g,[y_1,y_2]} = \frac{P(\Phi^u > 0 | u \in U^{g,[y_1,y_2]})}{P(\Psi^u > 0 | u \in U^{g,[y_1,y_2]})} = \frac{|U^{\Phi,g,[y_1,y_2]}|}{|U^{\Psi,g,[y_1,y_2]}|}. \quad (S15)$$

S5.1 Relative Risk per gender

g	$ U^g $	$ U^{\nu \geq 2} $	$ U^{\Psi,g} $	$ U^{\Phi,g} $	RRC^F	RRI^F
Male	55,032	41,922	39,723	4,793	1.0000	1.0000
Female	77,690	62,889	59,738	10,734	1.0653	1.5864

Table S13: Absolute number of patients and relative risk measures per gender (g , 1st column). Columns 2 through 5 lists, per gender, absolute numbers of: patients ($|U^g|$), patients with at least 2 administrations ($|U^{\nu \geq 2}|$), patients with at least one co-administration ($|U^{\Psi,g}|$), and patients with at least one known DDI co-administration ($|U^{\Phi,g}|$). Relative Risk for women for both co-administration (RRC^F) and known DDI co-administration (RRI^F) are listed in columns 6 and 7, respectively.

rankp($RR_{i,j}^F, U^F$)	$ U^{\Phi,M} $	$ U^{\Phi,F} $	$\langle \lambda_{i,j}^u \rangle$	i	j	$RR_{i,j}^F$	severity
1 (1,49)	0	30	10 ± 3	Clavulanate	Ethinyl Estradiol	inf	None
2 (1,51)	0	27	8 ± 7	Prednisone	Estradiol	inf	Moderate
2 (1,51)	0	27	11 ± 6	Doxycycline	Ethinyl Estradiol	inf	Moderate
4 (1,57)	0	22	19 ± 28	Estrogens Conj.	Prednisone	inf	Moderate
5 (1,71)	0	13	35 ± 26	Carbamazepine	Ethinyl Estradiol	inf	Major
5 (1,71)	0	13	35 ± 26	Levonorgestrel	Carbamazepine	inf	Major
7 (76,1)	1204	3874	102 ± 95	Omeprazole	Clonazepam	2.28	Moderate
8 (1,83)	0	9	72 ± 128	Carbamazepine	Norethisterone	inf	Major
9 (1,89)	0	7	11 ± 4	Doxycycline	Iron (II) Sulfate	inf	Moderate
10 (1,94)	0	5	162 ± 120	Medroxyproges. Ac.	Phenobarbital	inf	Moderate
10 (1,94)	0	5	10 ± 6	Prednisolone	Ethinyl Estradiol	inf	Moderate
12 (1,98)	0	4	40 ± 29	Levonorgestrel	Phenobarbital	inf	Major
12 (1,98)	0	4	10 ± 2	Estrogens Conj.	Prednisolone	inf	Moderate
14 (1,102)	0	3	97 ± 94	Estrogens Conj.	Phenobarbital	inf	Moderate
14 (1,102)	0	3	40 ± 57	Methyldopa	Levodopa	inf	Minor
14 (1,102)	0	3	45 ± 43	Medroxyproges. Ac.	Warfarin	inf	None
14 (1,102)	0	3	40 ± 19	Digoxin	Verapamil	inf	Moderate
14 (1,102)	0	3	53 ± 16	Ethinyl Estradiol	Phenobarbital	inf	Major
14 (1,102)	0	3	136 ± 117	Ethinyl Estradiol	Aminophylline	inf	Moderate
20 (1,111)	0	2	23 ± 11	Doxycycline	Phenobarbital	inf	Moderate
20 (1,111)	0	2	79 ± 30	Norethisterone	Phenobarbital	inf	Major
20 (1,111)	0	2	288 ± 213	Phenytoin	Medroxyproges. Ac.	inf	Moderate
20 (1,111)	0	2	62 ± 53	Phenytoin	Norethisterone	inf	Major
20 (1,111)	0	2	62 ± 53	Phenytoin	Estradiol	inf	Moderate
20 (1,111)	0	2	79 ± 30	Estradiol	Phenobarbital	inf	Moderate
20 (1,111)	0	2	2 ± 0	Timolol	Fenoterol	inf	*
20 (1,111)	0	2	31 ± 0	Timolol	Aminophylline	inf	Major
20 (1,111)	0	2	6 ± 1	Estradiol	Prednisolone	inf	Moderate
29 (1,124)	0	1	117 ± 0	Haloperidol	Methyldopa	inf	Moderate
29 (1,124)	0	1	2 ± 0	Atenolol	Epinephrine	inf	Moderate
29 (1,124)	0	1	12 ± 0	Timolol	Methyldopa	inf	Major
29 (1,124)	0	1	29 ± 0	Phenytoin	Estrogens Conj.	inf	Moderate
29 (1,124)	0	1	2 ± 0	Erythromycin	Diazepam	inf	Moderate
29 (1,124)	0	1	4 ± 0	Erythromycin	Aminophylline	inf	Moderate
29 (1,124)	0	1	179 ± 0	Phenytoin	Ethinyl Estradiol	inf	Major
29 (1,124)	0	1	179 ± 0	Phenytoin	Levonorgestrel	inf	Major
29 (1,124)	0	1	15 ± 0	Phenytoin	Doxycycline	inf	Moderate
29 (1,124)	0	1	9 ± 0	Erythromycin	Fluoxetine	inf	Moderate
39 (104,2)	706	1411	53 ± 74	ASA	Ibuprofen	1.42	Major
40 (59,4)	198	992	127 ± 127	Amitriptyline	Fluoxetine	3.55	Major
41 (83,3)	400	1060	54 ± 77	Atenolol	Ibuprofen	1.88	Moderate
42 (75,5)	189	703	56 ± 61	Fluconazole	Simvastatin	2.63	Major
43 (62,7)	108	519	46 ± 54	Fluconazole	Clonazepam	3.40	None
44 (61,9)	86	415	44 ± 62	Propranolol	Ibuprofen	3.42	Moderate
45 (52,12)	46	309	86 ± 84	Fluoxetine	Propranolol	4.76	Moderate
46 (38,17)	1	178	10 ± 6	Ethinyl Estradiol	Amoxicillin	126.09	Moderate
47 (117,6)	369	630	87 ± 86	Omeprazole	Diazepam	1.21	Moderate
48 (53,14)	38	246	66 ± 57	Levothyroxine	Iron (II) Sulfate	4.59	Moderate
49 (81,10)	134	366	52 ± 75	Furosemide	Ibuprofen	1.93	Moderate
49 (54,15)	35	210	42 ± 40	Fluconazole	Amitriptyline	4.25	Moderate
51 (110,8)	265	487	30 ± 50	ASA	Dexamethasone	1.30	Moderate
52 (64,16)	48	209	123 ± 130	Imipramine	Fluoxetine	3.08	Major
53 (47,23)	12	104	9 ± 7	Norfloxacin	Iron (II) Sulfate	6.14	Moderate
54 (41,27)	7	95	4 ± 4	Diclofenac	Alendronate	9.61	Moderate
55 (39,29)	1	83	15 ± 26	Prednisone	Ethinyl Estradiol	58.79	Moderate
56 (115,11)	197	338	152 ± 132	Atenolol	Glyburide	1.22	Moderate
57 (40,35)	2	61	33 ± 28	Methyldopa	Iron (II) Sulfate	21.60	Moderate
58 (71,20)	31	124	68 ± 80	Amitriptyline	Salbutamol	2.83	Moderate
59 (112,13)	168	302	160 ± 133	Diltiazem	Simvastatin	1.27	Major
60 (84,18)	63	159	148 ± 139	Fluoxetine	Lithium	1.79	Major

Table S14: Top 60 known DDI pairs (i, j) most imbalanced for *females*, sorted by rank product (1st column; individual rank in parenthesis) of $RR_{i,j}^F$, the relative gender risk of DDI pair co-administration, and $|U^{\Phi,F}|$, the number of women affected by the DDI (7nd and 3rd columns, respectively). The number of men ($|U^{\Phi,M}|$) affected is shown in column 2. Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 5 and 6. DDI severity classification, according to *Drugs.com*, shown in column 8; DDIs or drugs not found in *Drugs.com* are labeled as *None* or ***, respectively.

rankp($RR_{i,j}^M, U^M$)	$ U^{\Phi,M} $	$ U^{\Phi,F} $	$\langle \lambda_{i,j}^u \rangle$	i	j	$RR_{i,j}^M$	severity
1 (1,32)	4	0	72 ± 61	Atenolol	Verapamil	inf	Major
2 (1,38)	3	0	185 ± 98	Phenytoin	Levodopa	inf	Moderate
3 (20,2)	280	244	243 ± 188	Haloperidol	Biperiden	1.62	Moderate
3 (40,1)	553	696	141 ± 124	ASA	Glyburide	1.12	Moderate
5 (1,43)	1	0	124 ± 0	Carbamazepine	Verapamil	inf	Major
5 (1,43)	1	0	6 ± 0	Erythromycin	Carbamazepine	inf	Major
5 (1,43)	1	0	31 ± 0	Phenytoin	Sulfadiazine	inf	Moderate
8 (18,5)	207	178	155 ± 125	Digoxin	Furosemide	1.64	Moderate
9 (13,9)	99	74	109 ± 96	Digoxin	Carvedilol	1.89	Moderate
10 (8,15)	37	10	135 ± 109	Allopurinol	Warfarin	5.22	Moderate
11 (41,3)	262	347	48 ± 93	Prednisone	ASA	1.07	Moderate
12 (33,4)	236	260	103 ± 87	ASA	Gliclazide	1.28	None
13 (17,8)	149	123	140 ± 114	Digoxin	Spirolactone	1.71	Minor
14 (6,24)	10	1	57 ± 46	Methylphenidate	Carbamazepine	14.12	None
15 (21,9)	99	87	142 ± 156	Haloperidol	Carbamazepine	1.61	Moderate
16 (7,32)	4	1	107 ± 123	Phenytoin	Amiodarone	5.65	Moderate
17 (12,22)	16	11	10 ± 6	Phenytoin	Ciprofloxacin	2.05	Moderate
18 (16,17)	29	23	118 ± 114	Digoxin	Amiodarone	1.78	Major
19 (46,6)	158	219	143 ± 138	Fluoxetine	Carbamazepine	1.02	Moderate
20 (11,26)	9	6	20 ± 17	Carvedilol	Fenoterol	2.12	*
21 (42,7)	156	208	110 ± 106	Carbamazepine	Simvastatin	1.06	Moderate
22 (9,38)	3	1	62 ± 44	Phenobarbital	Aminophylline	4.24	Moderate
23 (19,20)	23	20	144 ± 153	Phenytoin	Diazepam	1.62	Moderate
24 (15,26)	9	7	94 ± 83	Phenytoin	Furosemide	1.82	Minor
25 (14,28)	8	6	5 ± 3	Doxycycline	Amoxicillin	1.88	Moderate
26 (34,12)	70	79	115 ± 109	Phenytoin	Omeprazole	1.25	Moderate
27 (10,41)	2	1	9 ± 4	Phenytoin	Prednisolone	2.82	Moderate
28 (22,21)	20	19	82 ± 64	Gliclazide	Carvedilol	1.49	None
29 (36,13)	55	68	31 ± 43	Ibuprofen	Carvedilol	1.14	Moderate
30 (30,16)	35	36	169 ± 151	Phenytoin	Fluoxetine	1.37	Moderate
31 (48,11)	94	132	151 ± 145	Amitriptyline	Carbamazepine	1.01	Moderate
32 (32,17)	29	31	49 ± 95	Prednisone	Warfarin	1.32	Moderate
33 (31,19)	28	29	96 ± 96	Glyburide	Carvedilol	1.36	Moderate
34 (45,14)	50	67	126 ± 127	Digoxin	Hydrochlorothiazide	1.05	Moderate
35 (23,30)	7	7	9 ± 7	Furosemide	Gentamicin	1.41	Major
36 (24,32)	4	4	82 ± 54	Carbamazepine	Aminophylline	1.41	Moderate
36 (24,32)	4	4	67 ± 36	Diltiazem	Carbamazepine	1.41	Major
38 (35,23)	11	13	3 ± 2	Diclofenac	Warfarin	1.19	Major
39 (24,41)	2	2	4 ± 3	Doxycycline	Clavulanate	1.41	None
40 (24,43)	1	1	102 ± 110	Propranolol	Verapamil	1.41	Major
40 (24,43)	1	1	274 ± 218	Digoxin	Propylthiouracil	1.41	Moderate
40 (24,43)	1	1	2 ± 0	Phenytoin	Hydrocortisone	1.41	Moderate
43 (37,28)	8	10	33 ± 44	Fluconazole	Warfarin	1.13	Major
44 (47,24)	10	14	100 ± 85	Carbamazepine	Warfarin	1.01	Moderate
45 (37,32)	4	5	51 ± 91	Timolol	Salbutamol	1.13	Major
45 (37,32)	4	5	7 ± 1	Prednisolone	Phenobarbital	1.13	Moderate
47 (42,31)	6	8	88 ± 71	Phenytoin	Warfarin	1.06	Moderate
48 (42,38)	3	4	62 ± 97	Phenytoin	Trimethoprim	1.06	Moderate

Table S15: All 48 known DDI pairs (i, j) most imbalanced for *males*, sorted by rank product (1st column; individual rank in parenthesis) of $RR_{i,j}^M$, the relative gender risk of DDI pair co-administration, and $|U^{\Phi,M}|$, the number of men affected by the DDI (7nd and 2nd columns, respectively). The number of women ($|U^{\Phi,F}|$) affected is shown in column 3. Mean (\pm s.d.) co-administration length, $\langle \lambda_{i,j}^u \rangle$, is shown in column 4 (in days) for each DDI pair (i, j) whose English drug names are shown in columns 5 and 6. DDI severity classification, according to *Drugs.com*, shown in column 8; DDIs or drugs not found in *Drugs.com* are labeled as *None* or ***, respectively.

$RR_{i,j}^g \geq x$	$ D^{\Phi,F} $	$ D^{\Phi,M} $	Φ^F	Φ^M	Φ_{major}^F	Φ_{major}^M
1	68	46	133	48	31	10
2	56	17	80	12	21	3
3	49	13	65	9	16	3
4	45	13	58	9	13	3
5	38	11	49	8	13	3
6	36	8	47	6	13	3
7	35	8	45	6	12	3
8	32	8	42	6	12	3
9	31	8	41	6	11	3
10	29	8	40	6	11	3

Table S16: Number and proportions of drugs and interactions at increasing level of relative gender risk of DDI pair co-administration, $RR_{i,j}^g > x$ (1st column). Number of drugs by gender, is shown in columns 2 and 3. Number of drug pairs known to be a DDI, by gender, is shown in columns 4 and 5. Number of drug pairs, known to be a *major* DDI, by gender, is shown in columns 6 and 7. See also Table S17.

$RRI_{i,j}^g \geq x$	$ U^{\Phi,F} $	$ U^{\Phi,M} $	$ U_{major}^{\Phi,F} $	$ U_{major}^{\Phi,M} $	$\frac{ U^{\Phi,F} }{ U^F }$	$\frac{ U^{\Phi,M} }{ U^M }$	$\frac{ U_{major}^{\Phi,F} }{ U^F }$	$\frac{ U_{major}^{\Phi,M} }{ U^M }$
1	9,836	2,010	3,747	69	12.66%	03.65%	04.82%	00.13%
2	7,089	91	2,060	6	09.12%	00.17%	02.65%	00.01%
3	3,327	64	1,255	6	04.28%	00.12%	01.62%	00.01%
4	1,589	64	73	6	02.05%	00.12%	00.09%	00.01%
5	775	61	73	6	01.00%	00.11%	00.09%	00.01%
6	744	20	73	6	00.96%	00.04%	00.09%	00.01%
7	615	20	45	6	00.79%	00.04%	00.06%	00.01%
8	547	20	45	6	00.70%	00.04%	00.06%	00.01%
9	536	20	33	6	00.69%	00.04%	00.04%	00.01%
10	441	20	33	6	00.57%	00.04%	00.04%	00.01%

Table S17: Number and proportions of affected patients at increasing level of relative gender risk of DDI pair co-administration, $RRI_{i,j}^g > x$ (1st column). Number of patients by gender, is shown in columns 2 and 3. Number of patients by gender and major DDI, is shown in columns 4 and 5. The relative proportion of affected patients in relation to the Pronto population is shown in columns 6 through 9. See also Table S16.

S5.2 Relative Risk per severity

severity s	$ U_s^{\Phi, M} $	$ U_s^{\Psi, F} $	RRR_s^F
<i>Major</i>	1,433	3791	1.8739
<i>Moderate</i>	3,951	8760	1.5705
<i>Minor</i>	247	281	0.8059
<i>None</i>	409	905	1.5674
*	39	140	2.5428

Table S18: Absolute number of patients and relative risk measures per gender (g) and severity score (s , 1st column). Columns 2 and 3 lists absolute number of males ($g = M$) and females ($g = F$) affected by at least one DDI for each severity score, respectively. Column 4 lists the relative risk of interaction given a specific severity score and gender. DDIs or drugs not found in *Drugs.com* are labeled as *None* or *, respectively Notice that the same patient may have been administered DDI of more than one severity type.

S5.3 Risk Measures per age

$[y_1, y_2]$	$ U^{[y_1, y_2]} $	$ U^{\nu \geq 2, [y_1, y_2]} $	$ U^{\Psi, [y_1, y_2]} $	$ U^{\Phi, [y_1, y_2]} $	$RC^{[y_1, y_2]}$	$RI^{[y_1, y_2]}$
00-04	8,946	7,195	6,810	20	0.9465	0.0029
05-09	6,390	4,688	4,362	7	0.9305	0.0016
10-14	5,631	3,794	3,507	25	0.9244	0.0071
15-19	8,305	6,094	5,705	139	0.9362	0.0244
20-24	10,382	7,819	7,334	237	0.9380	0.0323
25-29	9,725	7,305	6,835	301	0.9357	0.0440
30-34	9,100	6,787	6,386	525	0.9409	0.0822
35-39	8,844	6,696	6,259	687	0.9347	0.1098
40-44	9,184	7,043	6,615	1,023	0.9392	0.1546
45-49	10,085	8,039	7,610	1,426	0.9466	0.1874
50-54	10,650	8,617	8,200	1,868	0.9516	0.2278
55-59	9,236	7,686	7,386	1,956	0.9610	0.2648
60-64	8,179	7,049	6,801	2,006	0.9648	0.2950
65-69	6,315	5,572	5,444	1,794	0.9770	0.3295
70-74	4,412	3,916	3,843	1,311	0.9814	0.3411
75-79	3,398	3,042	2,968	1,057	0.9757	0.3561
80-84	2,129	1,909	1,874	638	0.9817	0.3404
85-89	1,174	1,029	1,007	349	0.9786	0.3466
90+	637	531	515	158	0.9699	0.3068

Table S19: Absolute number of patients and risk measures per age range ($[y_1, y_2]$, 1st column). Columns 2 through 5 lists, per age range, absolute numbers of: patients ($|U^{[y_1, y_2]}|$), patients with at least 2 drug administrations ($|U^{\nu \geq 2, [y_1, y_2]}|$), patients with at least one co-administration ($|U^{\Psi, [y_1, y_2]}|$), and patients with at least one known DDI co-administration ($|U^{\Phi, [y_1, y_2]}|$). Per age range risk for both co-administration ($RC^{[y_1, y_2]}$) and known DDI co-administration ($RI^{[y_1, y_2]}$) are listed in columns 6 and 7, respectively.

$[y_1, y_2]$	$ U^{M,[y_1,y_2]} $	$ U^{\nu \geq 2,M,[y_1,y_2]} $	$ U^{\Psi,M,[y_1,y_2]} $	$ U^{\Phi,M,[y_1,y_2]} $	$RC^{M,[y_1,y_2]}$	$RI^{M,[y_1,y_2]}$
00-04	4,537	3,664	3,473	8	0.9479	0.0023
05-09	3,319	2,416	2,239	3	0.9267	0.0013
10-14	2,932	1,926	1,776	14	0.9221	0.0079
15-19	3,518	2,390	2,247	33	0.9402	0.0147
20-24	4,204	3,020	2,838	76	0.9397	0.0268
25-29	4,066	2,890	2,708	99	0.9370	0.0366
30-34	3,692	2,641	2,500	1,68	0.9466	0.0672
35-39	3,428	2,488	2,317	1,90	0.9313	0.0820
40-44	3,504	2,559	2,394	2,79	0.9355	0.1165
45-49	3,945	3,043	2,892	4,17	0.9504	0.1442
50-54	4,142	3,219	3,048	5,25	0.9469	0.1722
55-59	3,638	2,953	2,829	6,06	0.9580	0.2142
60-64	3,257	2,731	2,622	6,26	0.9601	0.2387
65-69	2,525	2,197	2,148	6,45	0.9777	0.3003
70-74	1,729	1,494	1,461	4,27	0.9779	0.2923
75-79	1,303	1,162	1,127	3,44	0.9699	0.3052
80-84	718	649	637	1,86	0.9815	0.2920
85-89	361	312	304	98	0.9744	0.3224
90+	214	168	163	49	0.9702	0.3006

Table S20: Absolute number of *male* patients and risk measures per age range ($[y_1, y_2]$, 1st column). Columns 2 through 5 lists, per age range, absolute numbers of: male patients ($|U^y|$), male patients with at least 2 drug administrations ($|U^{\nu \geq 2,M,[y_1,y_2]}|$), male patients with at least one co-administration ($|U^{\Psi,M,[y_1,y_2]}|$), and male patients with at least one known DDI co-administration ($|U^{\Phi,M,[y_1,y_2]}|$). Per age range women risk for both co-administration ($RC^{M,[y_1,y_2]}$) and known DDI co-administration ($RI^{M,[y_1,y_2]}$) are listed in columns 6 and 7, respectively.

$[y_1, y_2]$	$ U^{F,[y_1,y_2]} $	$ U^{\nu \geq 2,F,[y_1,y_2]} $	$ U^{\Psi,F,[y_1,y_2]} $	$ U^{\Phi,F,[y_1,y_2]} $	$RC^{F,[y_1,y_2]}$	$RI^{F,[y_1,y_2]}$
00-04	4,409	3,531	3,337	12	0.9451	0.0036
05-09	3,071	2,272	2,123	4	0.9344	0.0019
10-14	2,699	1,868	1,731	11	0.9267	0.0064
15-19	4,787	3,704	3,458	106	0.9336	0.0307
20-24	6,178	4,799	4,496	161	0.9369	0.0358
25-29	5,659	4,415	4,127	202	0.9348	0.0489
30-34	5,408	4,146	3,886	357	0.9373	0.0919
35-39	5,416	4,208	3,942	497	0.9368	0.1261
40-44	5,680	4,484	4,221	744	0.9413	0.1763
45-49	6,140	4,996	4,718	1,009	0.9444	0.2139
50-54	6,508	5,398	5,152	1,343	0.9544	0.2607
55-59	5,598	4,733	4,557	1,350	0.9628	0.2962
60-64	4,922	4,318	4,179	1,380	0.9678	0.3302
65-69	3,790	3,375	3,296	1,149	0.9766	0.3486
70-74	2,683	2,422	2,382	884	0.9835	0.3711
75-79	2,095	1,880	1,841	713	0.9793	0.3873
80-84	1,411	1,260	1,237	452	0.9817	0.3654
85-89	813	717	703	251	0.9805	0.3570
90+	423	363	352	109	0.9697	0.3097

Table S21: Absolute number of *female* patients and risk measures per age range ($[y_1, y_2]$, 1st column). Columns 2 through 5 lists, per age range, absolute numbers of: female patients ($|U^y|$), female patients with at least 2 drug administrations ($|U^{\nu \geq 2,F,[y_1,y_2]}|$), female patients with at least one co-administration ($|U^{\Psi,F,[y_1,y_2]}|$), and female patients with at least one known DDI co-administration ($|U^{\Phi,F,[y_1,y_2]}|$). Per age range women risk for both co-administration ($RC^{F,[y_1,y_2]}$) and known DDI co-administration ($RI^{F,[y_1,y_2]}$) are listed in columns 6 and 7, respectively.

S5.4 Risk Ratios per number of drug

# of drugs ν	$ U^\nu $	$ U^{\Psi,\nu} $	$ U^{\Phi,\nu} $	RRC^ν	RRI^ν
1	27,911	-	-	-	-
2	25,032	20,517	283	1.0	1.0
3	19,163	18,468	677	1.1758	3.1249
4	14,305	14,185	929	1.2098	5.7443
5	11,026	11,010	1,208	1.2183	9.6908
6	8,587	8,583	1,425	1.2195	14.6785
7	6,438	6,438	1,512	1.2201	20.7735
8	4,970	4,970	1,477	1.2201	26.2865
9	3,877	3,877	1,417	1.2201	32.3283
10	2,932	2,932	1,335	1.2201	40.2742
11	2,264	2,264	1,089	1.2201	42.5462
12	1,691	1,691	936	1.2201	48.9600
13	1,214	1,214	754	1.2201	54.9366
14	937	937	641	1.2201	60.5101
15	618	618	413	1.2201	59.1113
16	482	482	368	1.2201	67.5320
17	366	366	285	1.2201	68.8768
18	268	268	218	1.2201	71.9500
19	177	177	142	1.2201	70.9617
20	131	131	105	1.2201	70.8969
>20	333	333	313	1.2201	83.1398

Table S22: Absolute number of patients, join probabilities and relative risk per number of distinct drugs dispensed, ν^u (1st column). By definition, patients who had only one distinct drug dispensed could not have had any co-administration or interaction. Columns 2 through 4 lists, per distinct drugs dispensed, absolute numbers of: patients ($|U^\nu|$), patients with at least one co-administration ($|U^{\Psi,\nu}|$), and patients with at least one known DDI co-administration ($|U^{\Phi,\nu}|$). Per number of distinct drugs dispensed relative risks for both co-administration (RRC^ν) and known DDI co-administration (RRI^ν) are listed in columns 5 and 6, respectively.

S5.5 DDI Networks

For all pair of drugs known to interact we built two different networks, which are weighted versions of Δ . In these networks weights are defined by either $\tau_{i,j}^\Phi$ or $|U_{i,j}^\Phi|$. In this section we show alternatives plotting schemes, additional subgraphs, and tables containing values used for plotting or inference.





Figure S7: **Left.** Node degree, $deg(i)$, and node degree strength, $degstr(i) = \sum_j \tau_{i,j}^\Phi$, of weighted version of network Δ where weights are defined by $\tau_{i,j}^\Phi$. **Right.** Edge distribution of weighted version of network Δ , where weights are defined by either $\tau_{i,j}^\Phi$ or $|U_{i,j}^\Phi|$.






Figure S9: A weighted version of network Δ where weights are defined by $\tau_{i,j}^{\Phi}$. **Top left.** Female DDI network. **Top right.** Male DDI network. **Bottom left.** Major DDI network. **Bottom center.** Moderate DDI network. **Bottom right.** Minor DDI network. **Nodes** denote drugs i involved in at least one co-administration known to be a DDI. Node color represents the highest level of primary action class, as retrieved from Drugs.com (see legend). Node size represents the probability of interaction, $P(I(i))$, as defined in main text. **Edges weights** are the value of $\tau_{i,j}^{\Phi}$, obtained from eq. 4, a normalized measure of the degree to which a specific DDI is co-prescribed. **Edge colors** denote $RRI_{i,j}^g$, where $g \in \{M, F\}$, to identify DDI edges that are higher risk for females (blue) or males (red). Color intensity for $RRI_{i,j}^g$ varies in $[1, 5]$; that is, values are clipped at 5.




Figure S10: Principal Component Analysis (PCA) of network where weights are defined by $\tau_{i,j}^{\Phi}$. **Top Left.** Explained variance ratio for the first 9 principal components. **Additional plots.** Projection of network nodes (drugs) given the respective principal component. Nodes with loading ≥ 2 s.d. in either component are annotated.




Figure S11: Principal Component Analysis (PCA) of network where weights are defined by $|U_{i,j}^\Phi|$. **Top Left.** Explained variance ratio for the first 9 principal components. **Additional plots.** Projection of network nodes (drugs) given the respective principal component. Nodes with loading ≥ 2 s.d. in either component are annotated.

i	$deg(i)$	$degstr(i)$	$betweenness(i)$	$PI(i)$	class
Phenytoin	24	6.51	0.30	0.20	CNS agents
Phenobarbital	15	2.17	0.28	0.05	CNS agents
Ethinyl Estradiol	9	1.78	0.03	0.04	Hormones
Doxycycline	8	1.39	0.02	0.04	Anti-infectives
Prednisone	7	0.96	0.02	0.03	Hormones
Prednisolone	6	0.54	0.03	0.00	Hormones
Diazepam	5	1.12	0.05	0.09	CNS agents
Erythromycin	5	0.20	0.18	0.01	Anti-infectives
Estradiol	4	0.57	0.00	0.01	Hormones
Estrogens Conj.	4	0.58	0.00	0.01	Hormones
Norethisterone	3	0.73	0.00	0.00	Hormones
Levonorgestrel	3	0.79	0.00	0.00	Hormones
Medroxyprog. Ac.	3	1.06	0.00	0.00	Hormones
Omeprazole	3	0.85	0.00	0.05	Gastrointestinal agents
Folic acid	2	0.50	0.00	0.00	Nutritional Products
Clonazepam	2	0.42	0.00	0.09	CNS agents
Amoxicillin	2	0.30	0.00	0.00	Anti-infectives
Clavulanate	2	0.23	0.00	0.00	Anti-infectives
Sulfadiazine	1	0.51	0.00	0.01	Anti-infectives
Trimethoprim	1	0.16	0.00	0.00	Anti-infectives
Carbamazepine	18	4.84	0.20	0.18	CNS agents
Fluoxetine	10	3.41	0.02	0.06	Psychotherapeutic agents
Haloperidol	6	2.32	0.03	0.20	Psychotherapeutic agents
Lithium	9	2.05	0.13	0.17	Psychotherapeutic agents
Fluconazole	10	1.74	0.09	0.11	Anti-infectives
Salbutamol	7	1.53	0.00	0.03	Respiratory agents
Amitriptyline	5	1.47	0.00	0.08	Psychotherapeutic agents
Imipramine	5	1.31	0.01	0.07	Psychotherapeutic agents
Nortriptyline	5	1.30	0.00	0.09	Psychotherapeutic agents
Fenoterol	8	0.81	0.13	0.01	Respiratory agents
Biperiden	1	0.70	0.00	0.13	CNS agents
Methylphenidate	1	0.24	0.00	0.02	CNS agents
Losartan	1	0.21	0.00	0.00	Cardiovascular agents
Captopril	1	0.18	0.00	0.00	Cardiovascular agents
Metronidazole	3	0.17	0.16	0.00	Anti-infectives
Enalapril	1	0.16	0.00	0.00	Cardiovascular agents
Methyldopa	7	2.30	0.01	0.06	Cardiovascular agents
Iron (II) Sulfate	5	1.12	0.02	0.04	Nutritional Products
Levodopa	3	0.97	0.03	0.01	CNS agents
Ciprofloxacin	4	0.35	0.21	0.01	Anti-infectives
Norfloxacin	2	0.29	0.00	0.01	Anti-infectives
Metoclopramide	1	0.11	0.00	0.00	Gastrointestinal agents

Table S23: Louvain modules of weighted version of network Δ where weights are defined by $\tau_{i,j}^{\Phi}$. Each Louvain module is shown separated by a horizontal line. Drugs nodes (i ; 1st column) and their respective degree, degree strength, and betweenness centrality measure, shown in columns 2, 3, and 4, respectively Column 5 shows the drug probability of interaction, $PI(i)$. Drug class is shown in column 6. Continues on Table S24.

i	$deg(i)$	$degstr(i)$	$betweenness(i)$	$PI(i)$	class
Digoxin	9	3.70	0.03	0.24	Cardiovascular agents
Warfarin	14	3.31	0.17	0.13	Coagulation modifiers
Diltiazem	6	2.66	0.03	0.13	Cardiovascular agents
Amiodarone	3	1.40	0.00	0.02	Cardiovascular agents
Furosemide	5	1.31	0.05	0.04	Cardiovascular agents
Levothyroxine	3	1.15	0.00	0.01	Hormones
Simvastatin	4	1.07	0.00	0.02	Metabolic agents
Propylthiouracil	2	0.87	0.00	0.01	Hormones
Hydrochlorothiazide	2	0.69	0.00	0.00	Cardiovascular agents
Spirolactone	1	0.55	0.00	0.02	Cardiovascular agents
Allopurinol	1	0.46	0.00	0.01	Metabolic agents
Amlodipine	1	0.34	0.00	0.00	Cardiovascular agents
Acetaminophen	1	0.22	0.00	0.00	CNS agents
Gentamicin	1	0.12	0.00	0.02	Anti-infectives
Diclofenac	2	0.09	0.03	0.01	CNS agents
Tobramycin	1	0.08	0.00	0.00	Topical Agents
Azithromycin	1	0.07	0.00	0.00	Anti-infectives
Alendronate	1	0.04	0.00	0.01	Metabolic agents
Aminophylline	10	1.93	0.23	0.01	Respiratory agents
Hydrocortisone	3	0.06	0.20	0.01	Hormones
Timolol	7	1.11	0.16	0.06	Cardiovascular agents
Ibuprofen	7	1.28	0.06	0.05	CNS agents
Atenolol	8	2.22	0.05	0.06	Cardiovascular agents
Propranolol	14	4.81	0.06	0.10	Cardiovascular agents
ASA	7	1.57	0.01	0.07	CNS agents
Verapamil	4	1.11	0.01	0.04	Cardiovascular agents
Glyburide	5	2.29	0.00	0.12	Metabolic agents
Carvedilol	6	1.70	0.00	0.07	Cardiovascular agents
Gliclazide	5	1.64	0.00	0.12	Metabolic agents
Chlorpromazine	1	0.33	0.00	0.00	CNS agents
Dexamethasone	3	0.24	0.00	0.03	Hormones
Maprotiline	1	0.23	0.00	0.01	Psychotherapeutic agents
Epinephrine	1	0.0	0.0	0.02	Respiratory agents

Table S24: Continuation. See Table S23 for column description.

i	$deg(i)$	$degstr(i)$	$betweenness(i)$	$PI(i)$	class
Phenytoin	24	6.51	0.30	0.20	CNS agents
Phenobarbital	15	2.17	0.28	0.05	CNS agents
Ethinyl Estradiol	9	1.78	0.03	0.04	Hormones
Doxycycline	8	1.39	0.02	0.04	Anti-infectives
Prednisone	7	0.96	0.02	0.03	Hormones
Prednisolone	6	0.54	0.03	0.00	Hormones
Estradiol	4	0.57	0.00	0.01	Hormones
Estrogens Conj.	4	0.58	0.00	0.01	Hormones
Dexamethasone	3	0.24	0.00	0.03	Hormones
Norethisterone	3	0.73	0.00	0.00	Hormones
Hydrocortisone	3	0.06	0.20	0.01	Hormones
Levonorgestrel	3	0.79	0.00	0.00	Hormones
Medroxyproges. Ac.	3	1.06	0.00	0.00	Hormones
Folic acid	2	0.50	0.00	0.00	Nutritional Products
Amoxicillin	2	0.30	0.00	0.00	Anti-infectives
Clavulanate	2	0.23	0.00	0.00	Anti-infectives
Sulfadiazine	1	0.51	0.00	0.01	Anti-infectives
Trimethoprim	1	0.16	0.00	0.00	Anti-infectives
Propranolol	14	4.81	0.06	0.10	Cardiovascular agents
Methyldopa	7	2.30	0.01	0.06	Cardiovascular agents
Glyburide	5	2.29	0.00	0.12	Metabolic agents
Atenolol	8	2.22	0.05	0.06	Cardiovascular agents
Aminophylline	10	1.93	0.23	0.01	Respiratory agents
Carvedilol	6	1.70	0.00	0.07	Cardiovascular agents
Gliclazide	5	1.64	0.00	0.12	Metabolic agents
ASA	7	1.57	0.01	0.07	CNS agents
Salbutamol	7	1.53	0.00	0.03	Respiratory agents
Ibuprofen	7	1.28	0.06	0.05	CNS agents
Iron (II) Sulfate	5	1.12	0.02	0.04	Nutritional Products
Timolol	7	1.11	0.16	0.06	Cardiovascular agents
Verapamil	4	1.11	0.01	0.04	Cardiovascular agents
Levodopa	3	0.97	0.03	0.01	CNS agents
Ciprofloxacin	4	0.35	0.21	0.01	Anti-infectives
Chlorpromazine	1	0.33	0.00	0.00	CNS agents
Norfloxacin	2	0.29	0.00	0.01	Anti-infectives
Maprotiline	1	0.23	0.00	0.01	Psychotherapeutic agents
Metoclopramide	1	0.11	0.00	0.00	Gastrointestinal agents

Table S25: InfoMap modules of weighted version of network Δ where weights are defined by $\tau_{i,j}^\Phi$. Each InfoMap module is shown separated by a horizontal line. Drugs nodes (i ; 1nd column) and their respective degree, total degree strength ($degstr(i)$), and betweenness centrality measure, shown in columns 2, 3, and 4, respectively Column 5 shows the drug probability of interaction, $PI(i)$. Drug class is shown in column 6. Continues on Table S26.

i	$deg(i)$	$degstr(i)$	$betweenness(i)$	$PI(i)$	class
Carbamazepine	18	4.84	0.20	0.18	CNS agents
Fluoxetine	10	3.41	0.02	0.06	Psychotherapeutic agents
Fluconazole	10	1.74	0.09	0.11	Anti-infectives
Amitriptyline	5	1.47	0.00	0.08	Psychotherapeutic agents
Imipramine	5	1.31	0.01	0.07	Psychotherapeutic agents
Nortriptyline	5	1.30	0.00	0.09	Psychotherapeutic agents
Fenoterol	8	0.81	0.13	0.01	Respiratory agents
Methylphenidate	1	0.24	0.00	0.02	CNS agents
Digoxin	9	3.70	0.03	0.24	Cardiovascular agents
Warfarin	14	3.31	0.17	0.13	Coagulation modifiers
Furosemide	5	1.31	0.05	0.04	Cardiovascular agents
Levothyroxine	3	1.15	0.00	0.01	Hormones
Propylthiouracil	2	0.87	0.00	0.01	Hormones
Hydrochlorothiazide	2	0.69	0.00	0.00	Cardiovascular agents
Spirolactone	1	0.55	0.00	0.02	Cardiovascular agents
Allopurinol	1	0.46	0.00	0.01	Metabolic agents
Acetaminophen	1	0.22	0.00	0.00	CNS agents
Gentamicin	1	0.12	0.00	0.02	Anti-infectives
Tobramycin	1	0.08	0.00	0.00	Topical Agents
Azithromycin	1	0.07	0.00	0.00	Anti-infectives
Haloperidol	6	2.32	0.03	0.20	Psychotherapeutic agents
Lithium	9	2.05	0.13	0.17	Psychotherapeutic agents
Biperiden	1	0.70	0.00	0.13	CNS agents
Losartan	1	0.21	0.00	0.00	Cardiovascular agents
Captopril	1	0.18	0.00	0.00	Cardiovascular agents
Metronidazole	3	0.17	0.16	0.00	Anti-infectives
Enalapril	1	0.16	0.00	0.00	Cardiovascular agents
Diltiazem	6	2.66	0.03	0.13	Cardiovascular agents
Amiodarone	3	1.40	0.00	0.02	Cardiovascular agents
Simvastatin	4	1.07	0.00	0.02	Metabolic agents
Amlodipine	1	0.34	0.00	0.00	Cardiovascular agents
Diazepam	5	1.12	0.05	0.09	CNS agents
Omeprazole	3	0.85	0.00	0.05	Gastrointestinal agents
Clonazepam	2	0.42	0.00	0.09	CNS agents
Erythromycin	5	0.20	0.18	0.01	Anti-infectives
Diclofenac	2	0.09	0.03	0.01	CNS agents
Alendronate	1	0.04	0.00	0.01	Metabolic agents
Epinephrine	1	0.0	0.0	0.02	Respiratory agents

Table S26: Continuation. See Table S25 for column description.

S5.6 Null Model for RI^y

To test if sheer combinatorics explains the increased risk of DDI in older age, we compared the observed risk of interactions RI^y with a random null model, H_0^{rnd} . We separated all patients u in our dataset per age range y . From these subset of patients $U^{[y^1, y^2]}$ we also separated which drugs d were prescribed in their age range as $D^{[y^1-y^2]}$. For clarity, we will refer to all measures previously reported with an added star (\star) in the notation to indicate that these values are calculated for the null model (e.g., $RI^{y\star}$ is the null model value of the risk of interaction per age range, RI^y).

The null model is then computed by proportionally sampling patients for each age range, $u \in U^{[y^1-y^2]}$. For each drawn patient u we sampled $|D^u|$ drugs available to patients in the patient’s age range $D^{[y^1, y^2]}$, and then randomly drew Ψ^u co-administrations from the patient’s possible pairwise combinations $\binom{|D^u|}{2}$ of drugs, thus yielding random drug pairs $\psi_{i,j}^{u\star}$ that matched the observed number of co-administrations, $\Psi^u \equiv \Psi^{u\star}$. To decide if a co-administration is an interaction in the null model, we compare the randomly drawn pair of drugs against DrugBank to decide if $\varphi_{i,j}^{u\star}$ is an interaction or not.

This null model allow us to measure what is the expected number of interactions given the increase of co-administrations observed with age, assuming drugs are prescribed completely at random. In other words, it measures the risk of DDI if only age, and the drugs available to patients in these ages, were given to them at random with the same number of co-administrations.

To compute confidence intervals for the number of patients in the null model, we proportionally sampled the same number of patients observed in each age range, 100 times. Confidence intervals can be seen as background fills in Figures 4 and 6. To measure the significance of our null models, Table S27 shows the chi-square tests against the expected number of patients in each age bin, $|U^{[y^1, y^2]}|$, from our data. The null model rejects the hypothesis it was sampled from the same distribution as our data. This means the observed increase in DDI with age, seen in our data, cannot be explained alone by the increased combinatorics of drug co-administrations alone.

	model	chi-square	p -value
1	H_0^{rnd}	22378.5912	0.0

Table S27: Chi-square statistic when the number of patients in the null model, $|U^{y\star}|$, is compared to the observed values, $|U^y|$.

S6 Neighborhood Results

Figure S12 shows the number of drugs dispensed for each neighborhood N , colored by the average income of its residents, R\$ (*Reais*). Naturally, the larger the neighborhood population (Ω^N), the more drugs are dispensed (α^N), leading to a fairly clear linear relationship ($R^2 = 0.623$, $p = 0.0$). Some observed exceptions above and below the regression line are noteworthy, though. Three neighborhoods—*Itoupavazinha*, *Velha Central* and *Água Verde*—display dispensation levels below what is expected for their population (circled in Cyan in Figure S12-left). On the other hand, two neighborhoods that are also not among the wealthiest—*Fortaleza* and *Tribess*—are well above the expected drug dispensation (circled in magenta). Looking at these specific neighborhoods will require further work to be better understood. In any case, their identification highlights the benefits of analyzing EHR and a data science approach to support responsive public health policy.

For a visual inspection of how both official survey numbers and those analyzed in the main manuscript related geographically in the city of Blumenau, we have mapped neighborhoods to results in Figures S13 and S14. The first figure denotes neighborhoods mapped to official numbers from IBGE[S1], such as population, gender rate and income distribution. The second figure denotes dispensed drug intervals, distinct drugs, co-administrations and interactions mapped to each neighborhood.




Figure S12: Left. Number of drugs intervals dispensed α^N against population Ω^N in each neighborhood N . **Right.** Number of drug intervals dispensed (α^N) versus number of interactions (Φ^N), per neighborhood (N), normalized by population (Ω^N). Color denotes the average per capita income of neighborhood, in Brazilian *Reais* (R\$). Regression line shown in green. Patients who reported living in neighborhood *Other* were discarded from computation.




Figure S13: Data from IBGE [S1] mapped to geographical neighbourhoods in the city of Blumenau. **Left.** Population probability, $P(\Omega^N)$. **Center.** Gender rate, $\Omega^{N,g=F} / \Omega^{N,g=M}$. **Right.** Average income in Brazilian Reais (R\$/month). See §S7 for details on income.




Figure S14: Results from Pronto data mapped to geographical neighbourhoods in the city of Blumenau. **Top left.** Number of drug interval dispensed per capita, α^N/Ω^N . **Top right.** Distinct drugs dispensed per capita, ν^N/Ω^N . **Bottom left.** Number of co-administrations per capita, Ψ^N/Ω^N . **Bottom right.** Number of interactions per capita, Φ^N/Ω^N .

S7 Projected Cost of DDI in hospitalizations

Estimating the financial burden of DDI prescribed in primary and secondary care is difficult, since outcomes vary by a large margin and only few result in short-term symptoms requiring hospitalization. Measuring hospitalizations due to DDI are also strenuous, since underestimation of true risk can be masked in practitioners and pharmacists failing to recognize adverse patient outcomes caused by DDI as such. However, drug- and cohort-focused studies have shown that the number of DDI is associated with a significantly increased risk of hospitalization [S6, S7]. A review paper in 2007 [S8] estimated that DDI were held responsible for 0.054% of emergency room (ER) visits, 0.57% of hospital admissions (4.8% in the elderly population) and 0.12% of re-hospitalizations. The most common outcomes were gastrointestinal bleeding (32.8%), hypertension/hypotension (18%) and cardiac rhythm disturbances (18%).

In this section a study of the financial burden of possible DDI-related hospitalizations is presented. It considers various rates of hospitalization expected for major DDI co-administrations, and is based on a cost estimate of ADR hospitalizations in Canada [S9], and average hospitalization costs for Brazil at city, state and national levels. As average hospitalization costs were not found for the United States, results in Canadian dollars were also converted to US dollars. Our estimation then relies on guessing what proportion of patients with major DDI co-administrations are likely to have an ADR requiring hospitalization.

		Blumenau city	Santa Catarina state	Brazil national	Ontario province
Population		338,876	6,819,190	204,450,649	13,680,425
Hospitalization	Elective	9,761	146,395	3,391,088	-
	Urgent	24,592 (5,808)	507,189 (110,748)	13,440,043 (2,711,527)	-
	Work Accident	87	2,106	64,485	-
	External Causes	786	902	110,922	-
	Total	35,226	656,592	17,006,538	-
Avg. Cost	Elective	R\$ 3,764.62	R\$ 1,533.10	R\$ 1,583.45	-
	Urgent	R\$ 2,606.03	R\$ 1,379.13	R\$ 1,083.23	C\$ 8,443.14
	Work Accident	R\$ 1,663.27	R\$ 2,595.45	R\$ 1,541.38	-
	External Causes	R\$ 2,321.31	R\$ 2,203.50	R\$ 1,256.36	-

Table S28: Population, number of hospitalizations, and average cost per hospitalization in the analyzed period shown for city, state and national levels. Population follows the official projections for 2015. Hospitalization numbers and cost shown by type. Urgent hospitalization values in parenthesis shown for patients over 64 years old. Note Blumenau has a much higher average cost per hospitalization than state and national levels. Brazil data from Hospitalization Information System (*Sistema de Informações Hospitalares do SUS; SIH/SUS*) [S10]. Ontario data from Wu et al. [S9], adjusted for inflation.

To compute costs we gathered number of public health care hospitalizations and average costs for each level (see Table S28) from the national Hospitalization Information System (*Sistema de Informações Hospitalares do SUS; SIH/SUS*), a data source managed by the Informatics Department under the Executive Secretary of Brazil’s Ministry of Health [S10].

As reported, the number of patients prescribed a major DDI in Blumenau (city level) was $|U^{\Phi, s=major}| = 5,224$. For state and national levels, we estimated this number from the percentage of hospitalizations it represents at city level, a reasonable assumption due the lack of data that generalizes medical practice in Blumenau for the state and country. For example, say 261 (or 5%) Pronto patients prescribed a major DDI had to be hospitalized. In hospitalization terms, that accounts for 1.06% of all hospitalizations in the same period. At the state and national level, the same 1.06% accounts for 5,376 and 142,564 patients, respectively. Costs are then estimated by multiplying the number of patients assumed hospitalized by the average hospitalization cost in each level.

Wu et al. [S9] argued in 2007 that the average cost of ADR-related hospitalization for all adults over 65 in the province of Ontario (pop. 12M in 2006; 13.6M in 2014) was C\$ 7,528 (C\$ 8,443.14 or \$7,380.78 in 2014 when adjusted for inflation and exchange rate) for a total annual cost of C\$ 13.6 million (C\$ 15.2M or \$13.3M after adjusting), or estimated C\$ 35.7 million (C\$ 40M or \$35M after adjusting) in Canada. In an attempt to compare results, we also multiplied the number of patients assumed to have been hospitalized to their average cost of ADR-relation hospitalization (see columns 6 and 7 of Table S29). Moreover, Tables S29, S30 and S31 show the estimated costs at different percentages of hospitalizations at city, state and

national levels, respectively. Costs in Brazilian Reais (columns 4 and 5) are computed based on the average cost of hospitalization in Brazil. Costs in C\$ use Wu et al. [S9] as reference (columns 6 and 7), and then converted to US\$ with the average exchange rate between the two currencies for the whole period of our data (columns 8 and 9). The average exchange rate in the period was C\$1.00 Canadian dollar equals to \$0.8742 US dollar, and maximum and minimum rates were .9418 in January 4th 2014 and .7821 in March 14th 2015, respectively.

Our cost analysis first considers two previous studies of the proportion of emergency room visits that are due to DDI and ADR. Becker et al. [S8] reported that 0.57% of all hospital admissions they observed were due to DDI, which in our data would correspond to 140 patients, or $p_h = 2.68\%$ of all patients dispensed a major DDI (see Table S29). Wu et al. [S9], on the other hand, argued that 0.75% of all hospitalizations of patients over 65 years of age were due to ADR (not only from DDI), which corresponds in our data to 436 patients, or $p_h = 8.35\%$ of all patients who were co-administered a major DDI. Both of these conjectures are likely to err on the side of under-reporting emergency room admissions due to DDI or ADR, since this is a well-known problem in studies of this phenomenon [S11, S12, S13, S14, S15]. Indeed, the proportion of hospital admissions due to ADR has been reported in the literature to vary anywhere between 0.5% to 12% [S13], with DDI reportedly being responsible for 15% [S14] to 30% [S16] of all ADR. These ranges, if correct, put the proportion of hospital admissions due to DDI anywhere between $0.5\% \times 15\% = 0.075\%$ and $12\% \times 30\% = 3.6\%$, which in our Blumenau data would mean between 18 and 885 emergency room patients, or $p_h \in [0.35, 16.95]\%$ of all patients dispensed a major DDI. These ranges could be higher, since even in the more controlled hospital environment, the proportion of patients with ADR can be as high as 41% [S17]. Therefore, in addition to the costs derived from the numbers provided by Becker et al. [S8] and Wu et al. [S9], tables in this section also report cost estimates for various values of p_h , so that readers can judge what is an appropriate value to consider. Given the ranges just outlined, it is reasonable to assume, for instance, that $p_h = 10\%$ of all patients dispensed a major DDI will have to be hospitalized (522 patients).

The lowest estimate ($p_h = 2.68\%$, via Becker et al. [S8]) leads to a cost of DDI-related hospitalization in Blumenau of over \$1M in the 18-month period, after adjusting for Canadian cost, inflation and exchange rate to US dollar. The extrapolated costs to the state and the country are \$21M and \$565M, respectively (see Tables S30 and S31). The estimated costs obtained via Wu et al. [S9] ($p_h = 8.35\%$) reach \$3.2M, \$61M, and \$1.5B, for the city, state and country levels respectively. Finally, if we assume $p_h = 10\%$, the estimated costs reach \$3.9M, \$79M, and \$2.1B, for the city, state and country levels respectively.

All estimations lead to very substantial costs for the various levels of government. To compare them to the costs found for Canada [S9], we computed per capita measures of the burden of DDI-related hospitalizations. For instance, the lowest estimate $p_h = 2.68\%$ leads to a per capita cost for Blumenau of \$2.03, while the inflation-adjusted cost for Ontario (Canada) is \$0.97, suggesting that the financial burden of DDI is more severe than previously thought—even when considering only the lowest estimate of the proportion of hospitalizations that derive from co-administration of known major DDIs. For the state of Santa Catarina and Brazil as a whole, these numbers are \$2.09 and \$1.84, respectively. If we consider the higher estimates of $p_h = 8.35\%$ or $p_h = 10\%$, the per capita cost for Blumenau is \$6.33 and \$7.58, respectively.

To put these numbers in context, Brazil’s minimum monthly wage was R\$724 (R\$9,412/year⁶) in 2014, and workers in Blumenau received on average 2.9 wages a month [S1]. This constitutes an average gross income of R\$2,099.60 a month (R\$27,294.80/year). If we assume the same 140 patients were hospitalized due to ADR caused by DDI, the direct cost of such hospitalizations is equal to 3,707 lost productive worker/days (considering an 8 hour working day), with possible much higher indirect costs.

Some limitations should be noted. When comparing to Becker et al. [S8], data from IBGE [S1] includes patients over 64, while in their work the authors included patients over 65 years old. Our analysis then possibly contains additional patients exactly age 65, although we do not believe this affects the results presented given their large difference. In general, other studies [S8] divide hospital admissions only between two categories, emergency room (ER) visits and hospitalizations. It is not possible to conclude whether electives or external causes are included in their hospitalization numbers. SIH/SUS data are only available for patients that were hospitalized in the public system, meaning the cost of hospitalization was billed to the public system. Therefore, if a patient was hospitalized and his/her private insurance covered the costs,

⁶Brazilians receive a 13th salary in December. Thus, yearly gross income is calculated by a 13, and not by a 12, multiplier.

the SIH/SUS would have no record of it. Furthermore, SIH/SUS provides the number of hospitalizations broken down by type. These consist of “electives” (e.g., schedules cesareans), “urgencies”, “work accidents”, and “other external causes” (codes V01 to Y98 of ICD-10⁷; e.g., car accident, poisoning, and drowning). To better approximate reality, we have calculated the cost of DDI-related hospitalizations only using the number of urgent hospitalizations.

p_h	$ U_{major}^\Phi $	% of hosp.	Cost R\$		Cost CA\$		Cost US\$	
			18 months	12 months	18 months	12 months	18 months	12 months
100%	5,224	21.24%	13,613,909	9,075,940	44,106,963	29,404,642	38,557,213	25,704,809
50%	2,612	10.62%	6,806,955	4,537,970	22,053,482	14,702,321	19,278,606	12,852,404
30%	1,567	6.37%	4,083,652	2,722,434	13,230,400	8,820,267	11,565,688	7,710,458
25%	1,306	5.31%	3,403,477	2,268,985	11,026,741	7,351,161	9,639,303	6,426,202
20%	1,044	4.25%	2,720,697	1,813,798	8,814,638	5,876,425	7,705,538	5,137,025
10%	522	2.12%	1,360,349	906,899	4,407,319	2,938,213	3,852,769	2,568,513
5%	261	1.06%	680,174	453,450	2,203,660	1,469,106	1,926,384	1,284,256
2.68%	140	0.57%	364,844	243,230	1,182,040	788,026	1,033,310	688,873
8.35%	436	0.75%	1,136,230	757,487	3,681,209	2,454,139	3,218,022	2,145,348

Table S29: Projected cost of DDI for the city of Blumenau in Reais (R\$), Canadian Dollars (C\$) and US dollars (US\$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [S9]. Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization are considered, based on results of Becker et al. [S8]. In the 18 month period, Blumenau had a total of 24,592 public health care emergency hospitalizations, from which 5,808 were of patients age over 64 years old. Average cost per hospitalization in the city is R\$ 2,606.03. US\$ costs were calculated based on C\$ exchange rate of .8742, the average rate in the study period.

p_h	$ U_{major}^\Phi $	% of hosp.	Cost in R\$		Cost in CA\$		Cost in US\$	
			18 months	12 months	18 months	12 months	18 months	12 months
100%	107,726	21.24%	148,567,620	99,045,080	909,545,700	606,363,800	795,102,280	530,068,187
50%	53,863	10.62%	74,283,810	49,522,540	454,772,850	303,181,900	397,551,140	265,034,093
30%	32,307	6.37%	44,555,391	29,703,594	272,772,524	181,848,349	238,450,972	158,967,314
25%	26,931	5.31%	37,141,215	24,760,810	227,382,203	151,588,136	198,771,880	132,514,586
20%	21,555	4.25%	29,727,039	19,818,026	181,991,883	121,327,922	159,092,788	106,061,859
10%	10,752	2.12%	14,828,352	9,885,568	90,780,641	60,520,428	79,358,184	52,905,456
5%	5,376	1.06%	7,414,176	4,942,784	45,390,321	30,260,214	39,679,092	26,452,728
2.68%	2,890	0.57%	3,985,671	2,657,114	24,400,675	16,267,116	21,330,464	14,220,309
7.71%	8,306	0.75%	21,645,699	14,430,466	70,128,721	46,752,481	61,304,788	40,869,858

Table S30: Projected cost of DDI for the state of Santa Catarina in Reais (R\$), Canadian Dollars (C\$) and US dollars (US\$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [S9]. Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization are considered, based on results of Becker et al. [S8]. In the 18 month period, Santa Catarina had a total of 507,189 public health care emergency hospitalizations. Average cost per hospitalization in the state is R\$ 1,379.13. US\$ costs were calculated based on C\$ exchange rate of .8742, the average rate in the study period.

⁷http://www.datasus.gov.br/cid10/V2008/WebHelp/v01_y98.htm

p_h	$ U_{major}^\Phi $	% of hosp.	Cost in R\$		Cost in CA\$		Cost in US\$	
			18 months	12 months	18 months	12 months	18 months	12 months
100%	2,854,665	21.24%	3,092M	2,061M	24,102M	16,068M	21,070M	14,046M
50%	1,427,332	10.62%	1,546M	1,031M	12,051M	8,034M	10,535M	7,023M
30%	856,130	6.37%	927M	618M	7,228M	4,819M	6,319M	4,213M
25%	713,666	5.31%	773M	515M	6,026M	4,017M	5,267M	3,512M
20%	571,201	4.25%	619M	412M	4,823M	3,215M	4,216M	2,811M
10%	284,928	2.12%	309M	206M	2,406M	1,604M	2,103M	1,402M
5%	142,464	1.06%	154M	103M	1,203M	802M	1,051M	701M
2.68%	76,608	0.57%	83M	55M	647M	431M	565M	377M
7.12%	203,365	0.75%	530M	353M	1,717M	1,145M	1,501M	1,001M

Table S31: Projected cost of DDI for Brazil in Reais (R\$), Canadian Dollars (C\$) and US dollars (US\$) for the analysis period (18 months) and yearly (12 months). Each row calculates the associated cost based on different proportion of patients who had at least one major DDI and required hospitalization. Last row shows the projected cost when only 0.75% of all hospitalizations of patients over 64 years old are considered, based on results of Wu et al. [S9]. Similarly, second-to-last row shows projected cost when only 0.57% of all hospitalization are considered, based on results of Becker et al. [S8]. In the 18 month period, Brazil had a total of 13,440,043 public health care emergency hospitalizations. Average cost per hospitalization in the country is R\$ 1,083.23. US\$ costs were calculated based on C\$ exchange rate of .8742, the average rate in the study period.

S8 Statistical modeling

Here we show the complete results from runs of simple regression (SR), polynomial regression (PR), ordinary multiple regression (OMR) and linear mixed model (LMM) that were mentioned in the original text. For further details on LMM see [S18].

A SR is a linear regression model with a single explanatory variable. It works by fitting a line through the data that minimizes the sum of the squared of the residual, where the residuals are differences between the observed values to the predicted values of the model. For example, when predicting the number of interactions from the number co-administrations, the SR equation would look like

$$\Phi^u(x) = \beta^0 + \beta^1 x + \epsilon^u \quad (\text{S16})$$

where β^0 is the intercept (or bias), β^1 is the coefficient (or slope) and ϵ^u are the residuals.

Similarly, PR is a regression where the dependent variable being modeled is fitted with a n^{th} degree polynomial, but still a single explanatory variable. In the main manuscript we modeled RRI^y with a cubic (3^{rd} degree) polynomial. In our case, the PR equation would look like

$$RRI^y(x) = \beta^0 + \beta^1(x^3) + \beta^2(x^2) + \beta^3 x + \epsilon^y \quad (\text{S17})$$

where β^0 is the intercept (or bias), β^1 , β^2 and β^3 are coefficients (giving the characteristic shape of the cubic curve) and ϵ^y are the residuals.

An OMR is a widely used type of regression for predicting the value of one dependent variable from the value of a set of independent variables. Similar to SR, it works by fitting a hyperplane through the data that minimizes the sum of the squared of the residuals.

In our case, the OMR equation would look like

$$\Phi^u = \beta^0 + \beta^1 x^{u,1} + \beta^2 x^{u,2} + \dots \beta^j x^{u,i} + \epsilon^u \quad (\text{S18})$$

Where β^0 is the intercept (or bias), β^j are the coefficients (or slopes) and each $x^{u,i}$ is a predictor (covariate, regressor) such as age or number of drugs. ϵ^u is the error associated with the fit.

A LMM (also known as multilevel, mixed effects, random effects or hierarchical linear model) can be seen as extensions of the OMR where instances of the data belong to certain groups—like children in classrooms or cities in states. In our case, they are patients in specific neighborhoods.

The individual levels are usually defined as level-1 (within-group), and level-2 (between-group) for a two level model. Separate level-1 models (e.g., patients) are developed for each level-2 (e.g., neighborhoods).

Considering only one predictor, level-1 models take the form of simple regressions:

$$\Phi^{u,n} = \beta^{0,n} + \beta^{1,n}x^{u,n} + r^{u,n} \quad (\text{S19})$$

where $\beta^{0,n}$ is the intercept for the n neighborhood, $\beta^{1,n}$ is a coefficient (slope) associated with predictor $x^{u,n}$, and $r^{u,n}$ is the error.

In the level-2 models, the level-1 regression coefficients ($\beta^{0,n}$ and $\beta^{1,n}$) are used as outcome variables and are related to each of the level-2 predictors.

$$\beta^{0,n} = \gamma^{0,0} + \gamma^{0,1}g^n + u^{0,n} \quad (\text{S20})$$

$$\beta^{1,n} = \gamma^{1,0} + \gamma^{1,1}g^n + u^{1,n} \quad (\text{S21})$$

where g^n is the level-2 predictor, $\gamma^{0,0}$ and $\gamma^{1,0}$ are the overall mean intercept adjusted for g . $\gamma^{0,1}$ ($\gamma^{1,1}$) is the regression coefficient associated with g relative to level-1 intercept (slope) and $u^{0,n}$ ($u^{1,n}$) are level-2 random effects adjusted for g on the intercept (slope).

A combined two-level model is created by substituting Equations S20 and S21 into Equation S19:

$$\Phi^{u,n} = \gamma^{0,0} + \gamma^{1,0}x^{u,n} + \gamma^{0,1}g^n + \gamma^{1,1}g^n x^{u,n} + u^{1,n}x^{0,n} + u^{0,n} + \epsilon^{u,n} \quad (\text{S22})$$

The combined model incorporates the level-1 and level-2 predictors ($x^{u,n}$ and g^n), a cross-level term ($g^n x^{u,n}$) as well as the composite error ($u^{1,n}x^{u,n} + u^{0,n} + r^{u,n}$).

In practice, LMM coefficients are estimated using maximum likelihood methods.

S8.1 Simple Regression (SR) models

In Figure 5 of the main manuscript we show single regression models predicting the number of interactions. Specifically, ν^u predicts Ψ^u best with a quadratic regression ($R^2 = .857$) as shown in Figure 5-left. When it comes to predicting number of interactions (Fig. 5, center and right), on the other hand, there is much more dispersion of the data, which leads to a relatively small linear correlation between Ψ^u and Φ^u ($R^2 = .487$)—though better than the linear correlation between ν^u and Φ^u ($R^2 = .304$). However, higher order regressions do not improve the prediction of the variance of Φ^u , as demonstrated by the Pareto front in Fig. 5-top-right (see also §2.5)—thus discarding the hypothesis of a clear nonlinear relationship between co-administrations and interactions, which could explain the growth of RI with age.

Tables below contain additional information on these and additional regression models.

Listing S1: Ψ^u from ν^u linear model

=====	
Ψ^u	
ν^u	3.891*** (0.007)
Constant	-8.818*** (0.037)

Observations	132,722
R2	0.712
Adjusted R2	0.712
Residual Std. Error	8.650 (df = 132720)
F Statistic	328,478.000*** (df = 1; 132720)
=====	
Note:	*p<0.1; **p<0.05; ***p<0.01

Listing S2: Ψ^u from ν^u quadratic model

=====	
Ψ^u	
ν^u	-0.121*** (0.012)
$(\nu^u)^2$	0.273*** (0.001)
Constant	-0.023 (0.036)

Observations	132,722
R2	0.857
Adjusted R2	0.857

```

Residual Std. Error    6.088 (df = 132719)
F Statistic           399,075.300*** (df = 2; 132719)
=====
Note:                  *p<0.1; **p<0.05; ***p<0.01

```

Listing S3: Φ^u from ν^u linear model

```

=====
                                 $\Phi^u$ 
 $\nu^u$                         0.110*** (0.0005)
Constant                  -0.267*** (0.003)
-----
Observations              132,722
R2                        0.304
Adjusted R2              0.304
Residual Std. Error      0.580 (df = 132720)
F Statistic              58,011.640*** (df = 1; 132720)
=====
Note:                      *p<0.1; **p<0.05; ***p<0.01

```

Listing S4: Φ^u from ν^u quadratic model

```

=====
                                 $\Phi^u$ 
 $\nu^u$                         -0.009*** (0.001)
( $\nu^u$ )2                   0.008*** (0.0001)
Constant                  -0.007** (0.003)
-----
Observations              132,722
R2                        0.372
Adjusted R2              0.372
Residual Std. Error      0.551 (df = 132719)
F Statistic              39,357.930*** (df = 2; 132719)
=====
Note:                      *p<0.1; **p<0.05; ***p<0.01

```

Listing S5: Φ^u from Ψ^u linear model

```

=====
                                 $\Phi^u$ 
 $\Psi^u$                        0.030*** (0.0001)
Constant                  -0.033*** (0.002)
-----
Observations              132,722
R2                        0.487
Adjusted R2              0.487
Residual Std. Error      0.498 (df = 132720)
F Statistic              126,232.900*** (df = 1; 132720)
=====
Note:                      *p<0.1; **p<0.05; ***p<0.01

```

S8.1.1 RC^y models

In Figure 4 of the main manuscript two regressions were calculated to predict the growth of RC^y and RI^y based on age range ($y = [y1 - y2]$). Both RC^y and RI^y can be best approximated by a cubic polynomial regression (see Fig. 4 for R^2). The regression lines show different growth processes for co-administration and interaction risks. RC^y first decreases in children age range [5-14], followed by an almost flat level between ages [15,44] before a steeper growth is observed for older age groups (see shaded area in Fig 4-left). In contrast, RI^y is initially quite flat and only starts to increase after the age of 15, after which it has a much steeper growth curve than RC^y (note the difference in scale).

In addition, Tables below contain other regression models that were computed along with their respective ANOVA comparison, when appropriate.

A linear model is the simplest model one could fit to the increased risk of co-administration.

Listing S6: RC^y linear model

```

=====
                                 $RC^y$ 

```

```

-----
y                0.003*** (0.0004)
Constant         0.926*** (0.004)
-----
Observations    19
R2              0.798
Adjusted R2     0.787
Residual Std. Error 0.009 (df = 17)
F Statistic     67.336*** (df = 1; 17)
=====
Note:           *p<0.1; **p<0.05; ***p<0.01

```

A quadratic model fits slightly better but the increased model complexity is not significant.

Listing S7: RC^y quadratic model

```

=====
RC^y
-----
(y)^2           0.0001 (0.0001)
y              0.001 (0.001)
Constant       0.931*** (0.005)
-----
Observations    19
R2              0.820
Adjusted R2     0.798
Residual Std. Error 0.009 (df = 16)
F Statistic     36.493*** (df = 2; 16)
-----
Model 1: RC^y ~ y
Model 2: RC^y ~ (y)^2 + y
Res.Df  RSS Df Sum of Sq    F Pr(>F)
1      17 0.0013609
2      16 0.0012139  1 0.00014698 1.9374 0.183
=====
Note:           *p<0.1; **p<0.05; ***p<0.01

```

A cubic model gives almost perfect fit while being significant for the more complex model.

Listing S8: RC^y cubic model

```

=====
RC^y
-----
(y)^3          -0.0001*** (0.00001)
(y)^2          0.001*** (0.0003)
y             -0.008*** (0.002)
Constant       0.943*** (0.004)
-----
Observations    19
R2              0.936
Adjusted R2     0.923
Residual Std. Error 0.005 (df = 15)
F Statistic     72.789*** (df = 3; 15)
-----
Model 1: RC^y ~ y
Model 2: RC^y ~ (y)^2 + y
Model 3: RC^y ~ (y)^3 + (y)^2 + y
Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1      17 0.00136086
2      16 0.00121387  1 0.00014698  5.0807 0.0395787 *
3      15 0.00043394  1 0.00077993 26.9599 0.0001094 ***
=====
Note:           *p<0.1; **p<0.05; ***p<0.01

```

S8.1.2 RI^y models

Similarly to how we modeled RI^y , with the risk of known DDI co-administration (RI^y) we start with the simplest linear model possible.

Listing S9: RI^y linear model

```

=====
RI^y

```

```

-----
y                0.024*** (0.002)
Constant         -0.032* (0.016)
-----
Observations          19
R2                   0.932
Adjusted R2          0.928
Residual Std. Error  0.037 (df = 17)
F Statistic          233.631*** (df = 1; 17)
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

A quadratic model fits slightly better but the increased model complexity is not significant.

Listing S10: RI^y quadratic model

```

=====
                         $RI^y$ 
-----
(y)2                -0.0004 (0.0003)
y                   0.030*** (0.006)
Constant            -0.050** (0.023)
-----
Observations          19
R2                   0.937
Adjusted R2          0.930
Residual Std. Error  0.037 (df = 16)
F Statistic          119.823*** (df = 2; 16)
-----
Model 1:  $RC^y \sim y$ 
Model 2:  $RC^y \sim (y)^2 + y$ 
Res.Df  RSS Df Sum of Sq    F Pr(>F)
1      17 0.023355
2      16 0.021550  1 0.001805 1.3401 0.264
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

Finally, a cubic model gives us almost perfect fit while being significant for the more complex model.

Listing S11: RI^y Cubic model

```

=====
                         $RI^y$ 
-----
(y)3                -0.0003*** (0.00001)
(y)2                0.007*** (0.0004)
y                   -0.019*** (0.003)
Constant            0.013** (0.006)
-----
Observations          19
R2                   0.997
Adjusted R2          0.997
Residual Std. Error  0.008 (df = 15)
F Statistic          1,927.479*** (df = 3; 15)
-----
Model 1:  $RI^y \sim y$ 
Model 2:  $RI^y \sim (y)^2 + y$ 
Model 3:  $RI^y \sim (y)^3 + (y)^2 + y$ 
Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1      17 0.0233550
2      16 0.0215500  1 0.001805 30.391 5.96e-05 ***
3      15 0.0008909  1 0.020659 347.842 8.66e-12 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2 Multiple Regression (MR) models

This section displays several MR models that were generated in order to analyze the possible prediction of drug interaction based on patient demographics. Tables below contain the model results and also their respective ANOVA comparison when appropriate.

S8.2.1 Baseline (no transformation)

This is the baseline MR model with no transformation.

Listing S12: Baseline linear regression model

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.026*** (0.001)
 $\Phi^u$                 0.035*** (0.0002)
Constant              0.041*** (0.003)
-----
Observations          132,722
R2                    0.492
Adjusted R2           0.492
Residual Std. Error   0.496 (df = 132719)
F Statistic           64,377.810*** (df = 2; 132719)
=====
Note:                  *p<0.1; **p<0.05; ***p<0.01

```

S8.2.2 Baseline (transformed)

These are other baseline MR model with transformed variables

Listing S13: Transformed baseline MR model

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.004*** (0.001)
 $\Phi^u$                 0.040*** (0.0002)
 $(\nu^u)^2$             -0.003*** (0.0001)
Constant              -0.006** (0.003)
-----
Observations          132,722
R2                    0.497
Adjusted R2           0.497
Residual Std. Error   0.493 (df = 132718)
F Statistic           43,696.240*** (df = 3; 132718)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + (\nu^u)^2$ 
  Res.Df  RSS Df Sum of Sq      F    Pr(>F)
1 132719 32592
2 132718 32304 1    288.37 1184.7 < 2.2e-16 ***
=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.033*** (0.001)
 $\Phi^u$                 0.038*** (0.0002)
 $(\Phi^u)^2$           -0.00002*** (0.00000)
Constant              0.053*** (0.003)
-----
Observations          132,722
R2                    0.494
Adjusted R2           0.494
Residual Std. Error   0.495 (df = 132718)
F Statistic           43,145.430*** (df = 3; 132718)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + (\Phi^u)^2$ 
  Res.Df  RSS Df Sum of Sq      F    Pr(>F)
1 132719 32592
2 132718 32508 1    84.745 345.99 < 2.2e-16 ***
=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.008*** (0.001)
 $\Phi^u$                 0.041*** (0.0003)
 $(\nu^u)^2$             -0.003*** (0.0001)
 $(\Phi^u)^2$           -0.00000*** (0.00000)
Constant              0.001 (0.003)
-----
Observations          132,722

```



```

R2                                0.497
Adjusted R2                        0.497
Residual Std. Error                0.493 (df = 132717)
F Statistic                        32,786.680*** (df = 4; 132717)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + (\nu^u)^2 + (\Phi^u)^2$ 
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1 132719 32592
2 132717 32297  2    295.59 607.33 < 2.2e-16 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.3 Baseline + age + gender

This section shows the MR results when age and gender are included as dependent variables in the baseline model.

Listing S14: Baseline MR model added variables age and gender.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                             -0.027*** (0.001)
 $\Phi^u$                             0.034*** (0.0002)
age                                0.002*** (0.0001)
C(gender)Male                     -0.010*** (0.003)
Constant                           -0.021*** (0.004)
-----
Observations                       132,722
R2                                  0.496
Adjusted R2                        0.496
Residual Std. Error                0.494 (df = 132717)
F Statistic                        32,639.900*** (df = 4; 132717)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + \text{age} + \text{C}(\text{gender})$ 
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1 132719 32592
2 132717 32369  2    223.56 458.33 < 2.2e-16 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.4 Baseline (replacing Ψ^u with y)

Interestingly, number of co-administrations (Ψ^u) and age (y) are virtually exchangeable.

Listing S15: Baseline MR model exchanging variables Ψ^u and y .

```

=====
                                 $\Psi^u$ 
-----
 $\Phi^u$                             0.029*** (0.0001)
age                                0.002*** (0.0001)
Constant                           -0.100*** (0.003)
-----
Observations                       132,722
R2                                  0.491
Adjusted R2                        0.491
Residual Std. Error                0.496 (df = 132719)
F Statistic                        63,937.920*** (df = 2; 132719)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \Phi^u + \text{age}$ 
  Res.Df  RSS Df Sum of Sq  F Pr(>F)
1 132719 32592
2 132719 32702  0   -110.03
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.5 Baseline + education level

This section shows the OMR results when education level is included as one of the dependent variables in the model.

Note that this model fits a smaller dataset because the number of patients that have given their education level is smaller than the full dataset.

Listing S16: Baseline MR model added education level variable.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                                -0.015*** (0.001)
 $\Phi^u$                                0.033*** (0.0002)
C(education)Cant read/write          -0.027** (0.014)
C(education)Complete college         -0.007 (0.018)
C(education)Complete elementary      0.037*** (0.013)
C(education)Complete high school     0.003 (0.013)
C(education)Doctoral                 -0.106 (0.132)
C(education)Espec./Residency         0.009 (0.045)
C(education)Incomplete college       0.004 (0.018)
C(education)Incomplete elementary    0.024** (0.011)
C(education)Incomplete high school   -0.006 (0.014)
C(education)Masters                  -0.050 (0.119)
Constant                             0.018 (0.011)
-----
Observations                          61,060
R2                                    0.511
Adjusted R2                           0.511
Residual Std. Error                   0.602 (df = 61047)
F Statistic                           5,312.884*** (df = 12; 61047)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + C(\text{education})$ 
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1   61057 22127
2   61047 22107 10    19.845 5.4801 3.472e-08 ***
-----
Note:                                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.6 Baseline + marital status

This section shows the OMR results when marital status is included as one of the dependent variables in the model.

Listing S17: Baseline MR model added marital status variable.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                                -0.027*** (0.001)
 $\Phi^u$                                0.035*** (0.0002)
C(marital)Divorced                   0.105*** (0.025)
C(marital)Ignored                    -0.029*** (0.008)
C(marital)Married                    -0.005 (0.008)
C(marital)Not informed               -0.072*** (0.008)
C(marital)Separated                  0.080*** (0.011)
C(marital)Single                     -0.014* (0.008)
C(marital)Widower                    0.019* (0.011)
Constant                             0.077*** (0.008)
-----
Observations                          132,722
R2                                    0.494
Adjusted R2                           0.494
Residual Std. Error                   0.495 (df = 132712)
F Statistic                           14,420.090*** (df = 9; 132712)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + C(\text{marital})$ 
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1  132719 32592
2  132712 32464 7    128.13 74.829 < 2.2e-16 ***
-----
Note:                                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.7 Baseline + average neighborhood income assigned to patients

Listing S18: Baseline MR model added average neighborhood income variable.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.026*** (0.001)
 $\Phi^u$                 0.035*** (0.0002)
avg_income            0.00003*** (0.00000)
Constant              0.016*** (0.005)
-----
Observations          132,722
R2                    0.493
Adjusted R2           0.493
Residual Std. Error   0.495 (df = 132718)
F Statistic           42,944.890*** (df = 3; 132718)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + \text{avg\_income}$ 
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1 132719 32592
2 132718 32582  1    9.9727 40.622 1.853e-10 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.8 Baseline + neighborhood safety variables assigned to patients

Listing S19: Baseline MR model added neighborhood safety variables.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.026*** (0.001)
 $\Phi^u$                 0.035*** (0.0002)
theft_pc              -0.737*** (0.283)
robbery_p1000         -0.004 (0.003)
suicide_p1000         0.006 (0.009)
transitcrime_p1000    0.022*** (0.002)
traffic_p1000         0.008*** (0.002)
rape_p1000            -0.002 (0.004)
Constant              0.024*** (0.004)
-----
Observations          132,722
R2                    0.493
Adjusted R2           0.493
Residual Std. Error   0.495 (df = 132713)
F Statistic           16,148.060*** (df = 8; 132713)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + \text{theft\_pc} +$ 
         robbery_p1000 + suicide_p1000 +
         transitcrime_p1000 + traffic_p1000 +
         rape_p1000
  Res.Df  RSS Df Sum of Sq    F    Pr(>F)
1 132719 32592
2 132713 32538  6    54.096 36.773 < 2.2e-16 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.2.9 Baseline + neighborhood

Listing S20: Baseline MR model added neighborhood as categorical variables.

```

=====
                                 $\Psi^u$ 
-----
 $\nu^u$                 -0.026*** (0.001)
 $\Phi^u$                 0.035*** (0.0002)
C(hood)BADENFURT     -0.021 (0.014)
C(hood)BOA VISTA      0.009 (0.024)
C(hood)BOM RETIRO     0.150*** (0.036)

```

```

C(hood)CENTRO                0.012 (0.013)
C(hood)DA GLORIA             -0.009 (0.013)
C(hood)DO SALTO              -0.005 (0.016)
C(hood)ESCOLA AGRICOLA      -0.041*** (0.012)
C(hood)FIDELIS               0.005 (0.013)
C(hood)FORTALEZA            -0.030*** (0.011)
C(hood)FORTALEZA ALTA       -0.029** (0.014)
C(hood)GARCIA                -0.009 (0.011)
C(hood)ITOUPAVA CENTRAL     0.005 (0.011)
C(hood)ITOUPAVA NORTE       -0.023** (0.011)
C(hood)ITOUPAVA SECA        -0.037** (0.019)
C(hood)ITOUPAVAZINHA       0.012 (0.012)
C(hood)JARDIM BLUMENAU      -0.053 (0.047)
C(hood)NOVA ESPERANCA       -0.055*** (0.014)
C(hood)OTHER                 -0.067*** (0.010)
C(hood)PASSO MANSO           0.025* (0.015)
C(hood)PONTA AGUDA          -0.009 (0.013)
C(hood)PROGRESSO            -0.006 (0.011)
C(hood)RIBEIRAO FRESCO      0.010 (0.021)
C(hood)SALTO DO NORTE       0.019 (0.015)
C(hood)SALTO WEISSBACH      0.018 (0.018)
C(hood)TESTO SALTO         -0.009 (0.015)
C(hood)TRIBESS              -0.041*** (0.012)
C(hood)VALPARAISO           -0.015 (0.014)
C(hood)VELHA                -0.015 (0.011)
C(hood)VELHA CENTRAL        -0.009 (0.013)
C(hood)VELHA GRANDE         -0.031* (0.017)
C(hood)VICTOR KONDER         0.026 (0.024)
C(hood)VILA FORMOSA         -0.225*** (0.053)
C(hood)VILA ITOUPAVA        0.015 (0.017)
C(hood)VILA NOVA            -0.041*** (0.015)
C(hood)VORSTADT             -0.028** (0.014)
Constant                     0.067*** (0.010)
-----
Observations                  132,722
R2                            0.494
Adjusted R2                   0.494
Residual Std. Error           0.495 (df = 132684)
F Statistic                   3,502.150*** (df = 37; 132684)
-----
Model 1:  $\Psi^u \sim \nu^u + \Phi^u$ 
Model 2:  $\Psi^u \sim \nu^u + \Phi^u + C(\text{hood})$ 
  Res.Df  RSS Df Sum of Sq  F      Pr(>F)
1 132719 32592
2 132684 32486 35    106.61 12.441 < 2.2e-16 ***
=====
Note:                *p<0.1; **p<0.05; ***p<0.01

```

S8.3 Linear Mixed-Effect (LMM) models

To be sure that neighborhood did not differ in their DDI observations, we also ran a linear mixed-model (LMM) with neighborhood as a random effect. Intuitively, if there are variations in the number of interactions between neighborhoods that cannot be explained by the independent variables alone—due to, say, differences in policies or practices—we should see the random effect variable explaining a great deal of the variance in the model. Our results indicate that is not the case. In fact, the variance attributed to the neighborhood random effect is 0.00059 and therefore too small. This shows that at least in predicting the number of DDI, there is neighborhood homogeneity in how they are being prescribed and thus dispensed.

Listing S21: Linear Mixed Model with neighborhood as random effect.

```

Linear mixed model fit by maximum likelihood ['lmerMod']
Formula:  $\Psi^u \sim \nu^u + \Phi^u + (1 | \text{hood})$ 
Data: data

   AIC      BIC  logLik deviance df.resid
189980.7 190029.6 -94985.3 189970.7   132717

Scaled residuals:
  Min       1Q   Median       3Q      Max
-13.1462  -0.1846  -0.0678   0.0180  19.1046

Random effects:
 Groups   Name                Variance Std.Dev.

```

```
hood      (Intercept) 0.0005935 0.02436
Residual          0.2448642 0.49484
Number of obs: 132722, groups: hood, 36
```

Fixed effects:

```
                Estimate Std. Error t value
(Intercept)    0.0544948  0.0050850   10.72
 $\nu^u$         -0.0264618  0.0007270  -36.40
 $\Phi^u$          0.0348255  0.0001572  221.58
```

Correlation of Fixed Effects:

```
      (Intr)  $\nu^u$ 
 $\nu^u$   -0.411
 $\Phi^u$   0.268 -0.841
```

S9 Patient classification

We applied machine learning classifiers in order to predict if a specific patient had at least one DDI in the whole 18 month period. A binary classification task. Support Vector Machine (SVM)[S19] and Logistic Regression (LR)[S20] are considered both standard and reliable machine learning algorithm for binary classification problems. We built models for each classifier considering different sets of features, including demographic (i.e., age & gender) and drugs the patient was prescribed in the period. For baseline comparison we also ran against three null model classifiers. One with a “coin-toss” probability of classification (Uniform), another with a bias with respect to class probability (Biased), and a custom made (AgeGender) which finds the best age cutoff for each gender from which it consider all patients older than the cutoff as having a DDI. Regression and classification models were computed using R and Python [S21].

We present results as measures derived from a confusion matrix, also called a contingency table[S22]. The confusion matrix contains four categories: true positives (TP), patients correctly labeled as having a DDI; false positives (FP), patients incorrectly classified as having a DDI; true negative (TN), patients correctly labeled as not having a DDI; and finally false negatives (FN), patients with DDI but mislabeled as not having them. A contingency table example can be seen in Table S32.

	DDI	no DDI
predicted DDI	TP	FP
predicted no DDI	FN	TN

Table S32: Confusion Matrix.

From the confusion matrix we compute Precision and Recall as

$$\text{Precision} = \frac{TP}{TP + FP} \quad , \quad \text{Recall} = \frac{TP}{TP + FN} \quad , \quad (\text{S23})$$

where Precision is the fraction of patients with DDI correctly predicted, among all predicted patients with DDI; while Recall is the fraction of patients with DDI correctly predicted, among all patients with DDI. We also compute True Positive Rate (TPR) and False Positive Rate (FPR) measures as

$$\text{TPR} = \frac{TP}{TP + FN} \quad , \quad \text{FPR} = \frac{FP}{FP + TN} \quad , \quad (\text{S24})$$

where TPR measures the fraction of patients with DDI that are correctly classified and FPR measures the fraction of patients with no DDI incorrectly classified as having DDI. These four measures enables the plotting of the Receiver Operator Characteristic (ROC) and the Precision and Recall (P/R) space. In ROC space we plot FPR against TPR while in P/R space we plot Precision against Recall (Figure S15 displays the results). These plots are typically generated to evaluate the performance of machine learning algorithms, and to enable system users to inspect the trained algorithm’s precision at a specific recall level, for example. From both ROC and P/R curves we computes their respective interpolated area under the curve (AUC)[S22].

From Precision and Recall we also compute the F_1 -score (also called F -score or F -measure) as

$$F_1 = 2 \times \frac{\text{Precision} \times \text{Recall}}{\text{Precision} + \text{Recall}} \quad . \quad (\text{S25})$$

We also compute Matthew’s Correlation Coefficient (MCC)[S23], which is regarded as an ideal measure of the quality of binary classification in unbalanced scenarios[S24], as

$$\text{MCC} = \frac{TP \times TN - FP \times FN}{\sqrt{(TP + FP) + (TP + FN) + (TN + FP) + (TN + FN)}} \quad . \quad (\text{S26})$$

Below, we display results as measures of Precision, Recall, F_1 -score, MCC, AUC ROC curve and AUC P/R curve.

We also display the full table of feature weights for both classifiers. Since these are both linear classifiers, one can interpret positive (negative) values as contributing to the positive (negative) class—having a DDI.

The higher (smaller) the weight, the bigger (smaller) the contribution. All results are based on 4-fold cross validation.

† Gender is used as a categorical variable and expanded into the binary features ($g = M$ and $g = F$).

‡ Education level is used as a categorical variable expanded into individuals binary features (“Cant read/write”, “Can read/write a note”, “Incomplete elementary”, “Complete elementary”, “Incomplete high school”, “Complete high school”, “Incomplete college”, “Complete college”, “Espec./Residency”, “Masters”, and “Doctoral”).

S9.1 Simple model

Patients: 132,722

DDI (positive): 15,527 (11.70%)

no DDI (negative): 117,195 (88.30%)

Features: 127

Demographic: gender[†] (g), age (y), number of drugs (ν^u), number of co-administrations (Ψ^u).

Neighborhood: average income, number of thefts per capita, number of robberies per capita, number of suicides per capita, number of transit crimes per capita, number of traffic accidents per capita, number of rapes per capita.

Drug: all drugs D .

Fold	Precision	Recall	F_1	MCC	AUC ROC	AUC P/R
1	0.8196	0.6309	0.7130	0.6877	0.9676	0.8269
2	0.8241	0.6494	0.7264	0.7011	0.9702	0.8365
3	0.8127	0.6504	0.7226	0.6957	0.9697	0.8315
4	0.8187	0.6436	0.7207	0.6949	0.9690	0.8311
Mean	0.8188	0.6436	0.7207	0.6948	0.9691	0.8315

Table S33: Individual fold and mean performance of Support Vector Machine (SVM) classifier on stratified 4-fold cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.

Fold	Precision	Recall	F_1	MCC	AUC ROC	AUC P/R
1	0.8085	0.6535	0.7228	0.6953	0.9675	0.8249
2	0.8096	0.6669	0.7314	0.7037	0.9700	0.8337
3	0.7991	0.6662	0.7266	0.6977	0.9697	0.8299
4	0.8092	0.6612	0.7277	0.7002	0.9691	0.8304
Mean	0.8066	0.6619	0.7271	0.6992	0.9691	0.8297

Table S34: Individual fold and mean performance of Logistic Regression (LR) classifier on stratified 4-fold cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.

Classifier	Precision	Recall	F_1	MCC	AUC ROC	AUC P/R
Uniform	0.1181	0.5075	0.1916	0.0035	0.5	0.5585
Biased	0.1147	0.1153	0.1150	-0.0026	0.4987	0.1668
GenderAge	0.2044	0.8834	0.3320	0.2751	0.7139	0.5507

Table S35: Mean performance of Uniform (coin-toss), Biased (biased coin-toss on class distribution) and GenderAge (hard cutoff for gender and gender) classifiers on stratified 4-fold cross-validation, using demographic and drug features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.

S9.2 Complete model

Patients: 132,722

DDI (positive): 15,527 (11.70%)

no DDI (negative): 117,195 (88.30%)

Features: 154

Demographic: gender[†] (g), age (y), number of drugs (ν^u), number of co-administrations (Ψ^u), education levels[‡].

Neighborhood: average income, number of thefts per capita, number of robberies per capita, number of suicides per capita, number of transit crimes per capita, number of traffic accidents per capita, number of rapes per capita.

Drug: all drugs D .

Classifier	Precision	Recall	F_1	MCC	AUC ROC	AUC P/R
SVM	0.8186	0.6442	0.7210	0.6951	0.9690	0.8312
LR	0.8070	0.6619	0.7273	0.6994	0.9690	0.8295

Table S36: Mean performance of classifiers on stratified 4-fold cross-validation, using all possible features, including demographic, neighborhood and drugs dispensed. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.

S9.3 No Drugs model

This model is similar to the “simple” model, except no drug features are used.

Patients: 132,722

DDI (positive): 15,527 (11.70%)

no DDI (negative): 117,195 (88.30%)

Features: 5

Demographic: gender[†] (g), age (y), number of drugs (ν^u), number of co-administrations (Ψ^u).

Neighborhood: None.

Drug: None.

Classifier	Precision	Recall	F_1	MCC	AUC ROC	AUC P/R
SVM	0.7578	0.3791	0.5053	0.4971	0.9185	0.6539
LR	0.7172	0.4170	0.5273	0.5044	0.9130	0.6391

Table S37: Mean performance of classifiers on stratified 4-fold cross-validation, using only demographic features. Measures of performance shown are: Precision, Recall, F1 (balanced Precision and Recall), Matthew’s Correlation Coefficient, the Area Under the Receiver Operating Characteristic Curve, and the Area Under the Precision and Recall Curve.

S9.4 Precision & Recall and Receiver Operating Characteristic curves

S9.5 Feature loadings

Tables S38 and S39 shows the feature loading for both SVM and LR classifiers on model “simple”.




Figure S15: Precision and Recall (P/R) curve and Receiver operating characteristic (ROC) curve for individual cross-validation folds. Model containing demographic and drug features. Black and green dotted line shows the baseline and mean values, respectively.

feature	coef	feature	coef
d=Digoxin	1.1677	d=Acetaminophen	-0.1169
d=Diltiazem	0.8718	d=Tobramycin	-0.1185
d=Warfarin	0.6938	d=Hydrochlorothiazide	-0.1203
d=Haloperidol	0.6879	d=Norethisterone	-0.1225
d=Glyburide	0.6681	d=Propylthiouracil	-0.1242
d=Pyrimethamine	0.6549	d=Phenylephrine	-0.1309
d=Phenytoin	0.6015	d=Estrogens Conjugated	-0.1312
d=Biperiden	0.5807	d=Trimethoprim	-0.1325
d=Carbamazepine	0.5752	d=Sulfamethoxazole	-0.1325
d=Glucicazide	0.4735	d=Colchicine	-0.1333
d=Clonazepam	0.4717	d=Diclofenac	-0.1347
d=Methyldopa	0.4617	d=Ranitidine	-0.1374
d=Propranolol	0.4487	d=Neomycin	-0.1383
d=Lithium	0.3887	d=Bacitracin	-0.1383
d=Fluconazole	0.3716	d=Nimesulide	-0.1413
ν_i	0.3169	d=Fenoterol	-0.1446
Ψ_i	0.3119	d=Nystatin	-0.1508
$\Psi_{i,j}$	0.3080	d=Albendazole	-0.1514
d=Diazepam	0.3038	d=Nitrofurantoin	-0.1514
d=Omeprazole	0.2822	d=Loratadine	-0.1611
d=Amitriptyline	0.2810	d=Metamizole	-0.1624
d=Iron (II) Sulfate	0.2584	d=Spironolactone	-0.1634
d>Ethinyl Estradiol	0.2571	d=Tramadol	-0.1643
d>Ibuprofen	0.2170	d=Dexchlorpheniramine maleate	-0.1664
d=Imipramine	0.1825	d=Enalapril	-0.1671
d=Fluoxetine	0.1639	d=Azithromycin	-0.1672
d=Verapamil	0.1455	d=Miconazole	-0.169
d=Timolol	0.1452	d=Scopolamine butylbromide	-0.171
d=Atenolol	0.1432	d=Metronidazole	-0.1747
d=Nortriptyline	0.1159	d=Cephalexin	-0.1767
d=Doxycycline	0.1046	d>Ipratropium Bromide	-0.1779
d=Nifedipine	0.0973	d=Hydrocortisone	-0.1812
d=Methylphenidate	0.0638	d=Metoclopramide	-0.1832
d=Vaseline	0.0596	d=Levodopa	-0.1872
y	0.0518	d=Medroxyprogesterone Acetate	-0.1877
d=Phenobarbital	0.0274	d=Doxazosin	-0.1909
d=Prednisone	0.0232	d=Amlodipine	-0.1936
d=Estradiol	0.0181	d=Losartan	-0.1937
d=Atropine	0.0000	d=Metformin	-0.1943
d=Thiocolchicoside	0.0000	d=Mebendazole	-0.1945
d=Salbutamol	-0.0071	d=Fluphenazine	-0.204
d=Dexamethasone	-0.0102	d=Captopril	-0.2041
d=Penicillin G procaine	-0.0115	d=Amiodarone	-0.2042
d=Simvastatin	-0.0191	d=Bromazepam	-0.2063
d=Gentamicin	-0.0229	d=Codeine	-0.2064
d=Epinephrine	-0.0347	d=Valproic acid	-0.2083
d>Furosemide	-0.0395	d=Penicillin G Benzathine	-0.2123
d=Carvedilol	-0.0544	d=Aminophylline	-0.2133
d=Erythromycin	-0.0588	d=Clavulanate	-0.2141
d=Chlorpromazine	-0.0605	d=Clopidogrel	-0.2162
d>Methotrimeprazine	-0.0683	d=Carbidopa	-0.2269
d=Morphine	-0.0759	d=Insulin	-0.246
d=Levothyroxine	-0.0776	d=Isosorbide Mononitrate	-0.269
d=Alendronate	-0.0820	d=Nicotine	-0.3003
d=Amoxicillin	-0.0908	d=Glucose	-0.305
d=Ciprofloxacin	-0.0937	$g = M$	-0.3193
d=Prednisolone	-0.0944	$g = F$	-0.3213
d=Permethrin	-0.0978	d=Sodium chloride	-0.3474
d=Levonorgestrel	-0.0982	d=Isosorbide Dinitrate	-0.351
d=Folic acid	-0.0983	d=Oseltamivir	-0.3643
d>Promethazine	-0.1059	d=Betamethasone	-0.4765
d=Maprotiline	-0.1073	d=Spiramycin	-0.521
d=Norfloracin	-0.1100	d=Sulfadiazine	-0.5259
d=Allopurinol	-0.1148	-	-

Table S38: Feature weights for Support Vector Machine (SVM) classifier on model “simple”.

feature	coef	feature	coef
d=Digoxin	3.6826	d=Norethisterone	-0.4217
d=Diltiazem	2.7678	d=Amoxicillin	-0.4283
d=Haloperidol	2.3874	d=Promethazine	-0.4327
d=Warfarin	2.3423	d=Colchicine	-0.434
d=Glyburide	2.2139	d=Hydrochlorothiazide	-0.4526
d=Phenytoin	2.1363	d=Norfloxacin	-0.4545
d=Carbamazepine	2.1098	d=Estrogens Conjugated	-0.4683
d=Biperiden	1.9247	d=Tobramycin	-0.4763
d=Clonazepam	1.6984	d=Propylthiouracil	-0.4767
d=Methyldopa	1.6363	d=Trimethoprim	-0.4888
d=Propranolol	1.5735	d=Sulfamethoxazole	-0.4888
d=Gliclazide	1.5618	d=Acetaminophen	-0.502
ν_i	1.4941	d=Spiramycin	-0.506
d=Fluconazole	1.3668	d=Ranitidine	-0.5178
d=Lithium	1.3303	d=Diclofenac	-0.5242
d=Acetylsalicylic Acid	1.0479	d=Betamethasone	-0.5301
d=Diazepam	1.0178	d=Nimesulide	-0.5316
d=Omeprazole	1.0114	d=Neomycin	-0.5318
d=Amitriptyline	0.9684	d=Bacitracin	-0.5318
d=Iron (II) Sulfate	0.8905	d=Nystatin	-0.5508
$\Psi_{i,j}$	0.7721	d=Prednisolone	-0.5531
d=Ibuprofen	0.7282	d=Fenoterol	-0.5542
d=Pyrimethamine	0.6518	d=Spironolactone	-0.564
d=Fluoxetine	0.6245	d=Hydrocortisone	-0.5778
d=Imipramine	0.6188	d=Mebendazole	-0.5857
d=Atenolol	0.5100	d=Enalapril	-0.5955
d>Ethinyl Estradiol	0.4965	d=Albendazole	-0.5991
d=Verapamil	0.3885	d=Nitrofurantoin	-0.6128
d=Doxycycline	0.3681	d=Miconazole	-0.6173
y	0.3547	d=Ipratropium Bromide	-0.619
d=Timolol	0.3492	d=Loratadine	-0.6196
d=Nortriptyline	0.3217	d=Metamizole	-0.6206
d=Nifedipine	0.2797	d=Scopolamine butylbromide	-0.6347
d=Levonorgestrel	0.2220	d=Tramadol	-0.6364
d=Phenobarbital	0.1465	d=Metronidazole	-0.6476
d=Vaseline	0.1118	d=Dexchlorpheniramine maleate	-0.6534
d=Estradiol	0.0873	d=Medroxyprogesterone Acetate	-0.6733
d=Prednisone	0.0824	d=Metformin	-0.6762
d=Epinephrine	0.0357	d=Azithromycin	-0.6796
d=Erythromycin	0.0242	d=Captopril	-0.6855
d=Thiocolchicoside	-0.0044	d=Losartan	-0.6882
d=Atropine	-0.0128	d=Amlodipine	-0.6899
d=Sulfadiazine	-0.0250	d=Cephalexin	-0.6901
d=Penicillin G procaine	-0.0593	d=Doxazosin	-0.6929
d=Salbutamol	-0.0845	d=Metoclopramide	-0.7212
d=Phenylephrine	-0.0869	d=Aminophylline	-0.7297
d=Simvastatin	-0.0914	d=Codeine	-0.7311
d=Dexamethasone	-0.0917	d=Clopidogrel	-0.7375
d=Gentamicin	-0.1000	d=Amiodarone	-0.7402
d=Methylphenidate	-0.1019	d=Clavulanate	-0.7449
d=Sodium chloride	-0.1856	d=Valproic acid	-0.7461
d=Fluphenazine	-0.2091	d=Carbidopa	-0.7552
d>Furosemide	-0.2152	d=Bromazepam	-0.7571
d=Methotrimeprazine	-0.2171	d=Levodopa	-0.7619
d=Carvedilol	-0.2223	d=Penicillin G Benzathine	-0.8072
d=Chlorpromazine	-0.2356	d=Insulin	-0.8443
d=Maprotiline	-0.2791	d=Isosorbide Mononitrate	-0.9186
d=Morphine	-0.2889	d=Nicotine	-0.9342
d=Levothyroxine	-0.2929	d=Glucose	-0.9742
d=Folic acid	-0.3650	$g = M$	-1.116
d=Alendronate	-0.3683	$g = F$	-1.132
d=Allopurinol	-0.3954	d=Isosorbide Dinitrate	-1.178
d=Permethrin	-0.4101	d=Oseltamivir	-1.3
d=Ciprofloxacin	-0.4119	-	-

Table S39: Feature weights on Logistic Regression (LR) classifier on model “simple”.

References

- [S1] IBGE. *Instituto Brasileiro de Geografia e Estatística*. ibge.gov.br. 2018.
- [S2] Luis M. Rocha et al. “MyLibrary@LANL: Proximity and Semi-metric Networks for a Collaborative and Recommender Web Service”. In: *2005 IEEE/WIC/ACM International Conference on Web Intelligence (WI’05)*. IEEE Press. IEEE Press, 2005, pp. 565–571.
- [S3] Tiago Simas and Luis M. Rocha. “Distance closures on complex networks”. In: *Network Science* 3 (02 June 2015), pp. 227–268.
- [S4] Rion Brattig Correia et al. “Monitoring potential drug interactions and reactions via network analysis of Instagram user timeliness”. In: *Pacific Symposium on Biocomputing*. Vol. 21. 2016, pp. 492–503.
- [S5] *Drugs.com*. <http://www.drugs.com>. Accessed on Oct 13. 2015.
- [S6] Robert A. Hamilton et al. “Frequency of Hospitalization after Exposure to Known Drug-Drug Interactions in a Medicaid Population”. In: *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 18.5 (1998), pp. 1112–1120.
- [S7] Juurlink DN et al. “Drug-drug interactions among elderly patients hospitalized for drug toxicity”. In: *JAMA* 289.13 (2003), pp. 1652–1658. eprint: [/data/journals/jama/4874/joc22124.pdf](http://data.journals/jama/4874/joc22124.pdf).
- [S8] Matthijs L Becker et al. “Hospitalisations and emergency department visits due to drug–drug interactions: a literature review”. In: *Pharmacoepidemiology and Drug Safety* 16.6 (2007), pp. 641–651.
- [S9] Chen Wu et al. “Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments: A Retrospective Study”. In: *Drug Safety* 35.9 (2012), pp. 769–781.
- [S10] Ministério da Saúde. *Sistema de Informações Hospitalares – SIH/SUS*. datasus.gov.br. Accessed on Jan 6. 2018.
- [S11] Anna Patrignani et al. “Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants”. In: *Giornale italiano di cardiologia (2006)* 19.1 (Jan. 2018), pp. 54–61. DOI: [10.1714/2852.28779](https://doi.org/10.1714/2852.28779).
- [S12] Francisca González-Rubio et al. “Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study”. In: *Pharmacoepidemiology and drug safety* 20.12 (2011), pp. 1287–1294. DOI: [10.1002/pds.2172](https://doi.org/10.1002/pds.2172).
- [S13] ML Ponte et al. “Drug-Drug Interactions: An Under-Estimated Problem”. In: *Drug Safety*. Vol. 33. 10. 2010, pp. 894–894.
- [S14] Paulino A. Alvarez et al. “Adverse drug reactions as a reason for admission to an internal medicine ward in Argentina”. In: *International Journal of Risk & Safety in Medicine* 25.3 (2013), pp. 185–192. DOI: [10.3233/JRS-130596](https://doi.org/10.3233/JRS-130596).
- [S15] Nicholas P Tatonetti et al. “A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports”. In: *Journal of the American Medical Informatics Association* 19.1 (June 2012), pp. 79–85. DOI: [10.1136/amiajnl-2011-000214](https://doi.org/10.1136/amiajnl-2011-000214).
- [S16] Srinivasan V Iyer et al. “Mining clinical text for signals of adverse drug-drug interactions”. In: *Journal of the American Medical Informatics Association* 21.2 (2014), pp. 353–362.
- [S17] Fabíola Giordani Cano and Suely Rozenfeld. “Adverse drug events in hospitals: a systematic review”. In: *Cadernos de Saúde Pública* 25.3 (2009), S360–S372.
- [S18] Heather Woltman et al. “An introduction to hierarchical linear modeling”. In: *Tutorials in Quantitative Methods for Psychology* 8.1 (2012), pp. 52–69. URL: <http://www.tqmp.org/RegularArticles/vol08-1/p052/p052.pdf>.

- [S19] Bernhard E. Boser et al. “A Training Algorithm for Optimal Margin Classifiers”. In: *Proceedings of the Fifth Annual Workshop on Computational Learning Theory*. COLT '92. Pittsburgh, Pennsylvania, USA: ACM, 1992, pp. 144–152.
- [S20] D.R. Cox. “Some procedures connected with the logistic qualitative response curve.” In: *Research Papers in Probability and Statistics (Festschrift for J. Neyman)*. Ed. by F.N. David. London: Wiley, 1966, pp. 55–71.
- [S21] F. Pedregosa et al. “Scikit-learn: Machine Learning in Python”. In: *Journal of Machine Learning Research* 12 (2011), pp. 2825–2830.
- [S22] Jesse Davis and Mark Goadrich. “The Relationship Between Precision-Recall and ROC Curves”. In: *Proceedings of the 23rd International Conference on Machine Learning*. ICML '06. New York, NY, USA: ACM, June 2006, pp. 233–240.
- [S23] B.W. Matthews. “Comparison of the predicted and observed secondary structure of T4 phage lysozyme”. In: *Biochimica et Biophysica Acta (BBA) - Protein Structure* 405.2 (1975), pp. 442–451.
- [S24] Pierre Baldi et al. “Assessing the accuracy of prediction algorithms for classification: an overview”. In: *Bioinformatics* 16.5 (2000), p. 412.